Skip to main content

November 2026: Male Aesthetics

Page 1

MALE AESTHETICS November 2026 | VOLUME 14 - ISSUE 12

Your Trusted Voice in the Aesthetics Specialty

GET READY FOR THE HOLIDAY SEASON WITH SCULPTRA®

EXCLUSIVE SAVINGS WITH MULTI-BUY

Available at our distribution partners

medfx For information on reporting adverse events, scan the QR code.

UKI-SCU-2600218 DOP OCTOBER 2026

CPD: Understanding Dermal Filler Rheology 6278 Sculptra October AJ Front Cover_v0.2-FA.indd 1

Dr Alison Colville explores properties of hyaluronic acid dermal fillers

Special Feature: Illustrating Profile Balancing for Male Patients Considering Polynucleotides for Atrophic Acne Scarring

ALSO IN THIS ISSUE

16/10/2026 14:17

Mr Vahe Karimyan explores non-ablative laser for androgenetic alopecia Amy Kapolnek shares a practical guide for patient retention


Scan QR codes for more information Professional Use by Qualified Practitioners Only


Contents • November 2026 06 News The latest product and specialty news

17 News Special: UK Government Announces Proposed Restrictions for High-Risk Procedures Aesthetics explores the Government’s proposals for tighter rules on who can perform high-risk procedures

20 Post-Event Report: Shaping the Future of Medical Aesthetics CCR 2026 delivered evidence-based education and breakthrough innovations

CLINICAL PRACTICE 24 Special Feature: Illustrating Profile Balancing for Male Patients Practitioners share approaches to male profile harmonisation

News Special: UK Government Announces Proposed Restrictions for High-Risk Procedures Page 17

29 30 Years of Backing the Science Behind Healthier Skin Analysis with LSE to quantify the impact of skin research funding

31 CPD: Understanding Dermal Filler Rheology Dr Alison Colville examines the rheological properties of HA dermal fillers

37 Managing AGA with Laser Therapy Mr Vahe Karimyan outlines fractional non-ablative laser in androgenetic alopecia

43 The Role of Hormones in Male Medical Aesthetics Dr Arsalan Baig and Dr Ducu Botoaca present an overview on the male patient

48 Considering Polynucleotides for Atrophic Acne Scarring Bernadette Tobin examines polynucleotides for acne scarring treatment

52 Skin Quality, Redefined Meet babyGLOW™ by Teoxane

54 Rethinking Assessment in Menopausal Patients Dr Jessica Halliley explores assessment and treatment planning in menopausal patients

56 One Complex, Five Solutions The science behind Nouveau Visage’s regenerative microneedling system

57 Abstracts The latest research highlights from Professor Sebastian Cotofana

IN PRACTICE 58 Exploring What it Takes to be a Key Opinion Leader Company representatives offer perspectives on their search for a KOL

60 Evaluating Retention as the Growth Strategy in Aesthetics Amy Kapolnek shares a practical guide to measuring patient retention

62 Highlighting the Voices from CCR 2026 Roundtables CCR roundtables expose the biggest debates, challenges and takeaways shaping aesthetic practice

65 In Profile: Dr Zunaid Alli Dr Zunaid Alli shares how to establish yourself in aesthetics

66 The Last Word: Are Subscriptions Dismantling Informed Consent? Michael Saul argues why clinic subscriptions affect patient consent

NEXT MONTH: DEVICES AND TECHNOLOGY • Stomach Tightening • Lipoedema • GLP-1 Skin Changes

Become a Subscriber!

Special Feature: Illustrating Profile Balancing for Male Patients Page 24

Clinical Contributors Dr Alison Colville is an aesthetics practitioner, general practitioner and founder of The Avery Clinic. She is UK Galderma Faculty, global research lead for Clinical Health Technologies and a member of the Joint Council for Cosmetic Practitioners Advisory Group. Mr Vahe Karimyan is a specialist surgeon and medical director of Dr Vahe Clinic, Chelsea, a medical, surgical and regenerative medicine practice. He also practises within the NHS at King’s College Hospital, has more than 20 years’ experience in aesthetic and regenerative medicine. Dr Arsalan Baig is a UK-based clinician, currently based at Dr Ducu clinics, with interests in surgery, regenerative medicine and evidence-informed aesthetic practice. His work focuses on male wellness, patient centred aesthetics and the integration of regenerative approaches. Dr Ducu Botoaca is a world-renowned aesthetic clinician and the Founder and Medical Director of Dr Ducu Clinics. He specialises in hair transplantation, eyebrow transplantation, non-surgical BBL and advanced aesthetic procedures, including SkinTight, his innovative skin-tightening treatment. Bernadette Tobin is an advanced nurse practitioner, independent prescriber and aesthetic practitioner. A former senior university lecturer at Anglia Ruskin University, she founded Visage Aesthetics and Aesthetics Unlocked, providing evidence-led clinical education and practical support. Dr Jessica Halliley is a general practitioner, aesthetic doctor and founder of Your Beauty Doctor in Nottingham. She graduated from the University of Sheffield with Honours and has a postgraduate qualification in Women’s Health and Medical Aesthetics.

Join the Aesthetics Community as a subscriber to receive the monthly Aesthetics Journal, among many other exclusive benefits. Visit aestheticsjournal.com to sign up!


Re-Awaken Skin from Within.

RADIESSE is a regenerative biostimulator that delivers firmer, tighter skin, supporting against visible signs of ageing.1,2 Shown to: Boost Collagen production up to*3

23x

Increase Elastin production up to*3

96%

Actual patient. Individual results may vary.

1. Kim JS. Multilayered Injection of Calcium Hydroxylapatite Filler on Ischial Soft Tissue to Rejuvenate the Previous Phase of Chronic Sitting Pressure Sore. Clin Cosmet Investig Dermatol. 2019;12:771-784. 2. Loghem JV, et al. Calcium Hydroxylapatite Over a Decade of Clinical Experience. J Clin Aesthet Dermatol. 2015;8(1):38-49. 3. Goldie, K., et al. Regeneration of an Extracellular Matrix Ecosystem Following Subcutaneous Injection With Different Radiesse Dilutions: A Histologic and Ultrasound Study. J Cosmet Dermatol. 2026; 25(5). *Based on a 6-month human tissue study, compared with measurements before treatment.

Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk. Reporting forms and information for Republic of Ireland can be found at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events should also be reported to Merz Aesthetics UK Ltd by emailing UKdrugsafety@merz.com or calling +44 (0) 333 200 4143.

©2026 Merz Aesthetics UK Ltd – All rights reserved. MERZ AESTHETICS and RADIESSE logos are trademarks and/or registered trademarks of Merz Aesthetics UK Ltd in the United Kingdom. Registered in England No. 14506945. Merz Aesthetics UK Ltd. Ground Floor Suite B, Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire, HP2 4TZ. www.merz-aesthetics.co.uk.

M-RAD-UKI-0718 Date of Preparation: October 2026


Editor’s letter More men are seeking aesthetic treatments, but their goals and concerns are as individual as those of any patient. In this November issue, we explore male aesthetics from several angles, starting with our Special Feature on profile balancing for the male face (p. 24). How do you create a result that feels balanced while respecting each patient’s features and preferences? It is a question that calls for careful consultation as much as technical skill.

Holly Carver Editor & Content Manager

We also look at male hormones, treating male acne and managing androgenetic alopecia. Together, these articles reflect the breadth of concerns that may come up in clinic and the importance of listening before making a treatment plan. In breaking news, the Department of Health and Social Care has announced a consultation on proposals to restrict high-risk cosmetic procedures to regulated healthcare professionals. The proposals would limit who can perform treatments including body filler injections and certain other procedures, as well as preventing under-18s

from undergoing high-risk cosmetic and wellbeing treatments. We spoke to associations and groups from across the specialty to hear their thoughts. Read more in our News Special on p.17. Please get involved in the discussion and let us know any thoughts by emailing editorial@aestheticsjournalcom. We also look back at the Clinical Cosmetic Regenerative Congress (CCR) 2026 in a four-page post-event review. I can’t believe it’s been a month already! It was our biggest CCR yet with over 4,078 attendees, and the feature captures the conversations, learning and connections that made it such a success. Registration for our next event, the Aesthetics Conference & Exhibition (ACE) 2027, is now open. You can also register your interest in the launch of the Aesthetics Business Show to receive updates. Finally, entries for The Aesthetics Awards have now closed, but tickets are available. Taking place on March 13, following on from Day 2 of ACE, it will be our biggest celebration of medical aesthetics yet, returning to the Grosvenor House. Make sure you get your tickets soon and make the most of the early bird rate. We hope to see you all there!

Clinical Advisory Board

Leading figures from the medical aesthetic community have joined the Aesthetics Advisory Board to help steer the direction of our educational, clinical and business content

Sharon Bennett is the former chair of the British Association of Medical Aesthetic Nurses (BAMAN), UK lead of the BSI committee for aesthetic non-surgical standards and member of the Clinical Advisory Group for the JCCP. She is a trainer and a registered university mentor in cosmetic medical practice, and is finishing her MSc at Northumbria University. Bennett has won the Aesthetics Award for Nurse Practitioner of the Year and the Award for Outstanding Achievement.

If you are interested in contributing to the journal, get in touch... Email: editorial@aestheticsjournal.com

Sharon Bennett, Clinical Lead Mr Naveen Cavale has been a consultant plastic, reconstructive and aesthetic surgeon since 2009. He has his own private clinic and hospital, REAL, in London’s Battersea. Mr Cavale is the national secretary for the ISAPS, president of the Royal Society of Medicine, and vice-chair for the British Foundation for International Reconstructive Surgery.

Dr Mayoni Gooneratne (MBBS, BSc, MRCS, MBCAM, AFMCP) was an NHS surgeon before establishing The Clinic by Dr Mayoni and founding Human Health – an initiative combining lifestyle with traditional and functional medicine to provide a ‘cell-up’ regenerative approach to aesthetics. She is also the co-founder of The British College of Functional Medicine.

Dr Sophie Shotter is the founder & medical director of Illuminate Skin Clinic in Kent and Harley Street, London. Her passion is for natural treatments delivered with utmost attention to safety. She works closely with Allergan as part of their UK and International Faculty.

Miss Elizabeth Hawkes is a consultant ophthalmologist and oculoplastic surgeon. She is the lead oculoplastic surgeon at the Cadogan Clinic, specialising in blepharoplasty and advanced facial aesthetics. Miss Hawkes is a full member of the BOPSS and the ESOPRS, and is an examiner and fellow of the Royal College of Ophthalmologists.

Jackie Partridge is an independent nurse prescriber. She is the clinical director and owner of Dermal Clinic in Edinburgh and a KOL for Galderma. She holds an MSc in Non-surgical Aesthetic Practice and a BSc in Dermatology. Partridge is a stakeholder group member with Scottish Government/HIS, Honorary BACN member and JCCP Fitness to Practice Nurse.

Dr Anjali Mahto is one of the UK’s leading consultant dermatologists. She is a Fellow of the Royal College of Physicians, member of the Royal Society of Medicine and a spokesperson for The British Skin Foundation. In 2023 Dr Mahto opened Self London, a dermatology and lifestyle clinic aimed at managing skin conditions holistically.

Mr Adrian Richards is a plastic and cosmetic surgeon with over 30 years’ experience. He is the clinical director of the aesthetic training provider Cosmetic Courses and surgeon at The Private Clinic. He is also a member of the British Association of Plastic and Reconstructive and Aesthetic Surgeons and the British Association of Aesthetic Plastic Surgeons.

Dr Souphi Samizadeh is a dental surgeon with a Master’s degree in Aesthetic Medicine and a PGCert in Clinical Education. She is the founder of the Great British Academy of Medicine and Revivify London Clinic. Dr Samizadeh is a Visiting Teaching Fellow at University College London and King’s College London.

Dr Stefanie Williams is a dermatologist with a special interest in adult acne, rosacea and aesthetic medicine. She is the founder and medical director of multi-award winning EUDELO Dermatology & Skin Wellbeing in London, and creator of Delo Rx skincare. She is the author of three books and has published more than 100 scientific articles, book chapters and abstracts.

ARTICLE PDFs AND REPRO

PUBLISHED BY PORTFOLIO MANAGEMENT Shannon Kilgariff • Publisher & Event Director T: 0203 196 4351 | M: 07557 359 257 shannon.kilgariff@easyfairs.com EDITORIAL Holly Carver • Editor and Content Manager T: 0203 196 4427 | holly.carver@easyfairs.com Amer Saleh • Journalist T: 020 3196 4270 | amer.saleh@easyfairs.com Mia Sawyer • Journalist T: 020 3196 4242 | mia.sawyer@easyfairs.com Sophia-Fai Roche • Journalist T: 0203 196 4391 | sophia-fai.roche@easyfairs.com DESIGN Callum Benyon • Graphic Designer Kitty Butler • Junior Graphic Designer

ADVERTISING & SPONSORSHIP Judith Nowell • Head of Sales T: 0203 196 4352 M: 07765 407629 judith.nowell@easyfairs.com Charlotte Norville • Senior Sales Executive T: 020 3196 4418 charlotte.norville@easyfairs.com MARKETING Susana Burguera • Head of Marketing T: 020 3196 4281 | susana.burguera@easyfairs.com Siji Braithwaite • Senior Marketing Executive T: 020 3196 4285 | Siji.Braithwaite@easyfairs.com Jodie King • Marketing Executive T: 020 3196 4404 | jodie.king@easyfairs.com

@aestheticsjournaluk

Aesthetics

Aesthetics

Material may not be reproduced in any form without the publisher’s written permission. For PDF file support please email, contact@aestheticsjournal.com

© Copyright 2026 Aesthetics. All rights reserved. Aesthetics is published by Aesthetics Media Ltd, which is registered as a limited company in England; No 9887184

DISCLAIMER: The editor and the publishers do not necessarily agree with the views expressed by contributors and advertisers nor do they accept responsibility for any errors in the transmission of the subject matter in this publication. In all matters the editor’s decision is final.


Insider News

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Regulation

In the Spotlight... A monthly snapshot of the people, products and ideas generating real time buzz in aesthetics

Regulation LBC discuss the proposed crackdown on unsafe cosmetic procedures Talk radio show, Leading Britain’s Conversation (LBC) examined what the Department of Health and Social Care’s proposals to restrict high-risk cosmetic procedures to regulated healthcare professionals could mean for patient safety. Speaking to Nick Ferrari, NHS doctor and GP Dr Raj Arora said, “My biggest concern is patient safety. When safeguards around who can perform treatments are not followed, the consequences can be fatal.” She stressed that qualified professionals must be able to manage complications and provide aftercare, adding that the proposed rules could create a clearer legal framework, with criminal penalties for non-compliance. Patient safety discussed on LBC

Practitioner Responsibility ICAM warns against using celebrity faces as aesthetic case studies The Irish College of Aesthetic Medicine (ICAM) has urged practitioners to stop using celebrity faces as subjects for online procedure speculation, warning the trend can reinforce harmful scrutiny of women’s appearances. ICAM states, “As medical professionals, we need to stop reinforcing the idea that women’s faces and bodies are there to be scrutinised, dissected and publicly judged. As aesthetic practitioners, we have a particular responsibility.” ICAM also calls on practitioners to consider who benefits from this type of content, adding, “A woman’s face is not a case study simply because she is famous.” ICAM challenges treatment speculation

Practitioners discuss the aesthetic blind spots Aesthetic practitioners Dr Kam Lally, Dr Tauseef Zia and Dr Naomi McCullum shared the issues they believe aesthetic practitioners do not worry about enough during an Instagram discussion. Dr Lally says, “Practitioners often overlook the potential cumulative effect of having lots of treatments over a long period of time, particularly the implications that five, 10 years down the line, how it potentially changes tissue architecture and physiology.” By contrast, Dr Zia argues that too few practitioners give sufficient attention to social media compliance. Dr McCullum adds that many focus narrowly on mastering a single technique, without fully considering its wider impact on the patient.

6

The Medicines and Healthcare products Regulatory Agency (MHRA) has welcomed the sentencing of Medicina Ltd co-founder Kenneth Harrison, following an investigation into the illegal supply of medical devices to hospitals across the UK. Harrison’s convictions, announced in July 2026, followed an investigation by the MHRA’s Device Compliance Unit, which began after concerns were first raised in 2013. The investigation found that several products – including enteral feeding pumps, gastrostomy button devices and blunt fill needles – had been supplied with invalid CE marking. At Manchester Crown Court on September 23, 2026, Harrison received a three-year sentence, with concurrent sentences imposed across all counts. Judge Timothy Smith also ordered Harrison to complete 175 hours of unpaid work and 10 days of rehabilitation activity, as well as disqualifying him from acting as a company director. A sentencing date for Medicina Ltd has yet to be set. According to BBC News, Harrison is understood to have left the company. James Pound, MHRA executive director of Innovation and Compliance, commented, “Healthcare professionals need to be able to trust that the medical devices they use have been properly assessed and meet the standards designed to protect patients.” International Delegation

Canadian nursing regulator updates injectable supervision rules Ontario nursing regulator, the College of Nurses of Ontario (CNO) council, has approved new requirements for nurses providing aesthetic services. Under the updated CNO standards, a nurse must remain onsite for the entire procedure when it is delegated to someone who does not otherwise have the authority to perform a controlled act, such as an unregulated care provider administering a substance by injection.

Specialty Oversight

Overlooked risks

MHRA responds to sentencing over falsely certified devices

Nurses must also use patient-specific orders, rather than general directives, for treatments involving prescription drugs or controlled acts. Across nursing settings, the standards clarify that an authorised provider must complete an initial assessment, either in person or virtually, and establish a care plan with follow-up before issuing a patient-specific order. According to CNO, nurses who delegate procedures remain responsible for ensuring that the person carrying them out can do so safely and remain accountable for the patient’s ongoing care. The updated standards take effect on March 1, 2027. Silvie Crawford, nurse practitioner and CNO registrar and chief executive officer, commented, “These changes put patient safety first by setting clearer expectations for nurses and strengthening safeguards wherever nursing care is provided. Ontarians should be able to feel confident that their care is based on their individual needs and delivered with appropriate oversight.”

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

Insider News

aestheticsjournal.com

Keynote Speakers

Vital Statistics

CCR announces Keynote Speakers for 2027

Neurotoxin procedures account for 35% of new aesthetic patients treatment offerings

Plastic surgeon Dr Steven Dayan and dermatologist Dr Sabrina Fabi have been confirmed as international Keynote Speakers for the Clinical Cosmetic Regenerative Congress (CCR) 2027. The announcement follows CCR 2026, which commenced on October 1-2, and welcomed 4,078 attendees across two days. The US-based specialists will contribute educational content across both days of the conference programme, providing delegates with the latest international perspectives. Holly Carver, editor and content manager at Aesthetics, commented, “We are delighted to confirm Dr Dayan and Dr Fabi as Keynote Speakers for CCR, 2027. Their combined expertise, clinical insight and international perspective will bring significant value to the education programme. Further programme details will be shared in the lead-up to the event, and those interested in attending can register their interest via the CCR website.”

(Guidepoint Qsight, 2026)

67.6% of 5,400 adults across the UK, Germany, Spain, Russia and Saudi Arabia prefer aesthetic treatments that do not involve needles (Cynosure Lutronic, 2026)

Out of 898 working women within the US, 31% consider changing jobs, roles or reducing hours at work due to menopause

Treatment Insights

ISAPS survey shows decline in aesthetic procedures

(Live Career, 2026)

The International Society of Aesthetic Plastic Surgery (ISAPS) has published its survey of aesthetic procedures performed in 2025. Drawing on responses from 2,900 plastic surgeons worldwide, botulinum toxin remained the most popular non-surgical procedure, followed by hyaluronic acid (HA) treatments and non-surgical skin tightening. Of these three categories, only skin tightening increased compared with 2024. Botulinum toxin procedures fell by 7%, while HA procedures declined by 25.2%. Overall, the survey recorded a 14.7% decrease in non-surgical procedures worldwide. Across surgical and non-surgical procedures combined, the percentage change from 2024 was -7.7% for women and -14.1% for men.

Among 12,000 beautyinvolved patients across nine global markets, 34% favour long-term treatment plans over individual treatments or a short-term approach (Allergan Aesthetics, an AbbVie company, 2026)

Prescription-only Medicines

ASA releases POM rulings

81% of 6,000 participants recognise the importance of protecting their skin beyond UV exposure

The Advertising Standards Authority (ASA) has upheld two complaints against Pharmacy Online over advertising for oral semaglutide weight-loss treatment. One advertisement, seen before approval, suggested an oral treatment offered the “same medication” and mechanism as injectable weight-loss medicines. The ASA found that this made medicinal claims for an unlicensed product, contrary to the Committee of Advertising Practice (CAP) Code. Pharmacy Online said the materials had been produced by an external agency and were withdrawn as a precaution. It said it would review its advertising processes. Catherine Drewett, investigations manager at the ASA, commented, “The licencing of oral glucagon-like peptide-1 medicines represents a significant development in treatment options but also new challenges for regulators. These are powerful medicines so it’s important that ads don’t encourage people to seek treatment in ways that could put them at risk.”

(CeraVe, 2026)

Across 6,503 adults in 12 countries, 68% say individuality is the most important factor in defining beauty (Journal of Cosmetic Dermatology, 2026)

Aesthetics | November 2026

7


Insider News

Events diary

@aestheticsjournaluk

12th-13th March 2027 Aesthetics Conference & Exhibition and Aesthetics Business Show 13th March 2027 The Aesthetics Awards

aestheticsjournal.com

ADAP launches at CCR 2026 The Association of Dentists in Aesthetic Practice (ADAP), a new professional association for dentists working in facial aesthetics, was introduced at the Clinical Cosmetic Regenerative Congress (CCR) 2026.

14th November 2026 IAAFA Aesthetics Conference

21st-22nd November 2026 The Anatomy & Injection Experience, BAMAN

Aesthetics

Dentists

7th November 2026 RAMCE

21st November 2026 Interface Expo

Aesthetics

According to the organisation, ADAP has been established to provide representation, professional support and a collective voice for dentists practising in the rapidly growing field of non-surgical facial aesthetics. ADAP says it aims to promote clinical excellence, patient safety, education and professional development, while providing members with access to training, networking opportunities, advocacy and professional guidance tailored to dentists offering non-surgical facial aesthetic treatments. Paul Burgess, executive chair of ADAP, commented, “The response to ADAP at CCR has been incredibly encouraging. The feedback we received from dentists and stakeholders clearly demonstrated that there is a genuine need for an organisation that represents and supports dentists working in non-surgical facial aesthetics. The field has evolved significantly over recent years, with dentists playing an increasingly important role in delivering safe, effective and clinically led treatments.”

Medical Tourism

Professional Body

Longevity association debuts in the UK

Concerns arise over blepharoplasty performed overseas A BBC News investigation has drawn attention to risks reported by patients following lower-cost upper eyelid blepharoplasty performed abroad. One patient, Nikita Morgan, travelled from Dublin to Düsseldorf (Faceland) in November 2025 for an upper blepharoplasty after seeing the procedure advertised on TikTok for £650 – a contrast to the £3,400 cost of undergoing the same surgery in Ireland. Morgan told the BBC that she experienced severe pain during surgery and subsequent bleeding, swelling and visual difficulty. She returned home by air on the day of her procedure, which she later said she regretted. Düsseldorf provider, Faceland, said it offers “safe and quality” treatment, with consultations and signed consent undertaken before procedures. It stated that fewer than 1% of procedures had resulted in a complaint. Aesthetics reached out to ophthalmologist and oculoplastic surgeon Dr Jonathan Roos, who commented, “To ensure an optimal outcome an ophthalmology specialist who can assess for dry eye, blepharitis, eyelid inflammation and other eye problems is essential. The eyelids are not just a piece of skin; they protect vision and the eye surface. In addition to a careful preoperative assessment, including a full history of risk factors, practitioners should offer a direct post-operative communication channel so that every patient can access their operating surgeon 24/7 with any questions.”

A new association, the UK Society of Medical Longevity, has launched to establish standards for longevity medicine in the UK. Founded by aesthetic practitioner Dr Mayoni Gooneratne, the organisation aims to provide governance, evidence-based standards and a professional home for doctors practising longevity medicine both within and outside the National Health Service. As part of its launch, the society has announced its inaugural scientific meeting, which will take place at Electric House, Notting Hill on November 13. Open to doctors registered with the General Medical Council, the event will explore the science of healthy ageing and practical approaches to integrating longevity medicine into clinical practice. Dr Gooneratne commented, “As the curator of the Medical Longevity Summit at the Clinical Cosmetic Regenerative Congress, my job is to stay on top of the science and ahead of the curve. Unfortunately, there has been a massive influx of practices and advice that may not always have the strongest medical backing. I want to help doctors who are practising true longevity medicine to do so safely. I have seen the massive benefits for patients who are experiencing these changes in health. We created the society to give doctors the space to do this and to develop the guardrails that will help clinicians practise the art form that is longevity.”

Portfolio Expansion

Galderma agrees acquisition of ZO Skin Health Pharmaceutical company Galderma has entered into an agreement to take ownership of skincare brand ZO Skin Health. Galderma adds it will acquire the business from its existing shareholders, including funds managed by Blackstone and the Obagi family. According to Galderma, the acquisition is expected to expand its dermatological skincare portfolio and strengthen its presence in the medical-grade skincare market. The company stated that ZO Skin Health’s portfolio will complement its existing dermatological skincare range and support its relationships with dermatologists, plastic surgeons and aesthetic practitioners. The deal remains subject to regulatory approvals and customary closing conditions, with completion anticipated during the fourth quarter of 2026 or early 2027. 8

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Insider News

Ceremony

The Aesthetics Awards early-bird tickets on sale now The Aesthetics Awards will bring the medical aesthetics community together following the final day of the Aesthetics Conference & Exhibition (ACE), on March 13, 2027. The ceremony gives practitioners and specialty colleagues a chance to reflect on achievements across the profession, reconnect with peers, and celebrate the work happening in aesthetics. It also provides a chance for teams to share an evening together away from the demands of day-to-day practice. Early bird tickets are available until December 31, with standard pricing taking effect from January 1, 2027. Seats are allocated in tiers according to booking date, so those hoping for a closer view may want to secure their place sooner. Aesthetic distributor Healthxchange returns as the Gold Sponsor of The Aesthetics Awards. Silver sponsors of this prestigious event include pharmaceutical companies Galderma, IBSA, Allergan Aesthetics, an AbbVie company, and Evolus; aesthetic device companies Candela and Lumenis; skincare platform GetHarley; health platform Nicoya; aesthetic manufacturers Revance and TSK Labs UK; and aesthetic distributor DermaFocus. Aesthetic supplier Church Pharmacy joins as Bronze Sponsor. Holly Carver, editor and content manager at Aesthetics, said, “The Aesthetics Awards are a chance to pause and recognise the dedication, skill and collaboration behind the work we see across the profession. After ACE, it is especially valuable to come together, celebrate colleagues’ achievements and share an evening with the people who make this community what it is today. Want to be closer to the stage when the Winners are announced? Book through The Aesthetics Awards ticket page before the early bird deadline.” Referral Platform

Harley Academy introduces complications service UK training provider Harley Academy has launched its Aesthetics Referral Centre. According to Harley Academy, the platform connects practitioners to a multidisciplinary team (MDT), supporting both them and the patient if something goes wrong. The training provider explains that practitioners must submit a short referral form, including treatment details and photographs, via the member portal. Additionally, patients receive an immediate booking link, avoiding triage queues and unnecessary delays, while the referring practitioner remains informed throughout. The training provider adds that patients are assessed and treated by named Harley Academy faculty specialists at the Copthall Avenue complications clinic, and following discharge, they return to their original practitioner with a comprehensive clinical summary. The subscription includes referral rights, a clinical governance pack and access to an extensive protocol library, shares the company. Dr Tristan Mehta, founder and chief executive officer of Harley Academy, commented, “We built the Aesthetics Referral Centre so there’s always somewhere to turn. A full MDT supports both patient and practitioner, with no judgement, from referral through to discharge. Keeping it affordable was deliberate, because a safety net only works if everyone can reach it.” Aesthetics | November 2026

BAMAN UPDATES A round-up of the latest news and events from the British Association of Medical Aesthetic Nurses

BAMAN’S VISION FOR THE FUTURE This month marks ten years since I joined the association, now known as BAMAN. Throughout that time, I have seen our organisation grow, evolve and strengthen Gareth Lewis its ambitions. As CEO, chief executive my focus is on ensuring officer (CEO) that our next chapter delivers meaningful progress for members and the profession. Our direction brings together three priorities; supporting nurses in practice, strengthening professional education and ensuring that nursing expertise informs decisions affecting medical aesthetics. This November, our collaboration with Cotofana Anatomy brings The Anatomy and Injection Experience to Edinburgh. With auditorium teaching through live dissection and an advanced hands-on cadaver masterclass, the programme offers an exceptional opportunity to deepen anatomical understanding. Alongside our events, we are preparing our eLearning platform and Career and Competency Framework, connecting accessible learning with a clearer structure for professional development. Our work with the University of Plymouth also supports our ambition to develop academic pathways aligned with clinical practice, with the first cohort anticipated in January 2027. Representation remains equally important. We have opened dialogue with the Royal College of Nursing about restrictions affecting independent nurse prescribers, including access to emergency stock medicines. This work is ongoing, with practical concerns being raised through appropriate professional channels. Behind these activities is a continuing commitment to sound governance, effective operations and responsible use of our resources. These foundations enable BAMAN to pursue its ambitions and remain accountable to members and the professional opportunities of tomorrow. To find out more information, visit the events page via the QR Code below.

This column is written and supported by BAMAN

9


Insider News

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Combination Procedures

13 March 2027, Grosvenor House, London

Study explores menopausal skin treatments

Event Spotlight: Celebrate Excellence in Medical Aesthetics

Pharmaceutical company Galderma has released data that suggest the sequence of injectable treatments may influence skin-quality outcomes in menopausal women.

Get your tickets to The Aesthetics Awards 2027

Taking place on Saturday March 13, following Day 2 of the Aesthetics Conference & Exhibition, the Aesthetics Awards returns to The Great Room at Grosvenor House, Park Lane, London – an iconic setting for an unforgettable evening of recognition, connection and celebration. What’s included? Your ticket includes entry to the ceremony, a networking drinks reception, a three-course dinner with half a bottle of wine per guest and a range of soft drinks. You will also enjoy live entertainment, dancing and access to the official Awards Afterparty. As the final Award is announced, the celebration continues at the official Awards Afterparty. Supported by Healthxchange as Gold Sponsor, it is the place to catch up with peers, make valuable new connections and celebrate the evening’s biggest moments with live entertainment, a DJ and an electric atmosphere. Don’t just take our word for it “The energy at the Awards was incredible. The Awards represent prestige, recognition and, importantly, an appreciation for the craft, recognising the practitioners who are genuinely committed to excellence.” Dr Zoya Awan Get your tickets today Early Bird tickets are available until December 31, so secure your place now and be part of an evening that celebrates all those in the medical aesthetics specialty.

Scan the QR code to secure your ticket

10

An eight-month investigator-initiated trial, led by plastic surgeon Dr Andreas Nikolis and supported by Galderma, assessed two treatment sequences across the face and décolletage. Participants received either a hyaluronic acid skin booster (Restylane Skinboosters) before a poly-L-lactic acid collagen stimulator (Sculptra), or the reverse sequence. According to the study findings, the skin-booster-first protocol produced an earlier visible response and greater dermal remodelling. In a survey of 5,090 women in the UK, US, Brazil and China, facial dermal thickness increased by 27.3% in this group, compared with 15.7% among those receiving the collagen stimulator first. Anne-Cécile Chevrier, global head for injectable aesthetics at Galderma, commented, “We are committed to advancing the understanding of menopausal skin and providing women with clear, trusted information and science-backed solutions, so they can make informed choices and feel confident in their skin throughout this important stage of life.” Dentist Representation

BCAM expands support for dentists The British College of Aesthetic Medicine (BCAM) is developing its dental faculty to provide stronger representation, education and peer support for dentists building careers in aesthetics. BCAM shares that the move reflects the growing number of dental professionals offering facial aesthetics, injectables and skin-rejuvenation treatments. BCAM says the faculty will help dentists connect with medical peers, access accredited education and contribute to higher standards of patient safety and clinical governance across the sector. BCAM president and aesthetic practitioner Dr Sophie Shotter commented, “We see a real opportunity for BCAM to provide better professional representation for dentists, helping to fulfil both their needs and to signpost patients towards practitioners ethically working across both specialties.” Artificial Intelligence

MHRA to monitor healthcare artificial intelligence The Medicines and Healthcare products Regulatory Agency (MHRA) has announced its role in implementing the Government’s response to the National Commission into the Regulation of Artificial Intelligence (AI) in Healthcare. The intention is to assess how devices perform in real clinical settings over time, rather than depending primarily on a single pre-market assessment, according to the organisation. The MHRA has opened applications for Phase 3 of its AI Airlock regulatory sandbox. The programme will focus on post-market surveillance, bringing developers, healthcare partners and regulators together to test methods for monitoring AI tools once deployed. By December 2026, the MHRA expects to issue draft guidance on managing changes to AI-enabled devices as they adapt or are updated. It will also consult next year on how such products should be qualified and classified. Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Upcoming Event

Interface Expo conference returns Medical aesthetics event Interface Expo will be commencing at the Queen Elizabeth II Conference Centre, on November 21. The event will feature a range of educational content, with an opening from the event founder and oral and maxillofacial surgery registrar Mr James Olding. Throughout the day, delegates will be able to access a range of sessions discussing regulation, glucagon-like peptide-1 therapies, the role of multi-disciplinary teams and regenerative medicine. According to the event organisers, attendees will also be able to witness live injection demonstrations. Mr Olding commented, “What began as an event for those early in their careers is now the UK’s largest single-stream aesthetics event, and we remain proudly independent, with education first. Alongside roundtables, live injections and debates, our multi-disciplinary panel of dermatologists, surgeons and specialists return, and we will present peer-reviewed research shaping how we deliver training from 2027.” Patient Safety

Superdrug and Save Face showcase initiative Health and beauty retailer Superdrug has launched its Back Street To High Street safety campaign with independent accreditation body Save Face as chosen charity partner. According to the company, the initiative is calling for greater safety and accountability in the UK non-surgical aesthetics field and positioning face-to-face consultations as essential before treatment. The campaign follows Superdrug previously launching aesthetic clinics, with all clinicians accredited by the Joint Council for Cosmetic Practitioners (JCCP) and Save Face. Patient-led research commissioned by Superdrug, involving 2,003 participants, found that 54% consider clear information on risks and expected results critical to safe, effective treatment, 53% want stronger regulation and licensing of clinics and practitioners and 51% believe practitioners should have appropriate medical training and qualifications. Speaking with Aesthetics, Ashton Collins, director of Save Face, commented, “Our collaboration with Superdrug combines Save Face’s expertise in practitioner verification and patient protection with Superdrug’s reach and public trust. Through the Back Street to High Street campaign, we want to make credible safety information as visible and accessible as the marketing promoting these treatments.” Business Training

New aesthetic training framework launches AB Aesthetic Business Academy, the training arm and sister company of AB Aesthetic Consultant Services (ABACS) has introduced a new framework called Master the Business of Aesthetics. Intended for clinic owners and practitioners, the company explains the framework covers core themes ranging from setting up and structuring a business to pricing, marketing, sales and growth. ABACS adds the content is delivered as live, interactive webinars, running across four phases, with 19 core modules and four bonus modules.

Insider News

60

Dr Hasaneen Al Janabi lead UK KOL for AUTENTICA AUTENTICA has just launched in the UK. What’s the big idea behind it? It sits somewhere between improving skin quality and creating a subtle structural effect. Hydration is only one part of the picture. Powered by Regenyal’s patented PHYSIOLOGIC TECH and 64mg of ultra-pure hyaluronic acid (HA), it’s delivered using the Anti-Gravity TechniqueTM, placing product within the superficial adipose layer to support the skin’s natural structure, rather than adding visible volume. What’s got you personally excited about bringing this into clinic? The precision. Most boosters offer hydration alone – this allows a genuinely considered approach to placement, tailored by patient age and need, using either needle or cannula. It’s a far more technique-led treatment than practitioners may be used to, which is exactly what makes it so interesting from a clinical perspective. What is the importance of ongoing training for new HA regenerative products coming onto the UK market? Training remains critical, as newer biostimulators and regenerative injectables coming into the UK differ greatly not only in their function, but in the placement technique – you can’t just assume one HA product is analogous to another. For AUTENTICA, the Anti-Gravity TechniqueTM relies on precise placement deeper than traditional biostimulators – that’s why we’re running practitioner courses and a protocol-focused webinar from October. There’s also an introductory event at King Street Townhouse on November 10 for clinics and prospective training partners. Where does skin quality fit in the bigger picture for aesthetics right now? Patients are increasingly asking for better skin quality rather than more volume and demand for bio-regenerative, restructuring treatments continues to grow. AUTENTICA responds directly to that shift. It offers practitioners a genuinely different way of thinking about hyaluronic acid.

AUTENTICA is available now through Fox Pharma, exclusive UK distributor, and MedFx, official UK pharmacy partner. For training enquiries, contact academies@foxgroupint.co.uk This advertorial was written and supplied by

Amanda Elbourn, founder and director of ABACS, commented, “I created this to bridge that divide, equipping healthcare professionals with commercial understanding, business management skills, and the confidence to build profitable, sustainable businesses without compromising exceptional patient care.” Aesthetics | November 2026

11


Insider News

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Latest Appointments Aesthetics rounds up the latest company appointments announced within the aesthetics community Pharmaceutical company Galderma welcomes Gillian Kennedy as new business unit head. With 30 years of experience across consumer health, medical devices and pharmaceuticals, Kennedy brings a broad perspective to the healthcare field, according to the company. Her experience combines an understanding of healthcare professionals’ needs with a focus on delivering results for patients and the business, according to Galderma. Kennedy said, “What excites me most about my new role with Galderma is the opportunity to support healthcare professionals through education that makes a difference to their patients and helps their practices grow.” The International Society of Aesthetic Plastic Surgery (ISAPS) has announced plastic surgeon Mr Ozan Sozer as president-elect. The election follows Mr Sozar’s long-standing involvement with ISAPS, where he currently serves as treasurer, leading as chair of education, according to the organisation. Mr Sozar will assume presidency in 2028. Mr Sozer commented, “I have always believed that aesthetic surgery advances when physicians share knowledge, challenge one another and continue learning. I look forward to helping further ISAPS’ commitment to global education, innovation and patient safety.” Aesthetic practitioner Dr Souphi Samizadeh has been appointed president of the Royal Society of Medicine’s (RSM) Section of Aesthetic Medicine and Surgery. As president,

she will support scientific progress by advancing research, discovery and knowledge within medical aesthetics and surgery, explains RSM. Her priority is to ensure that practice remains evidence-based, guided by robust proof rather than trends. Dr Samizadeh commented, “It is an honour to take office as president of the Section of Aesthetic Medicine and Surgery at the RSM, as the Section’s second president and the first woman to hold the role.” The British Association of Aesthetic Plastic Surgeons (BAAPS) has appointed consultant plastic surgeons Mr Anthony MacQuillan as president and Mr Mike Tyler as vice president. Succeeding Ms Nora Nugent, who has held the position for the past two years, BAAPS shares that Mr MacQuillan will focus on strengthening patient safety, addressing the growing influence of artificial intelligence-generated and manipulated imagery on patient expectations. He will also expand on training opportunities for the next generation of aesthetic surgeons, according to the organisation. Mr Tyler was appointed as a consultant plastic surgeon in 2001 and is also a member of the BAAPS Council. According to organisation, the new leadership team will continue BAAPS’ work promoting the highest standards of aesthetic surgery, patient safety and professional training across the UK.

Setting the new standard in microneedling Feature-led: • Easy-to-install RFID cartridge • Interactive Digital Display • All-new ActiSine™ technology

Enquire today at enquiries@revance.com

12

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Insider News

Panel Discussion

Galderma discusses menopause with Aesthetics Pharmaceutical company Galderma welcomed members of the press for a breakfast event held at The Swan, London. Broadcaster and journalist Ateh Jewel chaired the panel discussion, which featured Galderma’s global head of injectable aesthetics, Anne-Cécile Chevrier and plastic surgeon Ms Priya Chadha. The panel discussed how menopause can be an imprecise and isolating term for patients, encompassing a range of symptoms that can emerge and fluctuate over time. Aesthetics asked Ms Chadha how the specialty can address the current knowledge gap and reduce patient frustration. She responded, “Women want to engage with this conversation because they finally feel seen, heard and validated, and that recognition is long overdue. There is a responsibility to educate, but it’s important to strike the right balance between providing genuine, evidence-based information and promoting your own clinical or commercial interests. It’s a fine line, but one the specialty needs to navigate thoughtfully.” Injectable Launch

AUTENTICA debuts in UK market Hyaluronic acid (HA) skin restructurer AUTENTICA has launched in the UK, with Fox Pharma and MedFx confirmed as its exclusive distributors. Developed by aesthetic manufacturer Regenyal, AUTENTICA is intended for advanced skin bio-restructuring, hydration and dermal-quality improvement. Each syringe contains 64mg of ultra-pure, high-molecular-weight HA (800-1200 kDa), formulated to support hydration, firmness and tissue vitality without adding visible volume, according to the distributors. Fox Pharma and MedFx add that the product uses Regenyal’s proprietary PHYSIOLOGIC TECH, a controlled production process designed to create a stable HA structure without chemical cross-linkers or 1,4-butanediol diglycidyl ether. Dr Hasaneen Al Janabi, founder of Dr Hass Clinic and lead UK key opinion leader, commented, “AUTENTICA sits somewhere between improving skin quality and creating a subtle structural effect. This allows for a much more considered approach to product placement, with the aim of supporting the skin’s natural structure and creating a subtle lifting effect.” On The Scene

Candela hosts treatment launch Medical device company Candela held an event for the debut of its new Glacē facial treatment at the Broadwick Soho hotel in London. Delegates attended a breakfast and networking session before a panel discussion featuring aesthetic practitioners Dr Wassim Taktouk, Dr Brendan Khong, Dr Zoya Awan and Dr Ariel Haus. Dr Taktouk explained that the protocol combines microdermabrasion for cleansing and exfoliation; hydro-infusion with targeted serums; two cupping massage stages intended to support sculpting and lymphatic drainage; and either a light-emitting diode or thermal finishing step. According to Candela, Glacē designed to target concerns including dullness, uneven texture, dehydration, fine lines and congestion. Alex Moulle-Berteaux, chief marketing officer for Candela, commented, “Building on Glacē’s momentum in the US, we wanted to introduce it to the UK through four of the country’s leading aesthetic practitioners, bringing their professional perspectives, first-hand experiences and genuine interest in the technology to the conversation.” Aesthetics | November 2026

Aesthetics’ festive gift guide Discover the latest gift set collections for this year’s festive season SkinCeuticals unveils four gift sets Skincare company SkinCeuticals has released four festive sets. The SkinCeuticals Radiance Regime Set features a 30ml P-TIOX Serum and a 15ml P-TIOX Cream, designed to target skin clarity and surface smoothness, according to the company. The next gift set is the SkinCeuticals Strength & Repair Set, which includes a 48ml Triple Lipid and 15ml of C E Ferulic, designed for mature skin and protect against atmospheric skin ageing, shares SkinCeuticals. An additional set includes SkinCeuticals A.G.E. Defying Set, featuring a 48ml A.G.E. Interrupter Advanced Cream and 15ml A.G.E. Interrupter Ultra Serum, aiming to target visible signs of ageing and maximise visible lifting. The last set, SkinCeuticals Glow & Pump Set, includes 30ml C E Ferulic and 15ml P-TIOX Serum designed to protect against environmental stressors and improve the appearance of contraction lines. AestheticSource launches two festive collections Aesthetic distributor AestheticSource has unveiled two sets, across skincare companies Senté and Revision Skincare. The Senté Bright & Balanced Edit is a four-piece skincare collection featuring the Daily Soothing Cleanser, Defense C Serum, Hydrate+ Serum, Dermal Repair Cream and a cosmetic bag. According to Senté, the products are designed to brighten, hydrate and soothe by supporting the skin’s moisture barrier and improving the appearance of uneven tone, texture and redness. The Revision Skincare Skin & Lip Replenish Kit combines the Gentle Cleansing Lotion, D·E·J Daily Boosting Serum, YouthFull Lip Replenisher and a cosmetic bag to enhance radiant skin and hydrated lips, according to the company. Waken debuts two Christmas gift sets British oral care brand Waken has entered the Christmas gifting market for the first time, launching two products. The range includes a Whitening Toothpaste Cracker and Sonic Smile Washbag, which features a sonic toothbrush and oral care essentials. According to the company, the launch, supported by investor and creative director Rylan Clark, builds on Waken’s growth, with sales increasing 45% year-on-year and distribution exceeding 1,350 UK stores.

13


Insider News

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Business Conference

RISE Global Summit 2026 welcomes guests Medical aesthetics and business event RISE invited specialty individuals to the Global Summit in Houston, Texas. Founded by digital marketing specialist Rick O’Neill and nurse practitioner Cheryl Haseeb, day one of RISE featured continuing medical education-accredited sessions, covering clinical and business-related topics. Day two focused on practical clinical training and business development. Attendees rotated through six hands-on clinical education stations led by experienced providers, while business presentations covered financial key performance indicators, exit planning and leadership characteristics associated with the effective management of medical aesthetics practices. The programme concluded with a stage presentation combining cadaveric demonstration and live injections. Speaking with Aesthetics, O’Neill commented, “The faculty we pulled together is never seen in the same room at the same time again, and the energy that was created around the inspiring talks, cutting edge training and life-changing conversations, was electric. It’s a must-attend event in 2027 if you want to take your practice to the next level.” Skincare

AlumierMD introduces retinol launch Skincare company AlumierMD invited Aesthetics to its unveiling of two retinol products in Shoreditch, London. Following from the launch of the 0.3+, the event introduced IntelliRET 0.5+ and 1.0+, with the company highlighting that the IntelliRET series is supported by the brand’s proprietary Intelligent Retinol technology. The product features niacinamide – aiming to reinforce the skin barrier and a matrix-supporting peptide to enhance the skin barrier, according to AlumierMD. AlumierMD key opinion leader and aesthetic practitioner Dr Tom Kamal commented, “The new high strength IntelliRET 0.5+ and 1.0+ support skin tolerance and barrier function by combining encapsulated retinol with a bio-inspired botanical booster to enhance retinol’s tolerability and efficacy. This enables patients’ consistent use, unlocking better long-term results, providing a clear progression pathway for safe advancement to higher strengths.” Longevity

VIVE-LONDON releases health supplement The longevity brand of Inside Out Biotech, VIVE-LONDON, has launched VIVE-GLYNAC, a new glutathione-precursor supplement designed to support cellular health. According to the company, VIVE-GLYNAC contains 300mg of N-acetylcysteine and 300mg of glycine per capsule, with a recommended daily serving of up to three vegan capsules. The supplement is manufactured in line with GMP standards and undergoes third-party testing. Annoushka Hempel, director of VIVE-LONDON, said, “Aesthetic patients increasingly want results that start at a cellular level, not just on the surface. Quality, purity and integrity are at the heart of everything we do, which is why clinics trust our independently tested NAD+. With GLYNAC, NMN and the Explorer Pen, practitioners can build that same standard into a complete programme.” 14

Aesthetics | November 2026

News in Brief Training academy debuts Medical aesthetics clinic KAST, led by nurse prescriber Amy Bird, has launched KAST Academy. According to Bird, KAST Academy is an independent training academy for aestheticians, advanced skin therapists and medical professionals. Its programmes cover foundational qualifications and advanced skin health management, including skin anatomy, skin disease management, dermoscopy, assessment skills and appropriate referral. A partnership with aesthetic distributor Healthxchange also provides access to training, business support and development opportunities. ChitoCare Beauty introduces cleanser Icelandic skincare company ChitoCare Beauty has released its Waterless Enzyme Cleanser. ChitoCare shares that this powder-to-lather cleanser exfoliates the skin and removes makeup and impurities. Its formula contains papaya fruit extract, papain extract and protease, which aim to help break down dead surface skin cells and refine skin texture, explains the company. ChitoCare adds that marine chitosan, a marine-derived biopolymer also used in medical wound care, is included to help support the skin barrier and maintain skin comfort. Phorest unveils insights into patient booking expectations Software solution company Phorest has unveiled a new patient report titled The Modern Patient Experience 2026-2027. The report analysed responses from 795 patients and found that effective communication remains a key priority throughout the patient journey. Orla Phelan, director of MediSpa and Medi-Aesthteic Operations at Phorest, commented, “An enquiry, booking confirmation, consultation form, reminder, treatment quote or follow-up message may seem operational from the clinic’s perspective.” Nordberg Medical hosts clinical forum Aesthetic manufacturer Nordberg Medical invited practitioners to its Expert Forum in London, forming part of its international roadshow conference series. The series explores the science and clinical application of collagen bioregeneration, including Nordberg Medical’s PLLA-LASYNPRO platform, which is used in poly-L-lactic acid biostimulator JULÄINE.


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

ASA Scrutiny Grows Over Peptide and Wellness Claims

News Feature ASA Guidelines

adverts mustn’t make medicinal claims for unlicensed products and prescription-only medicines (POMs) cannot be advertised to the public.2,3

Aesthetics reflects on the ASA’s latest report on online health claims and what practitioners need to consider when marketing treatments Advertising statements for research peptides, hair-regrowth treatments and hormone-balancing products are among the health claims facing scrutiny in a new report from the Advertising Standards Authority (ASA).1 The Pulse Report: Understanding Health Claims in Online Ads examined online advertising across seven priority areas, including research peptides, women’s hormonal health, menopause, men’s sexual performance and hormonal health, as well as hair loss.1 The report uncovered that 43% of research-peptide adverts assessed were rated high risk, which are considered more likely to breach UK advertising rules.1 Many adverts also implied the products were for consumer use, by offering small order quantities, direct WhatsApp ordering, discounts, fast home delivery, discreet shipping and linking product benefits to specific health, body goals or symptoms.1 Elsewhere, 15% of hair-loss adverts were rated high risk, while 10% of adverts relating to men’s hormonal health and sexual performance received the same rating.¹ To understand this topic in more detail and where practitioners may be unknowingly at risk of a breach, Aesthetics spoke with communications consultant and founder of Kenrick PR Julia Kendrick, and Isabel Dharmasiri, media relations officer at the ASA.

Where the ASA identified the greatest risk The ASA identified risk across several online health-advertising categories. The ASA found that “research use only” and “not for human consumption” disclaimers did not always align with the adverts’ imagery, messaging or route to purchase on research peptide products.¹ Some used coded language alongside images of vials, syringes and refrigerators – an approach the ASA says can make the products harder for platforms to identify, while remaining recognisable to interested consumers.¹ Peptide adverts were also linked to weight loss, menopause, polycystic ovary syndrome, diabetes, pain, hair loss, anxiety and recovery, at times positioning products as alternatives to established care.¹ Women’s hormonal health, fertility and menopause was the report’s largest category, encompassing 16,530 adverts; 83% were rated medium risk and a further 4% were rated high risk.¹ The report also identified adverts aimed at people using glucagon-like peptide-1 medications, including claims relating to side effects such as nausea, bloating, fatigue and hair loss.¹

Understanding ASA positioning Dharmasiri explains that claims must be evidence-based. “Claims about balancing hormones, reversing ageing, restoring hair growth or alleviating symptoms must be properly substantiated and must not mislead consumers about what a treatment can realistically achieve,” she says. In addition, Dharmasiri warns that

For practitioners, Kendrick believes that aesthetics can be especially exposed, given the wide range of devices, treatments and services marketed online. She adds that reassurance-based language can often create a further compliance risk, referring to wording such as “No downtime,” “no side-effects,” “natural” and “suitable for everyone” as potentially reducing a patient’s perception of risk. Kendrick adds, “This precisely why regulators scrutinise them,” she notes. Kendrick adds that terms like ‘Botox’ are effectively a household name with high consumer awareness and recognition, adding, “Practitioners can sometimes forget they still must abide by the stricter POM regulations when it comes to discussing these treatments.”

Competitive pressure and compliance risk From Kendrick’s experience, some practitioners feel pressure to differentiate their services as the market is extremely competitive, which therefore makes them more vulnerable to overstating what treatments can deliver. “With so many clinics now competing for consumer attention and consideration – many of whom are using the same (or interchangeable) categories of treatments – the temptation is to compete on outcomes, and this is exactly where claims can get stretched,” she notes. She continues by saying that competitive pressure may also make some clinics feel the need to rush their communications and marketing, potentially cutting corners or not checking as thoroughly in the rush to ‘get out there’ and be ‘the first’ with a new treatment. Dharmasiri is clear that from an ASA standpoint, if the regulator discovers an advert breaks the rules, they generally require the advertiser to amend or withdraw it. This may be in the form of a formal ruling, which is published on the ASA website.4 She adds, “If an advertiser continues to break the rules, we have a number of further sanctions available to us, including working with online platforms to have non-compliant adverts removed. In some instances, we may also refer cases to other relevant regulators, such as the Medicines and Healthcare products Regulatory Agency where there are concerns about potentially medicinal products or claims that fall within its remit.”5

Staying compliant with the ASA For practitioners looking to avoid any potential breaches of ASA guidelines, Dharmasiri explains that they should make sure that any claims they make about a treatment are accurate, backed up by evidence and give people a realistic idea of what they can expect.6 They should avoid exaggerating the benefits or promising results they can’t guarantee. Dharmasiri continues, “Ultimately, adverts should give people clear, truthful information to help them make informed decisions about whether to go forward with a treatment.” To help practitioners distinguish between providing useful, educational information about a treatment and making claims that could mislead patients, Kendrick advises that a simple way to judge content is to ask whether it helps someone make an informed decision, or whether it is simply designed to make them feel they need treatment. “Practitioners carry real authority, so they need to use it carefully. It helps to be clear about the difference between fact and professional opinion,” she concludes. VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026

15


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

UK Government Announces Proposed Restrictions for High-Risk Procedures Aesthetics explores the Government’s proposals for tighter rules on who can perform high-risk procedures The Department of Health and Social Care (DHSC) has announced a consultation on proposals to restrict high-risk cosmetic procedures to regulated healthcare professionals.1 Under the draft rules, injecting filler into parts of the body other than the face would be legally classified as cosmetic surgery. This would include liquid Brazilian butt lifts (BBLs), in which filler is injected into the buttocks, and would therefore mean that only doctors could perform the procedures.1 Other treatments classed as high risk – including deep chemical peels, platelet-rich-plasma (PRP) facials, dermal micro-coring and certain laser procedures – would be restricted to doctors, dentists and specified nurses, midwives and pharmacists who have completed an accredited training course, which means they are legally authorised to prescribe medications to patients.1 Only nurses, midwives and pharmacists who have completed an accredited training course, which means they are legally authorised to prescribe medications to patients. The precise scope of those restrictions remains subject to consultation.1 The proposals would also prevent under-18s from undergoing high-risk cosmetic and wellbeing treatments.1 Cosmetic botulinum toxin injections and dermal filler for under-18s are already restricted under separate legislation.2 In addition, the DHSC states that providers who breach the proposed rules could face criminal proceedings and unlimited fines, or fixed penalties of up to £4,000. These measures are not yet law.

Debating what constitutes a high-risk procedure Reacting to the proposed restrictions, the Aesthetics Clinical Advisory Board (CAB) says restricting the highest-risk procedures to regulated healthcare professionals is the right approach. They commented, “For years, patients have had no reliable way of knowing whether the person holding the syringe or the laser has undergone appropriate training, understands the fundamentals of the procedure or would recognise a complication, let alone manage one.” In addition, the CAB welcomes the proposed ban on treatments for under-18s, stating, “Young people are too often offered procedures they do not need and cannot properly consent to, and this measure would offer them meaningful protection.” Questions remain, however, about which procedures should fall within the highest-risk category. The CAB questions whether body filler should be classed as surgical. “This is something the consultation will need to consider carefully. It is a high-risk treatment and should rest with practitioners equipped to deal with complications but defining it as surgery may not be the most appropriate solution,” they explain. Dr Sophie Shotter, aesthetic practitioner and president of British College of Aesthetic Medicine, raises a related concern about the exclusion of facial fillers from the proposed high-risk restrictions. She elaborates, “Dermal fillers carry significant risks, including rare but catastrophic outcomes such as blindness and stroke, particularly when involving

News Special Proposed Regulation

high-risk areas like the nose. There is an inconsistent approach to risk assessment.” For Dr Shotter, this reflects a wider failure to recognise that aesthetic interventions require medical oversight, regardless of how “properly” a practitioner claims to perform them. Gareth Lewis, chief executive officer of the British Association of Medical Aesthetic Nurses (BAMAN) says BAMAN are pleased to see patient safety and professional accountability at the centre of these proposals. However, he notes it is essential that the regulatory framework goes beyond professional registration alone. Lewis adds, “Practitioners must be able to demonstrate appropriate education, training and clinical competence in the specific procedures they undertake, supported by clear standards for managing complications and providing safe patient care.” He also highlights that access to emergency medicines, appropriate clinical oversight and how the proposed requirements will operate for nurse-led aesthetic practices needs to be addressed.

What a licensing scheme needs to achieve The consultation follows the Government’s announcement in August 2025 that it would prioritise restrictions on the highest-risk procedures and develop a separate local authority licensing scheme for lower-risk treatments, including botulinum toxin injections and facial fillers.3 Those plans followed a 2023 consultation on non-surgical cosmetic procedures, which received nearly 12,000 responses.4 Separate to the consultation, the Government stated that it remains committed to implementing a licensing scheme to ensure that clinics delivering botulinum toxin products, dermal fillers and other lower-risk treatments meet strict safety standards.1 Paul Burgess, chair of the Association of Dental Aesthetic Practitioners, notes that the enforcement of regulation in the Amber category, which includes injectables and dermal fillers, will fall to local authority Environmental Health Officers (EHOs). “There will be a major debate around training and resources for EHO as local authorities face many financial pressures on budgets,” he believes. Lewis says the separate scheme should address the full patient journey, rather than become a paperwork exercise. “We believe this needs to establish meaningful and enforceable standards for training, premises, infection prevention, patient assessment and the management of complications, rather than simply introducing another administrative requirement,” he adds. Lloyd Bracey, chair at the Joint Council for Cosmetic Practitioners, commented, “We urge the Department to maintain momentum by moving promptly to implement the next phase of regulation for Amber and Green categories, ensuring public protection across all levels of aesthetic practice.” Dr Shotter calls for the separate scheme to be introduced promptly, with safeguards that patients can verify. “The scheme should license both the practitioner and the premises and set one national training standard.” She also calls for a public register and mandatory reporting of complications. “Without enforcement, a licence is just an impressive looking certificate on the wall,” she concludes.

Deadline and next steps The consultation invites clinicians, regulators, businesses, members of the public and other specialists to give their views on the draft regulations, with the survey remaining open until 11:59pm on January 13. The proposals are then expected to proceed to the parliamentary process in spring 2027, although the measures remain subject to consultation and are not yet law. The CAB concludes, “With thoughtful design, adequate investment and continued dialogue, this consultation could mark a real step forward, and it is an opportunity we should all embrace.” VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026

17


EVERY TREATMENT DESERVES RECOVERY The post-procedure skincare recovery protocol from Epicutis. As clinicians, you're already aware that every injectable treatment triggers an inflammatory response as skin repairs. Epicutis combines clean, conscious, clinically proven formulations with patented biotechnology, designed specifically for post-procedure skin.

Learn how to generate incremental revenue for your clinic, with no additional chair time. Scan to discover more, or visit shop.healthxchange.com

E XC LUSIVE LY D I ST R I B U T E D BY


Protect your patients' investment by adding one simple, yet effective solution: The Recovery Care Set.

“ The Epicutis Recovery Care Set is something I can’t live without in my clinic. It’s a low-cost add-on that I recommend to patients following treatment. I’ve found it’s incredibly effective at settling inflammation and supporting recovery. ” Dr Marcus Turner, Aesthetic Doctor, The Heath Clinic, London


CCR Post-show report

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Shaping the Future of Medical Aesthetics CCR 2026 delivered evidence-based education and breakthrough innovations

The UK’s largest medical aesthetics conference, the Clinical Cosmetic Regenerative Congress (CCR), welcomed 4,078 attendees, 160+ exhibitors and 170+ speakers to Excel, London, on October 1-2.

enabled visitors to gain up to 16 CPD points. This was complemented by a vibrant event floor and a diverse range of organisations taking part.”

This year’s Headline Sponsor was Galderma, and delegates were welcomed on arrival by aesthetic distributor Healthxchange, the event’s registration sponsor.

She continued, “I would like to extend my sincere thanks to every speaker who contributed their knowledge, latest research and practical demonstrations. We were particularly honoured to welcome our international Keynote Speakers, Dr Tapan Patel and Dr Tatjana Pavicic, whose insights into regenerative medicine added a valuable global perspective to the programme. Thank you also to our sponsors, exhibitors, partners and the Clinical Advisory Board. We look forward to bringing the community together again at our next event, the Aesthetics Conference & Exhibition (ACE), in March, 2027.”

Shannon Kilgariff, event director and publisher of the Aesthetics portfolio, said, “CCR 2026 brought together an exceptional community of medical aesthetics professionals, specialty leaders and innovative brands, with a 6% visitor increase from 2025. The calibre of education across the scientific and business programme, as well as the Medical Longevity Summit (MLS), was remarkable, and 20

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

CCR Post-show report

Educational highlights from Headline Sponsor Galderma Pharmaceutical company Galderma returned as CCR Headline Sponsor to deliver educational insights and live demonstrations. In the first session with Dr Yusra Al-Mukhtar and Dr Jessica Halliley, attendees were able to explore the specific science of the menopausal face and learn a structured, practical approach to treating it. On Day 2, nurse prescriber Mary Irving and Dr Natalie Ball combined expertise from cosmetic dentistry and aesthetic nursing to explore a multidisciplinary workflow for the perioral region.

International and regenerative insights at the Aesthetics Journal Arena Bringing the Aesthetics Journal to life, this Arena was the go-to place for the latest scientific research and innovative techniques. International Keynote Speakers Dr Tatjana Pavicic and Dr Tapan Patel opened the show, presenting the latest scientific and clinical updates shaping the future of regenerative treatments, alongside video demonstrations and practical insight for today’s practitioners. Other highlights included a full-face live demonstration from Miss Priyanka Chadha, Dr Lara Watson and Dr Lee Walker; as well as a live demonstration performing profhiloplasty on a GLP-1 patient with Professor Bob Khanna. Regenerative medicine took to the forefront on Day 2, with Dr Souphi Samizadeh chairing an educational agenda covering fat grafting, fat regeneration and maxillofacial biomaterials. The Aesthetics Challenge returned this year, focusing on Mastering Precision Injectables in the Periorbital Zone. Chaired by Dr Tahera Bhojani-Lynch and Mr Richard Scawn; Dr Zunaid Alli, Dr Asad Naqvi and Dr Raul Cetto took to the stage to perform three live injectable demonstrations, while guiding delegates through structured assessments of the periorbital area, patient selection and consent, and an outline of dermal filler techniques.

Injectable techniques at the Aesthetics Mastery Theatre Top brands showcased their latest techniques through live treatment demonstrations at the Aesthetics Mastery Theatre featuring key opinion leaders (KOLs). Lunchtime Takeover Sponsor IBSA explored the burden of genitourinary syndrome of menopause, showcasing the Hyaluxelle injection procedure using a vulval simulator. Dr Alex Parys and Dr Max Greenfield also took to the stage on behalf of the company, treating two patients with injectable Profhilo Structura. Other companies which took to the Mastery Theatre included Amedica, Beautyform, Cutera, InMode, Klira, RELIFE. Dermapenworld celebrated the launch of its new treatment platform Dp SYNERGIST.

The Aesthetics Results Awards This year saw the launch of the Aesthetics Results Awards. Judged by Dr Catherine Fairris, nurse prescriber Sharon Bennett and Mr Dalvi Humzah, the Aesthetics Results Awards brought the Finalists’ case studies to life on stage as part of a live awards ceremony celebrating excellence in aesthetic practice. After a presentation by the top two practitioners in each category, the Winners were decided live on stage. The Winners will become automatic Finalists for The Aesthetics Awards. The Winners were: Best Full Face Transformation Using Injectables: Dr Ana Mansouri Best Skin Transformation: Dr Ophelia Veraitch Best Body Transformation: Michelle Mclean Most Challenging Aesthetic Case Study: Dr Cemal Kavasogullari

Business insights at the In Practice Zone Designed for practitioners and clinic owners at every stage of their career, the In Practice Theatre, supported by Theatre Sponsor Phorest, delivered practical, real-world insights on a variety of topics such as marketing, social media, patient engagement, as well as personal and business growth strategies. The annual Aesthetics Trends and Product Launches Report, sponsored by Klira, was launched to delegates during a session with founder of Rare. Ben Pask. The report, complied in partnership with Rare., draws on insights gathered from thousands of aesthetic clinics and distributors across the UK, and presents data on the most in-demand treatments, emerging treatment categories and areas experiencing a decline in popularity. The report was distributed to CCR attendees, and is currently available online exclusively for press and Aesthetics Journal subscribers. Other highlights included the Getting Started in Aesthetics agenda with partner Harley Academy, a panel on how to build brand presence, and a debate on protecting the professional title ‘nurse’. As the licensing scheme had not yet been announced by October 1-2, nurse prescriber Julie Scott chaired the 2026 Regulatory Update: Key Developments and Future Directions session. Andrew Rankin, Gareth Lewis and Sadie Van Sanden Cooke joined her to discuss the current regulatory landscape, proposed licensing requirements, training and competency standards, insurance, premises and patient safety.

Discovering new concepts at the Innovation Forum The Innovation Forum, with Theatre Sponsor Seriderm, provided delegates with 25-minute workshops and live demonstrations. Each session provided delegates with direct access to the latest products, protocols and techniques from some of the specialties most forward-thinking practitioners and suppliers. The stage featured the launch of several new products including Xerf from Seriderm, the PRX-S Advanced Skin Booster from M&S Pharma Group and EMFUSION with BTL Aesthetics. The Injectable Experience took place across Day 1, featuring sessions from Ameela, Teoxane and VIVACY showcasing hero products including Ameela, Teoxane RHA 4 and Novuma. Brand representatives and KOLs took the stage to represent companies including:

· · · · · · ·

ALMA Ameela Asclepion LaserTechnologies BTL Aesthetics Candela Fotona UK

· · · · · ·

M&S Pharma Group Novus Medical Promoitalia Sciton Seriderm UK & Ireland Sofwave

Hydrafacial

Aesthetics | November 2026

21


CCR Post-show report

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Where science meets wellness This year, the Medical Longevity Summit (MLS), which was co-located at CCR and sponsored by Nicoya Health, focused on inside-out ageing, optimising metabolic health for longer, better lives. The education was showcased across two stages: The Future Health Forum and The Discovery Stage. Curated in collaboration with Dr Mayoni Gooneratne, founder of Human Health Professionals, the programme featured expert insights and evidence-based strategies to support patients through integrative, regenerative and lifestyle treatments, helping clinics expand their wellness offering in this fast-growing area. International MLS keynote Dr Nasha Winters delivered insightful sessions on ‘Why Metabolism Matters’ and ‘Metabolic Health and Cancer Risk’ as well as leading a panel on the future of metabolic health.

Every year, CCR presents awards at the end of day 2 to recognise the hard work and effort by brands and speakers. Best Stand – Healthxchange Best Marketing Campaign – Roseway Labs Most Impactful Launch – Dermapenworld Best Visitor Experience – Galderma Most Influential Speaker – Vanessa Bird

On Day 2, the stage focused on hair, scalp and skin. Expert-led sessions by leading aesthetic practitioners and trichologists, explored a rounded perspective on diagnosis, treatment planning and patient care or advancing your role in medical aesthetics. Sponsors included Million Dollar Facial, Xyon Health, Sons, EMA.

The latest innovations in medical aesthetics As well as unmissable education, CCR offered delegates the opportunity to network and discover with more than 164 exhibitors on the show floor. Several of them offered education on their stands through Stand Seminars, including Deleo, IBSA and Galderma.

The new Spotlight Stage This year’s CCR introduced the dedicated Dentists in Aesthetic Practice Stage, with Theatre Sponsor Hawksley & Sons, on Day 1. The stage was created for dental professionals who are exploring, building or advancing your role in medical aesthetics. It was home 22

Companies at the Discovery Stage included Altheome, AlwaysSmile Medical, BIOguided, Fermented Green Papaya Enzyme, HALO IV, iiaa, Inside Out Biotech Ltd, Map Health, My Vital Metrics, Nicoya Health, Nuchido, Roseway Labs, The Power in Your Hands, Totally Derma and Wild Nutrition. to the launch of the brand new Dentists in Aesthetics Practice association, led by Paul Burgess.

Recognising excellence through CCR’s Award Winners

· · · · ·

On the success of the summit, Dr Gooneratne commented, “Metabolic health underpins so much of how we feel, function and age, which is why we placed it at the heart of this year’s Medical Longevity Summit at CCR. Our incredible speakers brought such depth of knowledge, energy and passion, connecting the science with what we can actually do for the person sitting in front of us. That’s what excites me most: helping clinicians turn that understanding into care that supports our patients’ health, now and for the years ahead.”

CCR brought delegates the latest products, services and solutions through the easily accessible Innovations Trail. The trail provided a direct way to discover the most influential products on the UK market, and tours were held each day to give delegates an interactive way to discover the latest in medical aesthetics.

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

CCR Post-show report

The products in the trail included:

Your next aesthetics event

Aerolase – Neo Elite BIOguided – BIOguided BTL – EMFUSION Galderma – ALASTIN Restorative Skin Complex IBSA – Hyaluxelle Medik8 – Exo-PDRN Prismatic+ Pro Concentrate Ninaveli London – NAD+ NMN Promoitalia – EXO-NAD Renaissance – X Blast Roseway Labs – Gold Peel Mask The Korea Zone also returned this year, in partnership with the International Beauty Industry Trade Association (IBITA), which showcased cutting-edge technology new and yet to be launched into the UK market. It enabled delegates to understand where innovation is heading internationally.

CCR might be over, but the education continues at your next aesthetics event: ACE 2027.

· · · · · · · · · ·

Uniting the medical aesthetics community As well as educational learning, CCR helped delegates to expand their professional community through the networking trail, sponsored by M&S Pharma Group. Throughout the two days, delegates experienced:

· Speaker & VIP Networking Hour drinks at the Dermapenworld VIP Lounge

· Aesthetics Journal Networking Drinks at the Aesthetics Lounge · Brands of Aesthetics Networking Drinks at the Aesthetics Lounge · Official CCR Networking Event & drinks reception at the Galderma & CCR Networking Lounge, with dedicated areas for nurses, doctors and dentists, as well as MLS visitors. Across the two days, the Aesthetics Journal hosted an exclusive, invite-only Roundtable Series, bringing together a carefully selected group of leading professionals to take part in informed, forward-thinking discussion on the issues shaping medical aesthetics today. Aesthetics Mentoring also returned to foster meaningful connections between aspiring and established professionals in the aesthetics specialty.

Taking place on March 12-13 at the Business Design Centre, ACE will once again empower the aesthetics community. 2027 sees the launch of the brand-new Aesthetics Business Show (ABS), transforming clinics into high performing businesses. And that’s not all! The Aesthetics Awards will be back with a bang after the second day of the conference, returning to the dazzling Grosvenor Hotel. Finalists for the event will be announced in our January issue, but tickets are on sale now. Make sure to purchase your tickets before December 31 to receive the early bird rate. We can’t wait to see you all again soon!

Hear from CCR attendees… “What I enjoy about CCR is the variety. You can attend talks to build your knowledge, connect with peers in the aesthetics community and discover the latest products and technology from the companies exhibiting. There’s so much to see and do.” Dr Bisma Hussain “CCR is a highlight of my professional calendar. Aesthetics can be isolating, so it’s invaluable to connect with colleagues, exchange ideas and techniques and discover innovations from both established and emerging manufacturers. While hands-on skills require dedicated training, CCR provides a forum for discussing evidence-based treatments and evaluating manufacturers’ efficacy claims. A critical, analytical approach is essential. Above all, it’s a genuinely positive networking opportunity across the field, and one I look forward to every year.” Dr Thana’a Mohajer “I keep coming back to CCR every year because I always find interesting new trends, and it’s great to see like new perspectives from other practitioners and people that deal with the business of running a clinic.” Nefise Tasdelen

Find out more

Aesthetics | November 2026

23


Special Feature Male Profile

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Illustrating Profile Balancing for Male Patients Practitioners outline their injectable approaches to achieve male profile harmonisation Profile balancing is the process of assessing how the key anatomical features of the face work together to create a harmonious, proportionate and distinct profile.1,2 This involves considering the relationship between the forehead, nose, lips, chin and jawline, alongside the underlying bone structure and soft tissue that influence facial shape and definition.2,3 Interest in treatments targeting these areas is growing. In one survey of 700 men aged 18-55, one in five said they were likely to consider dermal fillers, with the jawline and chin among the most requested treatment areas.4 However, focusing on a single feature is only the starting point. While patients may present to clinic with a specific concern, a comprehensive clinical assessment can reveal other factors contributing to the overall facial profile. Rather than evaluating individual features in isolation, practitioners consider how the forehead, nose, lips, chin and jawline work together, assessing their proportions, projection and angles to identify where features complement one another and where adjustments may help achieve greater harmony while preserving the patient’s natural masculine characteristics.2,3 Although profile balancing is not a new concept, research specifically exploring male facial harmonisation remains limited.5,6 By reviewing the treatment protocols illustrated by our three interviewees, this feature aims to explore current approaches to male profile balancing and consider how the findings can inform clinical practice.5,6

Common male concerns and patient suitability Aesthetic practitioner Dr Asad Naqvi explains a common concern among male patients is a lack of definition between the face and neck and facial asymmetry, noting, “This is usually due to weight.”7 24

He adds that patients do not always recognise the underlying anatomical issue, instead expressing concerns such as having a nose that looks too large or a chin that sits too far back.8 “In some cases, addressing chin projection can improve overall facial proportions, even when the chin was not the patient’s initial concern,” Dr Naqvi notes.8 Skin quality and tissue thickness are also important considerations, according to Dr Naqvi.9 “Patients with very thin skin may be more challenging to treat, as a thicker product is required to mimic the underlying bone structure, potentially resulting in visible lumps where there is insufficient skin and fat to provide adequate coverage,” he explains.10 Conversely, Dr Naqvi adds that excessive fat in the area can also compromise the outcome, limiting the definition achievable through treatment.11 Aesthetic practitioner Dr Chris Hutton believes male expectations are aligned with the rest of the population for profile balancing.12 “Male patients will request specific changes to the jawline and chin; they want definition, they want change, but a natural and subtle looking result,” he shares. In comparison to female expectations, Dr Hutton outlines that the general shift towards natural results is prominent, regardless of sex.13 He notes that a weak or retruded chin is a common concern amongst men, who have traditionally used beards to conceal it.14 “In profile, the chin should sit roughly in line with the base of the nose and lower lip. When the chin sits noticeably behind the lower lip, particularly by around 1cm or more, it may indicate significant chin retrusion,” Dr Hutton illustrates.15 The nose is a common source of insecurity for patients, whether due to a prominent bump or other features that affect their profile,

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Dr Hutton explains.16 He also highlights facial asymmetry as a frequent concern, adding, “The differences in the projection of the jaw angles or the height and position of each side of the chin when viewed from the front. These subtle imbalances can affect overall facial harmony.”17 Ophthalmologist Dr Tahera Bhojani-Lynch examines the stigma surrounding male patients in aesthetics, saying, “The main catchphrases are; ‘Don’t make me look overdone, don’t make me look feminine, nobody can know.’” She adds, “Some men worry that visible aesthetic treatments may undermine their masculinity, as skincare and beauty have historically been viewed as female oriented.”18 While Dr Bhojani-Lynch notices men don’t frequently approach clinic with specific profile balancing concerns, she outlines most of her male patients are experiencing crow’s feet and frown lines.19 She explains, “These concerns act as an initial motivator for male patients to visit the clinic, creating an opportunity to introduce profile balancing as part of a broader discussion about facial aesthetics.” Before

After

Special Feature Male Profile

oris, all of which can influence treatment planning,” Dr Hutton notes.27 Drawing on the consultation process, Dr Bhojani-Lynch notes, “Although men may be less aware of changes to their side profile, before-and-after photographs can make the results more apparent.” She highlights the three-quarter view as particularly effective, explaining, “These photographs are often the money shots when cheek support and chin augmentation help create a smoother, more balanced profile.”28 Outlining the examination of anatomical features, Dr Bhojani-Lynch notes, “We assess male faces in some ways like female faces. We look for volume loss, and areas where we can correct this without exaggerating or changing the overall shape of the face.”28 Specifying this comparison, she continues, “We know that for women having a bit of anterior projection and curve will feminise the face. For men having a flat plane in that area, a marginal amount of curve is adequate.”28 Dr Bhojani-Lynch adds that jawline enhancement is about achieving the right proportions between the cheeks and jaw, rather than simply increasing width, explaining, “Widening the jaw does not necessarily improve attractiveness, so careful facial assessment is essential.”28 She shares that she first evaluates the masseter muscle during clenching to determine whether the jaw already extends beyond the cheeks. She explains that she prefers to assess the patient from a three-quarter profile, observing the mid-cheek groove that dissects the cheek, as this is often where apparent volume loss becomes visible.29 “This assessment also helps determine whether additional anterior chin projection could improve definition without creating excessive width. Rather than adding volume at the gonial angle, treatment may instead focus behind it to create a subtle backward stretch,” illustrates Dr Bhojani-Lynch.28

Treatment protocols Figure 1: 35-year-old patient before and seven days after one session of Radiesse. Images courtesy of Dr Chris Hutton.

The interviewees presented a range of case studies demonstrating male profile balancing, from single-treatment approaches to more comprehensive, multimodal treatment plans.

Assessing facial anatomy

Biostimulators

Dr Naqvi emphasises the importance of using consistent lighting and positioning when evaluating patients, noting that gravity can significantly influence facial appearance.20 Discussing assessment tools such as Ricketts lines, he stresses, “These are just guidelines, they all differ – beauty is subjective.”21 He adds that ideal proportions vary across ethnic backgrounds, reinforcing the need for a subjective, individualised approach to assessment.22 Dr Naqvi highlights several patient factors to consider when aiming to achieve profile harmony. He explains that a degree of existing jawline definition is essential for successful enhancement, sharing, “If there’s no clear definition between the neck and the jawline, you can’t simply create a jawline from nothing. You need an existing baseline of jawline to work with and enhance.”23 Dr Hutton describes the Steiner line as his preferred assessment tool, explaining that he uses it during consultations to ask, “What part is off, or is anything off?”24 He shares that the approach helps determine whether a patient’s perceived profile imbalance is reflected in their facial proportions, noting, “The assessment may reveal that the profile is already well balanced.” He explains that the Steiner line evaluates the relationship between the nose, lips and chin, while assessment of the neck remains observational.24,25 For male patients, Dr Hutton emphasises evaluating chin projection, height and width, mandibular angle and thickness from both profile and anterior views, alongside the neck and submental region.26 “Other considerations include skin thickness, facial hair, masseter bulk and muscle activity, including the mentalis and depressor anguli

Dr Hutton shares his case featuring a 35-year-old patient (Figure 1), noting the patient presented to clinic wanting to project his chin and define the jawline. He adds, “The patient had a little bit of asymmetry from the front view with his chin. So, his left side kind of sat a little higher than the right, which frustrated him.” To address these concerns, Dr Hutton used calcium hydroxylapatite (CaHA) exclusively, selecting Radiesse as his product of choice. The treatment was performed entirely using a 22G 50mm cannula. “The chin is highly vascular, full of anatomical variations, alongside the midline, so I use a cannula as a safer option with less downtime,” he notes.30 Dr Hutton adds that the procedure used three syringes of CaHA, 4.5cc, to achieve the desired balance of projection and contour.31 For jawline contouring, Dr Hutton described entering near the anterior mandible before advancing the cannula posteriorly.30 He administered CaHA using a combination of small boluses and linear threads, prioritising anatomical awareness to minimise the risk of complications involving the facial artery and anterior border of the masseter.30 He explains, “This entry point also allowed me to refine the chin’s shape and enhance projection, particularly around the oral commissures, creating greater depth and definition. A second entry point, positioned on the chin just lateral to the oral commissure, provided access to the remaining area for further projection and contouring.”30 Dr Hutton continues that injection depth varied according to the treatment area. He details, “Along the jawline, CaHA was

Aesthetics | November 2026

25


Special Feature Male Profile Before

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

“This helped create a straighter, sharper contour from the chin to the pre-jowl area,” he explains.31 4ml of HA filler was placed on each side of the jaw – alongside 0.5ml per pre-jowl sulcus – using a cannula to enhance definition along the posterior jaw and strengthen the jawline.41 In total, 14.9ml of dermal filler was administered, with the majority allocated to the jawline.

After

He explains that products with a high G′ (elastic modulus) are particularly suited to this purpose.42 “A higher G′ indicates a stiffer filler that is more resistant to deformation and compression, helping to maintain structural definition,” Dr Naqvi explains.42 He identifies the Restylane portfolio as his products of choice for these areas – including Restylane Lyft, Restylane Kysse and Restylane Volyme, citing its high G′ and suitability for achieving the projection and support required for profile balancing.43 Figure 2: 34-year-old patient before and two weeks after an individual session of Restylane. Images courtesy of Dr Asad Naqvi.

placed in the subdermal plane, while the central chin required deeper placement, ideally beneath the mentalis muscle. The remaining chin treatment was performed subdermally, with the same approach replicated on the opposite side.”32 He states that this protocol enhanced jawline definition, subtly increased the gonial angle and improved the anatomical relationship between the bizygomatic and bigonial widths to create a more balanced facial profile.33 Dr Hutton shares that, when using CaHA for male profile balancing, he typically allows four to six weeks for the final result to settle in, sharing that patients can expect results to last for 18-24 months.34,35 Specifying his case study results, he shares it was just one treatment session. He explains, “At that point, we review the result and decide if we’re happy with the outcome, or do we want to push it a little more? It’s reasonable to do a little bit more at that stage, but usually the patients don’t need any more than that.” Approaching a more complex profile case, Dr Hutton shares staging is best protocol, suggesting, “I’d treat the jawline and the chin, and then bring the patient back into clinic to do the nose and lips, usually leaving a minimum of two weeks to allow swelling to settle down, as with lips and nose they’ll be treated with HA injectables for an enhanced result.”36,37 Dermal filler Dr Naqvi introduces the case of a 34-year-old male patient who presented with a retruded chin, a drooping nasal tip, limited cheek definition and a jawline that blended into the neck (Figure 2). He notes that the patient had some existing structure to work with, providing a foundation for enhancement. Dr Naqvi also explains that the jawline was the patient’s primary concern, with the overall objective of establishing a more defined, structured jawline. Dr Naqvi began treatment with the lateral cheeks, using a needle to administer 1.2ml of dermal filler for each side. This established lateral definition and created a comet-tail effect, maintaining a relatively horizontal contour in line with the upper portion of the ear. Starting with the cheeks allowed the lateral facial structure to be addressed before moving on to the central and lower facial profile.38 Attention then turned to the nose, where 0.5ml of filler was placed along the nasal bridge and tip using a needle. He explains, “This helped refine the nasal profile and create a more masculine appearance, with a subtle elevation of the nasal tip.”39 Additionally, Dr Naqvi shares he administered 1ml to the nasolabial folds.40 Dr Naqvi next addressed the chin, administering 2ml of filler to increase anterior projection and provide slight inferior extension. 26

Explaining the treatment sequence for this individual profile-balancing session, Dr Naqvi describes starting at the top of the face and working downwards to achieve an overall balanced result. “By starting at the top of the face, it can lift the bottom slightly, and that changes the perception of lines. I left the jawline till the end. I do the chin before the jaw because by doing the chin, it can stretch the skin and make the jaw look sharper and make the jaw from the anterior aspect look more in line with the chin. Therefore, you end up using less filler overall.”44

“Profile balancing harmonises facial proportions and anatomical relationships while respecting individual features” Dr Chris Hutton

Combining dermal filler and botulinum toxin Dr Bhojani-Lynch follows a structured approach to male profile balancing, beginning with the mid-face and correcting the mid-face groove. Where under-eye laxity is present, she shares that she may add lateral support to create a subtle lifting effect. “I then address the chin and pre-jowl sulcus before assessing whether further contouring behind the gonial angle is needed, taking existing masseter width into account,” Dr Bhojani-Lynch notes.23 Jawline refinement is only considered if necessary, with Dr Bhojani-Lynch explaining that she often reassesses patients at four weeks before proceeding. She notes this is because improving chin projection and facial support can create sufficient lift and definition without additional filler. As she explains, “If you bring them forward nicely, all of this picks up. The result can be a sharper, more balanced jawline without necessarily having to run the filler along the jaw.”45 Detailing the results of her case study, Dr Bhojani-Lynch explains, “The patient complained of a ‘drop’ and felt he was sagging. His focus was on his nasolabial folds, and the temptation is to fill them simply because that is what he asked for (Figure 3).”

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

However, she adds that the underlying concerns were more complex, stemming from a loss of subcutaneous fat in the mid-face and labiomental triangles, alongside reduced skeletal support due to a loss of projection in the chin and maxilla. “Balancing the profile is about restructuring the skeleton with a filler that can sit on bone, integrate with deep fat and provide shape. You then use a product that moves naturally within the subcutaneous fat layer, supporting the skin without bunching or looking unnatural,” Dr Bhojani-Lynch notes. Discussing the treatment protocol, she outlines, “The initial treatment consisted of one 1.2ml syringe of Resilient Hyaluronic Acid (RHA) 4 dermal filler, injected into the cheeks and chin at a deep tissue level using a 4mm needle.” She adds that the jawline was treated via subdermal injection using a 25G cannula and botulinum toxin type A (BoNT-A) was administered to the glabellar complex, lateral canthal lines and forehead lines, with Azzalure being her product of choice.46 “Three months later, RHA 1 dermal filler, 1ml per temple, was administered at the subdermal level using a 25G cannula,” she continues. Dr Bhojani-Lynch shares that RHA 2 was injected to provide subcutaneous volume support, with 0.6ml administered to each side of the mid-face and 0.8ml to the forehead. Additionally, she notes the BoNT-A treatment was repeated across the same facial areas. Dr Bhojani-Lynch typically schedules a six-month review to assess how the filler is settling and identify any further volume loss or emerging concerns. She explains, “First filler review at six months is common in my clinic. This ongoing assessment supports a tailored approach to maintaining facial harmony over time.”

Highlighting aftercare and maintenance Dr Naqvi describes aftercare as relatively straightforward. He explains that swelling, bruising and tenderness are normal following treatment, while asymmetry may be temporary due to swelling.47 However, he cautions that vascular occlusion can present more than 48 hours after treatment, with signs including paleness and spots appearing on the skin.47 Dr Hutton outlines a structured aftercare protocol, explaining that patients receive written guidance advising them to avoid heat, exercise and alcohol for the first day or two following treatment. He also emphasises the importance of monitoring for potential complications, including pain, blanching, mottling and changes in skin colour.48 Maintenance should be guided by the patient’s own perception of their results, rather than a fixed schedule, says Dr Naqvi, noting, “I don’t like to allocate a set time or date to top up on treatments,” emphasising that patients should avoid returning for further treatment before it is necessary, as this can lead to unnecessary expense. Before

After

Special Feature Male Profile

Considering safety practices Dr Naqvi emphasises the importance of controlled injection pressure when administering dermal filler, noting, “Unexpected resistance may indicate intravascular placement and should prompt caution.” He advocates a conservative approach, using small boluses to limit the amount of product deposited at any one time and potentially reduce the severity of complications should vascular occlusion occur.48,49 He limits each injection to a maximum of 0.1ml, allowing him to monitor tissue responses closely throughout treatment, “This measured technique supports careful assessment and helps prioritise patient safety,” Dr Naqvi notes. He also advocates aspiration when using a needle, saying, “Although its reliability in identifying intravascular placement remains debated, I consider it an additional precaution within a broader safety-focused approach to filler administration.”48,49 Dr Hutton emphasises that safe profile balancing relies on detailed anatomical knowledge and selecting the appropriate plane for product placement. “In the lower face, particular attention must be paid to the facial, submental and mental arteries, as well as the mental foramen and its branches, to minimise the risk of vascular complications,” he states.9,50 He explains that he routinely identifies and marks the facial artery before treatment, using its position to guide entry points and avoid areas where major vessels converge. Along the mandible, he highlights the importance of avoiding deeper structures, including the submental artery, while treatment around the chin requires awareness of the mental artery and its branches.9,50 To reduce risk, Dr Hutton favours a cannula-based approach to the lower face, alongside small volumes, low injection pressure and continuous observation for signs of vascular compromise. He adds, “Strict aseptic technique, conservative treatment planning and clear protocols for managing vascular occlusion are fundamental to safe practice. Nasal filler carries particularly significant vascular risks and should only be undertaken with appropriate training and emergency preparedness.”48-50 Dr Bhojani-Lynch similarly highlights the nose as a high-risk area, noting that treatment requires a thorough understanding of its vascular anatomy. “Although nasal enhancement may be less commonly requested by male patients, those undertaking it must understand the anatomical considerations and risks involved,” she stresses.50,51 Elsewhere, she explains that injection depth should be adapted to the treatment area and the location of underlying vessels. “In the mid-face, where major arteries may lie more superficially, deeper placement may be appropriate in selected areas. Conversely, along the jawline, where the facial artery runs deeper, a more superficial plane may be preferable,” Dr Bhojani-Lynch notes. She adds that the chin may allow deeper placement in suitable areas, while the pre-jowl sulcus can also be considered with careful anatomical assessment.9,50

Achieving a successful result Concluding the aim of a male profile balancing case, Dr Hutton summarises, “Profile balancing harmonises facial proportions and anatomical relationships while respecting individual features. The aim is to enhance definition and achieve a naturally balanced facial profile.” All three practitioners emphasise the significance of anatomical understanding and knowledge for a case study improving profile harmony, due to the several areas, products and techniques administered. Figure 3: 58-year-old patient before and four months after two sessions of RHA 1, RHA 2, RHA 4 and BoNT-A. Images courtesy of Dr Tahera Bhojani-Lynch.

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026

27


Introducing the the 2D 2D Stack Stack Introducing

LASER GENESIS + LIMELIGHT IPL LASER GENESIS + LIMELIGHT IPL

Laser Genesis is already a clinic favourite. Combined with LimeLight IPL, it goes further, treating Laser Genesis clinic favourite. withfacial LimeLight IPL,build it goes treating two layers is ofalready skin in aa single protocol. Combined One signature you can intofurther, your clinic. two layers of skin in a single protocol. One signature facial you can build into your clinic.

T WO L AY E R S . T WO L AY E R S .

Cutera’s treatment, gently activatingsignature collagenmicro-pulse below the surface to smooth activating collagen below surface to smooth texture, soften fine lines and the calm persistent redness. texture, soften fine lines and calm persistent redness.

After Limelight + Laser Genesis

Before

Photos Courtesy of Nina Desai, DO. Patient results may vary.

Laser Genesis, working deeper

Photos Courtesy of Nina Desai, DO. Patient results may vary.

After Limelight + Laser Genesis

“Laser Genesis has been in my treatment room for years. What’s changed with “Laser been inchoosing my treatment room for years. with xeo+ isGenesis that I’mhas no longer between depths. I canWhat’s addresschanged the surface xeo+ is that I’m noinlonger choosing betweenwhich depths. address surfaceto and work deeper the same appointment, hasI can made a realthe difference and deeper in the appointment, which has made a real difference to how work quickly patients seesame change.” how quickly patients see change.” Dr Tatiana Mandavia Dr Tatiana Mandavia Doctors Tatiana + Rishi Advanced Aesthetics Doctors Tatiana + Rishi Advanced Aesthetics

See the xeo+’s 2D stack in action See xeo+’sdemo 2Dorstack in action Book athe personalised get in touch with your Cutera representative today. Book a personalised demo or get in touch with your Cutera representative today.

T WO L AY E R S .

After Limelight + Laser Genesis

Photos Courtesy of Nina Desai, DO. Patient results may vary.

Photos Courtesy of Mira Kaga, MD. Patient results may vary.

O N E T R E AT M E N T.

Before Before

Photos Courtesy of Mira Kaga, MD. Patient results may vary.

LimeLight IPL, at the surface

After Limelight After Limelight

Laser Genesis, working deeper Laser Genesis, working deeper Cutera’s signature micro-pulse treatment, gently

Cutera’s signature micro-pulse treatment, gently activating collagen below the surface to smooth texture, soften fine lines and calm persistent redness.

Before Before

After Limelight

“Laser Genesis has been in my treatment room for years. What’s changed with xeo+ is that I’m no longer choosing between depths. I can address the surface and work deeper in the same appointment, which has made a real difference to how quickly patients see change.”

Targetsredness, pigmentation, and diffuse refiningfreckles, tone andsunspots clarity across diffuse redness, refining tone the upper layer ofand skin.clarity across the upper layer of skin.

Targets pigmentation, freckles, sunspots and diffuse redness, refining tone and clarity across the upper layer of skin.

Before

Photos Courtesy of Mira Kaga, MD. Patient results may vary.

LimeLight IPL, at the surface LimeLight IPL, freckles, at the sunspots surfaceand Targets pigmentation,

Dr Tatiana Mandavia Doctors Tatiana + Rishi Advanced Aesthetics

See the xeo+’s 2D stack in action

Book a personalised demo or get in touch with your Cutera representative today.

O N E T R E AT M E N T. O N E T R E AT M E N T.


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

30 Years of Backing the Science Behind Healthier Skin

Advertorial British Skin Foundation

For every £1 invested by BSF, research projects typically attract a further £4.75 in external funding. Some seed-funded projects have secured further funding within three to four years, with the quickest securing follow-on funding just one year after the original BSF grant.

As the BSF celebrates 30 years, new analysis with the London School of Economics (LSE) is helping to quantify the impact of three decades of funding skin research

That means a relatively small investment can help unlock much more funding for dermatology research and give researchers the opportunity to take their work further.

Building the future of skin research The people behind the research matter too. Since 1996, BSF has supported more than 752 principal investigators, while more than seven in ten BSF-funded researchers remain in dermatology for at least five years. It is this combination of funding people, supporting ideas and building research capacity that has helped BSF’s reach grow across the UK and Ireland. For those working in aesthetics, this matters because research shapes the knowledge that underpins better conversations about skin. Practitioners are often asked questions that go beyond aesthetics, whether that is about a skin condition, a changing lesion or general skin health. Having access to reliable, evidence-based information helps practitioners know when to advise, when to reassure and when someone may need further assessment.

Looking back, and looking ahead 30 years is a significant milestone, but there is still so much we don’t know about the skin. The work supported by BSF today will help shape what we understand tomorrow. As the charity celebrates its anniversary this November, the LSE analysis provides an opportunity to look beyond the headline figures and see the wider impact of that investment. 520 projects. £23.9 million invested. And a research community that continues to grow. For BSF, the next chapter is about continuing to support the people asking the questions that could change the future of skin health.

Skin is changing. Our understanding of it is too. For 30 years, the British Skin Foundation (BSF) has supported researchers working to answer some of the important questions around skin health and disease. To mark the charity’s 30th anniversary, BSF has worked with the London School of Economics (LSE) to look at the reach and impact of that investment.

We are all united by skin.

The findings show just how far that first grant in 1996 has travelled.

This advertorial was written and supplied by

Since then, BSF has funded 520 research projects and awarded £23.9 million to dermatology research. Its grants have reached at least 23 of the UK’s top 30 universities, as well as 21 of the 24 Russell Group universities.1

Where progress begins BSF’s first research grant was awarded in 1996 to support research into dermatitis in the rubber industry. Since then, the programme has grown considerably, supporting research into skin cancer, psoriasis, wound healing and many other areas of skin disease.

For more information, resources and to get involved in our mission of funding vital skin disease research, visit britishskinfoundation.org.uk and follow @bsfcharity on social media

But the impact of a grant doesn’t necessarily stop when the project ends.

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026

29


BELOTERO Balance is now approved for the treatment of Infraorbital Hollow and Horizontal Forehead Lines1

Actual patient, individual results may vary.

1. BELOTERO® BALANCE. INSTRUCTIONS FOR USE. 2026.

Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk. Reporting forms and information for Republic of Ireland can be found at: https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events should also be reported to Merz Aesthetics UK Ltd by emailing UKdrugsafety@merz.com or calling +44 (0) 333 200 4143. ©2026 Merz Aesthetics UK Ltd – All rights reserved. MERZ AESTHETICS and BELOTERO logos are trademarks and/or registered trademarks of Merz Aesthetics UK Ltd in the United Kingdom. Registered in England No. 14506945. Merz Aesthetics Ltd, Ground Floor Suite, Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire, HP2 4TZ. www.merz-aesthetics.co.uk.

M-BEL-UKI-2111 Date of Preparation October 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

CPD Rheology

Understanding Dermal Filler Rheology Dr Alison Colville explores the physicochemical and rheological properties of hyaluronic acid dermal fillers Hyaluronic acid (HA) dermal fillers have become a cornerstone of modern medical aesthetics and remain one of the most widely performed non-surgical cosmetic procedures worldwide. Global use has increased substantially over recent years; International Society of Aesthetic Plastic Surgery data recorded approximately 4.05 million HA filler procedures worldwide in 2020, rising to 6.34 million in 2024, an increase of 56.4% over four years.¹ Although more recent figures show some fluctuation in annual procedural numbers, HA filler remained the second most commonly performed non-surgical aesthetic procedure worldwide in 2025.² This popularity is also reflected in the UK; dermal filler was the most commonly reported procedure among respondents to the Department of Health and Social Care’s consultation on the licensing of non-surgical cosmetic procedures, while the 2024 British Association of Aesthetic Plastic Surgeons audit reported a 27% year-on-year increase in dermal filler treatments performed by its members.3,4 Although fillers are often considered in terms of their intended indication or treatment area, as defined by the manufacturer, such as the lips, cheeks or jawline, these descriptions barely capture what are in reality highly engineered biomaterials that differ in manufacturing, crosslinking, gel structure and mechanical behaviour.5 This CPD article provides a practical overview of the properties that determine how any HA filler behaves once implanted, and of how understanding them supports better clinical decisions, whatever the manufacturer.

Figure 1: From linear HA to a crosslinked network.

What is HA dermal filler composed of? HA is a naturally occurring glycosaminoglycan found throughout the skin and connective tissues, where it binds large amounts of water and contributes to volume, hydration and viscoelasticity.3 In its native, linear form it is highly hydrophilic but short-lived; unmodified HA injected into tissue is broken down within a day or two, far too quickly to serve as a filler.5,6 To create a durable product, manufacturers crosslink the HA chains, most commonly using 1,4-butanediol diglycidyl ether (BDDE), which forms chemical bridges between chains and builds them into a stable three-dimensional network.5,7 It is this network, rather than the HA itself, that resists degradation and gives a filler its mechanical properties.

The degree of crosslinking, the proportion of HA modified, the size of the resulting gel particles and the way the gel is processed all differ between technologies, and each choice alters the final material.7,8 The essential point is that a dermal filler is not simply HA. Two products may share the same base molecule, and even the same stated HA concentration, yet behave entirely differently in tissue, because they are engineered biomaterials whose behaviour is defined by how they are made.5

Applying rheology to clinical practice Rheology is the science of how materials deform and flow when force is applied.9 For an injectable filler, this matters throughout treatment. The product must pass through a needle or cannula, be placed accurately in the intended tissue plane, integrate appropriately with the surrounding tissue and continue to perform as the face moves.5,10 A gel behaves differently during injection than it does once implanted because the mechanical forces acting upon it change. As it passes through a narrow needle or cannula, the gel is exposed to high shear forces and undergoes shear-thinning, whereby its apparent viscosity decreases as shear increases, allowing it to flow more readily and facilitating extrusion.5,9 Once the shear force is removed following implantation, the gel recovers towards its pre-injection state and its elastic and cohesive properties become increasingly relevant. It must then resist deformation from the surrounding tissues while integrating appropriately and accommodating the repeated mechanical forces generated by facial movement.5,10 Clinically, these properties influence not only how a filler feels and behaves during injection, but also the precision of placement and its subsequent behaviour within static and dynamic areas of the face. Rheological measurements provide laboratory measures that can help clinicians understand these behaviours before treatment. They are commonly obtained using a rheometer, which applies controlled deformation to a gel and measures its response.11 Oscillatory testing can determine parameters including the elastic modulus (G′) and viscous modulus (G″), while progressively increasing the applied stress can identify how the gel responds within and beyond its linear viscoelastic region.11 Other clinically relevant characteristics, such as cohesivity, require separate testing methods.12 Together, these measurements help characterise the mechanical behaviour of different HA fillers and inform understanding of how they may perform clinically. Of all the rheological terms, G′, the elastic modulus, is the most widely quoted. It measures a gel’s elasticity, its resistance to deformation under shear; how firmly the material resists being pushed out of shape and then springs back.5,9 What determines G′ is more complex than any single manufacturing variable. It reflects the overall structure of the HA gel and is influenced by factors including HA concentration, molecular weight and the degree and type of crosslinking, as well as the specific manufacturing process used to create the gel.5 Physically, a high-G′ gel has a more mechanically resistant

Aesthetics | November 2026

31


CPD Rheology

@aestheticsjournaluk

network, requiring greater force to deform it and storing more elastic energy during deformation, whereas a low-G′ gel deforms more readily under the same applied force.9 Consequently, crosslinking technology or HA concentration should not be interpreted in isolation as a direct measure of G′; it is the interaction between these properties and the resulting gel architecture that determines its overall elastic behaviour. Clinically, G′ is associated with firmness, with the ability to provide support and projection, and with shape retention against the forces of the surrounding tissue.5,13 Higher-G′ gels are often selected for supraperiosteal placement where projection or support is required. Examples could include the chin, lateral cheek/zygomatic region, mandibular angle and pyriform aperture.14 Lower-G′ gels, where smooth integration and minimal palpability/visibility are important, particularly in thin or superficial tissues, or highly mobile areas such as perioral rhytides.15 Assessing filler performance As useful as it is, G′ is only one measurement, and relying on it alone is among the most common errors in product selection. Fillers with similar G′ values can behave quite differently during injection and once implanted because G′ describes only the elastic response of the gel to deformation. Other properties are required to characterise how strongly the gel holds together as a continuous mass (cohesivity), how readily it flows under applied force (viscosity), how far it can deform while maintaining its structure (flexibility), its capacity to absorb water and swell, and how it interacts with the surrounding tissue.16,11 A recent analysis of 24 commercially available HA fillers compared products from five manufacturers using a combination of oscillatory rheology, mechanical testing and enzymatic degradation studies. The authors measured multiple parameters, including G′, G″, crossover strain, recovery following deformation and measures of cohesion, and compared these with the manufacturers’ intended clinical indications. Despite substantial differences in G′ between products, no clear relationship was identified between G′ and intended indication. The authors concluded that G′, despite being the most widely reported rheological parameter, is not sufficiently predictive of filler performance when considered in isolation.17 Cohesivity Cohesivity is the internal adhesion that holds a gel together as a single mass, resisting fragmentation and spread once implanted.17 It is distinct from G′ and is assessed by dedicated methods, such as a validated cohesivity grading scale, rather than being inferred from G′.17,18 A highly cohesive gel stays as a defined bolus and can project and support tissue even at a modest G′, which is valuable for structure and contour, whereas a less cohesive gel spreads and integrates more diffusely, which suits soft, even correction and superficial-depth work.12,17 Because lift depends on cohesivity as well as elasticity, two gels with the same G′ but different cohesivity will lift and hold quite differently.12

Figure 2: G’ as a spring from resistance to deformation

32

Aesthetics

Aesthetics

aestheticsjournal.com

Flexibility Flexibility describes how readily a gel deforms and recovers with movement, and can be expressed rheologically as the crossover strain, the point at which a gel shifts from solid-like to liquid-like behaviour under increasing deformation.10,19 The face is dynamic, and in animated regions such as around the mouth a gel that is too rigid can look or feel unnatural and may become palpable, whereas a more flexible gel moves with the tissue and integrates for a natural result.10,11 Matching flexibility to the mobility of the area treated is central to natural-looking outcomes and to patient comfort. Viscosity Viscosity is a gel’s resistance to flow.5 It largely governs injection force and the tactile feel of a product as it is delivered, and it influences the choice between needle and cannula and the ease of moulding.9 A more viscous gel may need greater extrusion force and feel firmer to inject, while a less viscous gel flows more readily. Injectability is the everyday, practical expression of viscosity, and it affects control and precision.8 Crosslink density Crosslink density refers to the architecture of the network rather than simply the amount of HA present.5 The number and arrangement of crosslinks influence firmness, water binding, resistance to degradation and therefore longevity.7,8 Two gels of identical HA concentration can differ markedly if one is more densely or more efficiently crosslinked, which is why network structure, not HA content, is the better guide to mechanical behaviour.16 HA concentration Concentration is one of the most misunderstood figures on a product sheet. A higher HA concentration does not necessarily mean a firmer filler.8 Firmness depends far more on how the HA is crosslinked than on how much is present, and comparisons of commercial products show that concentration alone correlates only weakly with mechanical properties.8,16 Concentration also interacts with water binding and swelling, so it should be read alongside crosslinking rather than in isolation. Particle size In particulate gels, the size of the gel particles influences injectability, the smoothness of placement and the depth at which a product sits best.8 It is a common myth that larger particles automatically mean a firmer or higher-G′ gel; in reality, particle size and elasticity are determined by different aspects of manufacture, and the monophasic and biphasic labels often used in this context are themselves an oversimplification.7,20 Particle characteristics matter, but they cannot be inferred from firmness. Swelling behaviour Because HA is strongly hydrophilic, a gel draws water from the surrounding tissue after placement, and the extent of this swelling depends on concentration, the degree of crosslinking and the amount of free, uncrosslinked HA.5,8 Some products expand noticeably in the hours and days after treatment, which is critical in thin-skinned, delicate areas such as the tear trough or the lips, where over-correction and a heavy or lumpy result can follow if swelling is not anticipated.5 Predicting swelling is one of the most clinically useful applications of rheological understanding.

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

CPD Rheology

aestheticsjournal.com

Test your knowledge! Complete the multiple-choice questions and email memberships@aestheticsjournal.com to receive your CPD certificate!

Questions NOTE FROM DESIGNER:

1. Two HA fillers have the same stated HA concentration but substantially different mechanical behaviour. Which explanation is most consistent with the principles discussed in this article?

Figure 3: A filler is the sum of its properties

Figure 4: A framework showing casing the rationale from patients’ anatomy to product selection

Matching filler properties to the patient Rheology should inform product choice rather than dictate it. G′ is a useful and widely quoted figure, but it is only one piece of a much larger picture and treating it as a proxy for quality or suitability is a mistake. Every HA filler represents a unique combination of elasticity, cohesivity, flexibility, viscosity, crosslink density, concentration, particle characteristics and swelling behaviour, and it is this combination, interacting with the patient’s anatomy and tissues, that determines clinical performance. Understanding these properties allows clinicians to predict how a product will behave and to select rationally from any manufacturer’s range. Ultimately, the most appropriate filler is not the one with the highest G′ or the longest longevity, but the one whose material characteristics best match the anatomy, tissue quality and aesthetic goals of the individual patient.

Because HA is strongly hydrophilic, a gel draws water from the surrounding tissue after placement, and the extent of this swelling depends on concentration, the degree of crosslinking and the amount of free, uncrosslinked HA

2. Two fillers have similar G′ values but demonstrate different clinical behaviour. Which property could help explain why one remains as a more defined mass while the other distributes more diffusely? 3. When selecting a filler for an area exposed to substantial facial movement, which characteristic provides information that G′ alone does not adequately describe?

a. HA concentration should determine mechanical behaviour, so the difference is likely due to measurement error b. Differences in crosslinking, network architecture and manufacturing can produce different material properties despite the same HA concentration c. The filler with larger particles will necessarily have the higher G′ d. HA concentration determines cohesivity but not elasticity a. HA concentration b. Particle size c. Cohesivity d. G″ alone a. The total quantity of HA within the syringe b. The extent to which the gel can deform before transitioning from predominantly elastic to predominantly viscous behaviour c. The diameter of the needle supplied with the product d. The amount of BDDE used during manufacturer alone a. Higher HA concentration reliably indicates a firmer filler

4. Which statement about the physicochemical properties of HA fillers is most accurate?

5. A clinician is selecting an HA filler for a thin-skinned anatomical area where excessive post-treatment expansion would be particularly undesirable. Which combination of considerations best reflects the approach advocated in this article?

b. Larger particle size reliably predicts a higher G′ c. Greater viscosity reliably predicts greater structural support after implantation d. No single physicochemical or rheological measurement reliably characterises overall clinical performance a. Select the lowest HA concentration because this reliably predicts the least swelling b. Select according to G′ alone because elasticity predicts post-implantation water uptake c. Select the product with the lowest viscosity because easier extrusion predicts lower tissue expansion d. Consider swelling behaviour alongside the gel’s wider rheological profile, tissue characteristics, treatment plane and clinical objective Answers: B,C,B,D,D

LR

Possible answers

Dr Alison Colville is an aesthetic practitioner, general practitioner and founder of The Avery Clinic. An international speaker, educator and researcher, she is UK Galderma Faculty, global research lead for Clinical Health Technologies and a member of the Joint Council of Cosmetic Practitioners Clinical Advisory Group, with particular interests in evidence-based practice, rheology and complications. Qual: MbCHb, MRCGP, LF(Hom), PGDipMedAes, PGCertMedEd

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM Aesthetics | November 2026

33


Save the Date!

Empowering the medical aesthetics community

@aestheticsjournaluk

@aesthetics

www.aestheticsconference.com


Why the Aesthetics community gathers at ACE EDUCATION

NETWORKING

Mark your Calendar

INNOVATION


OWN YOUR DEVICE FOR THE COST OF RENTING

Explore flexible finance options designed to suit your clinic, your ambitions and your budget.

SCAN THE QR CODE TO ENQUIRE ABOUT OUR AFFORDABLE OPTIONS

AL036 Aesthetic Journal - Half Page Advert - Landscape V3.indd 1

09/10/2026 14:28

INTELLIGENT AGEING NAD+ S C I E N C E - B AC K E D LO N G E V I T Y F R O M T H E I N S I D E O U T.

w w w.v i v e - n a d .c o m


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Laser Androgenic Alopecia

Managing AGA with Laser Therapy Mr Vahe Karimyan outlines patient selection, treatment protocol and monitoring for fractional non-ablative laser as an adjunct in androgenetic alopecia Androgenetic alopecia (AGA) is the most common cause of hair loss, affecting approximately 80% of men and 50% of women during their lifetime.1-3 It is a chronic, progressive, patterned loss in which dihydrotestosterone (DHT), produced locally from testosterone by 5-alpha-reductase, acts on genetically susceptible follicles, shortens anagen and progressively miniaturises terminal hairs towards vellus hairs.1-3 Its psychological impact can be substantial.2 Current pharmacological treatments include minoxidil, finasteride and dutasteride (topical or oral), which act mainly on the androgen pathway or on the hair cycle and remain the foundation of care. However, energy-based treatments are emerging in this area, particularly non-ablative laser. This is because perifollicular blood flow is reduced, with lower transcutaneous oxygen tension and subcutaneous flow in balding than in non-balding scalp, and low-grade perifollicular inflammation with fibrosis is found around affected follicles.4-12 This article proposes an emerging treatment, utilising a non-ablative 1470 nm laser, whilst discussing the relevant evidence, patient suitability and clinical protocol.

Rationale for laser therapy Fractional photothermolysis delivers laser energy as an array of microscopic columns of controlled coagulation, termed microthermal zones (MTZs), each surrounded by untreated skin that drives rapid repair.13 The interest in AGA follows from the observation that wounding can trigger follicle regeneration. In mice, wounding induces Wnt-dependent de novo follicle formation, and ablative fractional laser induces anagen entry with upregulation of Wnt/beta-catenin signalling.14,15 Wnt/beta-catenin is central to anagen initiation and follicle morphogenesis, and repair signalling raises growth factors relevant to the follicle: vascular endothelial growth factor (VEGF) supports follicle vascularity and size, and insulin-like growth factor-1 (IGF-1) regulates the hair cycle and shaft differentiation.16-18 The bulge stem-cell reservoir supplies the responding cells.19 Two further effects are practical rather than molecular. Transient microchannels increase transdermal delivery of topical agents applied immediately after treatment, and the photothermal stimulus may improve local perfusion.20,21 At 1470 nm the principal interaction is photothermal. Classical photobiomodulation occurs mainly within

the 600-1100 nm range, so any mitochondrial effect at sub-ablative fluences should be regarded as secondary.22 The current clinical evidence for fractional laser therapy in pattern hair loss is derived predominantly from studies investigating adjacent, non-ablative wavelengths rather than the 1470 nm wavelength itself. Several small prospective clinical studies have reported potentially beneficial effects on hair parameters. In a pilot study of 20 men, a 1550 nm erbium-glass fractional laser given as five sessions at two-week intervals increased hair density, without a significant change in shaft calibre, and in 27 women ten sessions at two-week intervals increased both hair density and shaft thickness.23,24 An evaluator-blinded, split-scalp study of a 1927 nm thulium fractional laser in ten men, treated with 12 weekly sessions, reported increases in hair density and thickness.25 In a randomised, investigator-blinded, split-scalp trial involving 30 men, of whom 29 completed 24 weeks, combining a 1550 nm fractional laser every two weeks combined with topical 5% minoxidil produced greater improvements in hair density and diameter than minoxidil alone.26 However, these findings should be interpreted cautiously. Systematic and narrative reviews of fractional laser therapy have characterised the available evidence as promising but preliminary, with the literature largely comprising small prospective case series, non-blinded or split-scalp comparatives and studies employing heterogeneous treatment protocols.27,28 Important methodological limitations include small sample sizes, short follow-up periods, variation in laser parameters and treatment schedules and the absence of standardised outcome measures, which limit the ability to determine the magnitude, durability and reproducibility of any treatment effect.28 Furthermore, evidence generated using neighbouring wavelengths cannot necessarily be extrapolated directly to 1470 nm, as differences in wavelength influence tissue penetration, optical absorption, thermal distribution and consequently the biological response to treatment.28 Evidence specifically evaluating 1470 nm fractional laser treatment remains particularly limited. At present, the available evidence is restricted to a registered 10-patient pilot study that is still recruiting.29 Consequently, there is insufficient clinical evidence to establish the efficacy, optimal treatment parameters, durability of response, or safety profile of 1470 nm laser treatment for pattern hair loss. On the basis of current literature, 1470 nm fractional laser treatment should therefore be regarded as an emerging and off-label intervention rather than an established therapeutic modality. Patients should be counselled that, although findings from studies of related wavelengths provide a biologically plausible rationale for treatment, the efficacy of 1470 nm specifically remains unproven and requires confirmation in adequately powered, controlled clinical trials with standardised treatment protocols and validated outcome measures.

Aesthetics | November 2026

37


Laser Androgenic Alopecia

@aestheticsjournaluk

Patient selection and assessment Suitable candidates have early-to-moderate AGA, Norwood-Hamilton grades I-IV in men and Ludwig grades I-II in women, in which follicles are miniaturised but viable.30,31 Areas in which follicles have been lost or replaced by fibrous tissue are unlikely to respond, since perifollicular fibrosis is associated with a poorer response to medical therapy.6,32,33 Accurate staging and expectation setting are therefore essential.

Aesthetics

aestheticsjournal.com

Aesthetics

1470 nm diode laser, the Promoitalia AI Laser Advance, operated in fractional non-ablative mode. Other fractional non-ablative laser platforms available in the UK include the Sciton HALO, which combines a 1470 nm non-ablative wavelength with a 2940 nm ablative wavelength, and 1550-1565 nm erbium-glass systems such as the Lumenis ResurFX.29 Before

After

Assessment covers duration and pattern of loss, family history, medication, previous treatment and response. Trichoscopy documents hair-shaft diameter diversity, the proportion of vellus hairs and perifollicular signs and helps exclude scarring alopecia.34 In women, secondary causes should be excluded before confirming AGA, including thyroid dysfunction, iron deficiency and androgen excess where clinically indicated.2 Standardised photography at baseline, with fixed lighting, angle and parting, is the reference for every later review.

Treatment procedure and protocol Treatment is mapped to the areas of visible thinning (Table 1). In most men this is the vertex and mid-scalp.30 The frontal and temporal recessions are treated only where miniaturised hair persists: bare, shiny skin without follicular openings indicates follicles that have been replaced by fibrous tissue and will not respond.32,33 In women the diffuse central scalp is treated. The hair is parted in rows and does not need to be shaved. Energy is delivered in overlapping passes to give uniform coverage. Settings are kept within the manufacturer’s recommended operating range and adjusted for scalp skin thickness, Fitzpatrick type, hair density and tolerance. The patient should feel intermittent warmth or, at higher settings, a mild prickling sensation, never sustained heat.35 Immediately after the final pass, while microchannels remain open, a topical such as minoxidil solution or a growth-factor preparation may be applied to take advantage of enhanced absorption.20,21

Parameter

Standard setting

Adjusted (thin scalp, Fitzpatrick IV-VI, low tolerance)

Mode

Fractional non-ablative (AI-Frax)

Fractional non-ablative (AI-Frax)

Energy per MTZ (mJ)

10-15

6-10

Density (MTZ/cm2)

100-150 per pass (spacing approx. 1.0mm)

60-100 per pass (spacing approx. 1.2-1.5mm)

Pulse duration (ms)

10-15

8-10

Passes

1-2

1

Session time

30-45 minutes

30-45 minutes

Table 1: Treatment parameters used at the author’s clinic. Settings are device-specific and should be adapted to the platform in use.35

Case study This case showcases a 22-year-old male patient with AGA, Hamilton-Norwood grade III vertex. Before treatment the patient attended with clean, dry hair and no styling products. Baseline trichoscopy and photographs were taken, consent was confirmed and topical anaesthetic was applied for 20-30 minutes, although most patients tolerate treatment without it. For this present case study, treatment was performed using a 38

Figure 1: 22-year-old male AGA patient (Hamilton-Norwood grade III vertex) before and after six sessions of the Promoitalia AI-Laser Advance at four-week intervals, with mesotherapy with autologous PRP (DRV PRP kit) performed about one week after each laser session (three sessions).

The course comprised six laser sessions at four-week intervals. In the author’s combination protocol, the adjunct is administered at a separate visit, typically one week after each laser session, rather than on the same day; microneedling with autologous platelet-rich plasma (PRP), or an exosome or peptide preparation, with the next laser session following at week four. The order within each four-week cycle is not fixed and the adjunct can be scheduled either side of the laser session. For this patient, mesotherapy with PRP was performed two weeks after each laser session, giving three PRP sessions in total; PRP was prepared with the DRV PRP kit and mesotherapy with 4mm needle was performed. No exosome or peptide preparation was used, and the patient was not using minoxidil, finasteride or any other medical therapy during the course. Response is judged on the comparison of standardised photographs and trichoscopy against baseline, not on the patient’s impression alone. Trichoscopic hair count, mean shaft diameter and the proportion of vellus hairs are the most useful measures in clinic (Figure 1).36

Monitoring and maintenance Aftercare is simple for patients to adhere to; avoid heat, swimming, saunas and vigorous exercise for 24 hours while the barrier recovers, keep the scalp covered or use sunscreen for 48 hours, wash gently from the following day and resume home topicals as directed. Erythema is expected and typically settles within 24-48 hours; downtime is generally limited and most patients return to normal activities the same day.13,37 Patients are asked to report erythema persisting beyond 72 hours, crusting or pustules.13,37 A course typically consists of four to six sessions at four-to-six-week intervals. This schedule is a clinic protocol rather than a published standard; it is chosen to deliver repeated stimulation across the window in which anagen induction follows wounding, and it fits the practical constraint of a monthly visit. Published fractional protocols range from weekly to monthly over three to 12 sessions, and no optimal schedule has been established.23-28 This should be explained to patients when the course is planned.

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Laser Androgenic Alopecia

Patients are reviewed at each session and at three, six and 12 months.

· Weeks zero to 12 (sessions one to three): The wound-healing

and growth-factor response begins. Some patients notice transient shedding before regrowth; this should be anticipated in the consultation so that it is not mistaken for failure.

· Months three to four: Early changes may be visible

on trichoscopy, with increased hair count and the first improvement in calibre as miniaturised hairs move towards intermediate thickness.

· Months four to six: Continued improvement in calibre and coverage in responsive areas.

· Months six to 12: Density, calibre and coverage may continue to improve before reaching a plateau.

Based on the authors clinical experience, once the plateau is reached, maintenance treatment at approximately three-to-six-month intervals can be considered, alongside ongoing management of the androgenic process. A patient who has shown no trichoscopic change by month six is unlikely to benefit from further sessions, and the plan should be revisited.

Outlining adverse effects Adverse effects of non-ablative fractional treatment are mostly mild and self-limiting; transient erythema, oedema, warmth and pruritus are common and a temporary increase in shedding may occur in the first weeks.37,38 Less common effects include post-inflammatory hyperpigmentation (PIH), particularly in darker skin types (FST IV-VI), folliculitis, crusting and pain requiring anaesthetic.37,38 Burns, scarring and reactivation of herpes simplex virus are rare and are associated with excessive fluence or density.37,38 Unlike oral finasteride or dutasteride, which carry recognised systemic adverse effects, the laser itself involves no systemic drug exposure, although topical agents applied immediately after treatment may be absorbed more than with passive application.7,20,39 Combination protocols with PRP, growth-factor preparations or topical minoxidil are used in many practices and small studies suggest additive benefit with laser-assisted delivery.21,25,26,40 The evidence remains limited and protocols are not standardised, so combination should be presented as an option rather than a proven enhancement.28 Contraindications and precautions include: · Active scalp infection or inflammatory dermatosis in the treatment field37 · Scarring alopecia in the treatment field2,36 · Oral isotretinoin, current or recent (precaution rather than absolute contraindication)41,42 · Keloid or hypertrophic scarring tendency37 · Photosensitising medication or photosensitive dermatosis37 · Pregnancy and breastfeeding (precaution; no safety data)37 · Unrealistic expectations, or inability to commit to a course and follow-up37

Laser should be positioned as an addition to, not a replacement for, treatments that address the androgenic component of AGA Isotretinoin appears on the list because the UK Summary of Product Characteristics advises avoiding cutaneous laser treatment for five to six months after the end of a course, a recommendation that derives from early reports of delayed healing and atypical scarring after dermabrasion and fully ablative resurfacing.42 Two 2017 consensus reviews found no evidence to justify this delay for non-ablative fractional lasers, so in this protocol it is treated as a precaution rather than an absolute contraindication.37,38 The more relevant issue in AGA is that isotretinoin itself can cause hair shedding, which confounds baseline trichoscopy and the assessment of response, so the author’s practice is to defer the course until isotretinoin has finished and shedding has settled.42 Fitzpatrick skin types IV-VI are not excluded, but PIH is more frequent after non-ablative fractional treatment in darker skin, so density and fluence are reduced.37,38 Patients should continue their medical therapy (oral or aesthetic) journey if they are following one.

Utilising laser for hair loss Fractional non-ablative 1470 nm laser offers a non-surgical, well-tolerated adjunct for early-to-moderate AGA in patients who retain viable but miniaturised follicles. Its rationale rests on wound-healing-mediated follicle activation, growth-factor and Wnt/beta-catenin signalling, improved perifollicular perfusion and enhanced delivery of topicals, with supporting clinical data largely from 1550 nm and 1927 nm devices. Laser should be positioned as an addition to, not a replacement for, treatments that address the androgenic component of AGA.7,8,40 Appropriate staging, trichoscopic monitoring, honest framing of the evidence and realistic expectations give practitioners a structured way to incorporate it into a multimodal plan. Controlled studies of standardised 1470 nm protocols are needed to define efficacy, optimal parameters and patient selection. Mr Vahe Karimyan is a specialist surgeon and medical director of Dr Vahe Clinic, Chelsea, a medical, surgical and regenerative medicine practice. He also practises within the NHS at King’s College Hospital, has more than 20 years’ experience in aesthetic and regenerative medicine, and more than 30 peer-reviewed publications. Qual: MD, MS, PhD

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026

39


Scan the QR code to access BOCOUTURE Prescribing Information

AVAILABLE TO PURCHASE FROM:


For UK and Ireland Healthcare Professionals only.

TAILOR EVERY TREATMENT WITH CONFIDENCE BOCOUTURE is the first and only powder toxin free from complexing proteins by design.1,2 Double-purified using XTRACT technology.1 Formulated with only three ingredients.3

PURIFIED. PROVEN. PERFORMANCE BOCOUTURE is indicated for the temporary improvement in the appearance of upper facial lines in adults below 65 years when the severity of these lines has an important psychological impact for the patient1: • moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar frown lines) and/or • moderate to severe lateral periorbital lines seen at maximum smile (crow’s feet lines) and/or • moderate to severe horizontal forehead lines seen at maximum contraction. Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk/. Reporting forms and information for Republic of Ireland can be found at https://www.hpra.ie/homepage/about-us/report-an-issue. Adverse events should also be reported to Merz Aesthetics UK Ltd by emailing UKdrugsafety@merz.com or calling +44 (0) 333 200 4143.

1. https://patents.google.com/patent/WO2000074703A2/en (Last accessed: October 2026) 2. Kerscher M, et al. J Drugs Dermatol. 2019;18(1):52–57 3. BOCOUTURE (incobotulinumtoxinA) Summary of Product Characteristics. Merz Pharmaceuticals GmbH

M-BOC-UKI-0825 Date of Preparation: October 2026


APPROVED PARTNERS

BOOK YOUR TRAINING TODAY Mastelli® injectable solutions are Medical Devices Class III (CE 0373) – For medical use only


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Hormones Male Patients

obesity, nutritional deficiencies and metabolic dysfunction frequently produce symptoms that overlap considerably with age-related androgen decline.³ Although aesthetic practitioners are not responsible for diagnosing endocrine disorders, awareness of hormonal physiology can support more holistic consultation and help determine whether an aesthetic intervention is appropriate. Where the presenting concern relates primarily to skin quality, facial ageing, hair loss or changes in facial structure, aesthetic or regenerative treatment options may be considered.

The Role of Hormones in Male Medical Aesthetics Dr Arsalan Baig and Dr Ducu Botoaca present how hormones affect in-clinic treatments The male aesthetics market has expanded significantly over the last decade, with increasing numbers of men seeking treatment to maintain a youthful appearance, improve confidence and optimise physical wellbeing. In the UK, male engagement with medical aesthetics is increasing, with the British College of Aesthetic Medicine reporting that 16% of patients treated by respondents to its 2024 Annual Clinical Review identified as male.¹ Testosterone and its metabolites affect skin quality, fat distribution, muscle mass, libido and hair growth, which is why hormonal context is directly relevant at consultation.2,3 Visible ageing should not automatically be read as endocrine dysfunction, but clinicians who understand male hormone physiology are better placed to set realistic expectations, judge when medical assessment is needed and plan more individualised treatment.

Testosterone and dihydrotestosterone Testosterone remains the principal androgen hormone in men and is produced primarily by Leydig cells within the testes under regulation of the hypothalamic pituitary gonadal axis.² Testosterone levels naturally decline with age, typically beginning during the fourth decade of life. Longitudinal evidence suggests that total testosterone falls by approximately 1-2% annually, while free testosterone declines more rapidly due to rising sex hormone binding globulin concentrations.⁴ The biological effects of testosterone extend beyond muscle growth or sexual function. Testosterone acts directly through androgen receptors but is also converted into two important metabolites, including oestradiol, through aromatisation, and dihydrotestosterone, through the enzyme 5-alpha-reductase.² Dihydrotestosterone, commonly referred to as DHT, demonstrates stronger androgen receptor affinity and exerts important effects on tissues highly relevant to aesthetics, particularly the skin, sebaceous glands and hair follicles.⁵ In clinical practice, age-related hormonal changes may contribute to concerns commonly raised by male aesthetic patients. Reduced muscle tone, increasing abdominal adiposity, declining energy levels and changes in facial structure can collectively lead patients to feel that they look older, less healthy or less masculine than before.⁴ However, clinicians should avoid assuming that appearance alone reflects testosterone deficiency. Sleep deprivation, chronic stress,

However, symptoms such as persistent fatigue, reduced libido or erectile function, loss of muscle mass or strength, reduced body hair, gynaecomastia, or unexplained changes in body composition should raise suspicion of possible androgen deficiency or another underlying medical disorder.³ Rapid or unexplained weight change, marked deterioration in general health, or symptoms that appear disproportionate to normal ageing should similarly prompt further medical assessment rather than being attributed to hormonal ageing on appearance alone. In these circumstances, onward referral to a general practitioner or endocrinologist may be appropriate.³

Hormonal influence on skin quality Hormones significantly influence skin physiology throughout adult life. Male skin differs structurally from female skin in several important ways. It is generally thicker, contains greater collagen density and demonstrates increased sebaceous activity due to androgenic stimulation.⁶ Testosterone contributes to dermal thickness, hydration and structural integrity, helping maintain firmer skin during early adulthood.⁶ Clinicians should also establish whether patients are currently using prescribed testosterone replacement therapy, non-prescribed testosterone or anabolic-androgenic steroids obtained privately or online. Such use may alter the clinical and hormonal picture and should therefore form part of the medication and drug history.⁷,⁸ Where treatment is being used without appropriate medical supervision, or where adverse effects or symptoms of hormonal dysfunction are suspected, further medical assessment should be considered rather than attempting to interpret these changes solely within an aesthetic consultation.⁷,⁸ With advancing age, however, hormonal changes combine with environmental and lifestyle factors to alter skin quality and facial structure. Men frequently experience reduced elasticity, worsening skin texture and gradual loss of definition around the lower face. Temporal hollowing, heavier jowling and deeper facial folds are common features of male ageing.⁹ Male facial ageing should be approached differently from female rejuvenation. Most men seek refreshed, healthier and natural-appearing outcomes rather than dramatic change. Preservation of masculine facial characteristics usually remains a central objective. Structural support around the jawline and chin may be prioritised where this reflects the patient’s anatomy and treatment goals, while excessive or poorly distributed soft-tissue augmentation may alter traditionally masculine facial proportions.¹⁰ However, there is no single ideal male facial shape. Facial morphology, patterns of ageing and aesthetic preferences vary with age and ethnicity, while an individual patient’s gender expression and personal treatment goals may not conform to conventional concepts of masculinity.¹¹,¹² Treatment planning should therefore be based on individual facial assessment and a clear discussion of the patient’s desired outcome rather than applying a standardised ‘masculinising’ approach. This distinction carries practical importance for clinicians. A detailed understanding of male facial anatomy allows treatment plans to preserve facial strength and masculine proportions rather than simply replacing volume.

Aesthetics | November 2026

43


Introducing D·E·J BioStim™ Treatment Solution Firms & Lifts Like a Biostimulator.

Applies like a Peel.

• The first professional topical biostimulator designed to enhance natural collagen and elastin production through patent-pending D·E·J BioStim™ Technology • Clinically proven visible results in as little as 4 weeks, across all Fitzpatrick skin tones* • Non-invasive treatment with no needles, minimal discomfort and minimal downtime • Multi-Acid Delivery System creates micro-channels in the epidermis, helping D·E·J BioStim™ Technology penetrate deeper into the skin • Activates collagen and elastin production while supporting dermal-epidermal junction (DEJ) repair • Accelerates skin regeneration to support healthierlooking, more youthful skin • Designed to complement the D·E·J® Regimen and enhance age-defying results

A new approach to professional biostimulation — powered by D·E·J BioStim™ Technology.

Before

After 2 Treatments

Before

After 3 Treatments

Scan here to discover the latest innovation in topical biostimulation and the brand redefining skin longevity info@aestheticsource.com

After 2 treatments

After 3 treatments

54 year old subject, Fitzpatrick Skin Type III. Photo taken 4 weeks after 2nd treatment. Light source VISIA CR, Standard Light.

55 year old subject, Fitzpatrick Skin Type II. Photo taken 4 weeks after 3rd treatment. Light source VISIA CR, Parallel Polarized Light.

*DATA ON FILE. RESULTS MAY VARY.

@aestheticsourceofficial @revisionskincareuk


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Treatment plans for male patients Male treatment planning should reflect the interaction between facial anatomy, skin biology and the pattern of age-related change rather than relying on a standardised approach. Male skin is generally thicker and has greater collagen density and sebaceous activity, while differences in skeletal proportions, muscle mass and soft-tissue distribution can influence both the presentation of facial ageing and the response required from treatment.⁶,¹⁰,¹³ Where loss of structural support or projection predominates, particularly at the chin, mandibular angle and jawline, hyaluronic acid fillers may be used to restore or reinforce facial contours.¹³ Product rheology is relevant to this decision. Fillers with a higher storage modulus (G′) and greater resistance to deformation may be selected for deeper structural support and projection, while more flexible products may be better suited to areas requiring softer tissue integration or more subtle contour correction.¹⁴ Selection of product, volume and injection plane should nevertheless be determined by the individual patient’s anatomy and treatment goals.¹³,¹⁴ Where deterioration in skin quality is more prominent than structural volume loss, biostimulatory treatments may provide a more appropriate treatment objective. Calcium hydroxylapatite and poly-L-lactic acid stimulate neocollagenesis and can improve measures of dermal quality while providing varying degrees of structural or volumetric effect.¹⁵ Their effects develop progressively, and patients should therefore be counselled that improvement occurs over weeks to months rather than immediately.¹⁵ Energy-based devices provide a different treatment rationale and may be considered where laxity, textural change or photodamage predominates without a requirement for substantial volume replacement.¹⁶ Radiofrequency, ultrasound and laser-based technologies use different mechanisms of tissue heating or remodelling and should be selected according to the tissue target, skin characteristics and desired clinical endpoint.¹⁶ Treatment selection should therefore follow the predominant clinical finding. Structural deficiency may favour an appropriately selected filler; reduced dermal quality may favour a biostimulatory approach; and laxity or textural change may favour an appropriate energy-based modality. These treatments address the anatomical and cutaneous manifestations of ageing rather than hormonal decline itself, and treatment should remain individualised according to facial anatomy, skin quality and the patient’s aesthetic goals.¹³,¹⁶

Hair loss and dihydrotestosterone Hair loss remains one of the most psychologically significant concerns affecting men. Androgenetic alopecia (AGA) is the most common form of hair loss in men and is characterised by progressive follicular miniaturisation in a recognisable pattern.⁵,¹⁷ DHT plays a central role in the pathogenesis of male AGA. Testosterone is converted to DHT by 5-alpha-reductase and, in genetically susceptible scalp follicles, androgen signalling contributes to progressive follicular miniaturisation and shortening of the anagen phase, resulting in progressively finer and shorter hairs.⁵,¹⁸ Established medical treatments include topical minoxidil and oral finasteride and topical minoxidil. Finasteride inhibits type II 5-alpha-reductase, thereby reducing DHT production, while minoxidil promotes hair growth through several proposed mechanisms affecting follicular activity.¹⁸-²⁰ Patients should be counselled that response is gradual. Clinically appreciable improvement generally requires several months of continuous treatment, with response commonly assessed at approximately six months and potentially continuing to improve thereafter.¹⁸,²⁰ Treatment generally needs to be continued to maintain its effect, and benefits progressively diminish following discontinuation.¹⁸,²⁰ Counselling should also address adverse effects and individual suitability. Finasteride has recognised sexual adverse effects and

Hormones Male Patients

has also been associated with psychiatric adverse effects, which should form part of informed discussion before treatment.¹⁹,²¹ Where fertility or conception is a concern, this should be discussed with an appropriately qualified prescriber as part of individualised treatment planning.²¹ Topical minoxidil may cause scalp irritation and can produce a temporary increase in shedding during the initial treatment period.²⁰ Hair transplantation may be considered for appropriately selected patients with an established pattern of AGA and adequate donor hair.¹⁷ Assessment should consider the current extent of hair loss, donor availability and anticipated future progression because transplantation redistributes existing follicles but does not prevent continuing loss of non-transplanted androgen-sensitive hair.¹⁷ Long-term planning and, where appropriate, medical stabilisation of progressive hair loss are therefore important when considering transplantation.¹⁷ Regenerative treatments should be positioned as adjunctive rather than replacements for established medical management. Platelet-rich plasma (PRP) has evidence supporting improvements in hair density in some patients with AGA, although preparation methods, injection protocols and treatment schedules remain heterogeneous.²²,²³ The Joint Council for Cosmetic Practitioners additionally identifies PRP for hair restoration as a medical procedure and advises that PRP preparation should use appropriately regulated medical devices, including centrifuges and blood-collection tubes intended for autologous PRP preparation.24 Evidence for exosome-based treatments remains preliminary, with limited standardisation and a lack of robust long-term comparative clinical data.25 Polynucleotide treatments are also increasingly discussed for hair restoration, but the evidence base for their use in AGA remains substantially less established than that for finasteride and minoxidil. These emerging treatments should therefore be discussed with appropriate counselling regarding the limitations and uncertainty of the available evidence.23,24

Treating the male patient Hormones, particularly testosterone and DHT, play important roles in skin quality, hair retention, body composition and psychological health, influencing how men age and how they present within aesthetic practice. For clinicians, understanding endocrine physiology may improve consultation quality and support more personalised treatment planning. However, hormonal explanations should complement rather than replace broader medical assessment. A balanced and evidence-informed approach remains essential to delivering safe, natural and patient-centred outcomes for the modern male aesthetic patient. Dr Arsalan Baig is a UK-based clinician, currently based at Dr Ducu clinics, with interests in surgery, regenerative medicine and evidence-informed aesthetic practice. His work focuses on male wellness, patient centred aesthetics and the integration of regenerative approaches into modern clinical care. Qual: MD, PGCert (MedEd), FHEA, MAcadMEd Dr Ducu Botoaca is an aesthetic clinician and the founder and medical director of Dr Ducu Clinics. He specialises in hair transplantation, eyebrow transplantation, non-surgical Brazilian butt lifts and advanced aesthetic procedures. He regularly shares his expertise at major international conferences, including the IMCAS World Congress. Qual: MD

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026

45


THE FUTURE IS LIQUID RelfydessTM ready-to-use liquid formulation offers convenient and consistent dosing: Every vial, Every time1-3 STARTS LIQUID, STAYS LIQUID Minimise the risk of reconstitution-related errors or contamination1-3

HIGH PURITY Free from complexing proteins and human or animal-derived components2,3

SIMPLER PREPARATION Reduce preparation time and waste in your practice by eliminating the reconstitution step1,4

Relfydess™ (relabotulinumtoxinA) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines at maximum frown, and moderate to severe lateral canthal lines at maximum smile alone or in combination, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient. The majority of adverse reactions reported after one treatment with RelfydessTM in subjects receiving ≥50 units in all placebo-controlled studies in the development program were of mild-to-moderate intensity. The most frequently reported adverse reactions were injection site reactions and headache occurring in approximately 7% and 5% of subjects, respectively.1 *Based on the Injector Questionnaire completed for all ITT patients treated with Relfydess (n=99) in the RELAX Phase IIIb multi center, randomised, double-blind, placebo-controlled study evaluating aesthetic improvement and onset of effect after a single dose of Relfydess for the treatment of moderate-to-severe glabellar lines (N=132) over 12 months. Injectors (N=9) ‘agreed’ or ‘strongly agreed’ with the statements ‘The ready-to-use product is easy to use’, ‘I prefer this ready to use product over other neuromodulator products that need to be reconstituted prior to use’, ‘I like that this ready to use product reduces preparation time and hassle’, ‘I felt this ready to use product increased the amount of time I can spend with my patient’, and ‘The ready to use product increases my confidence in dosing consistency’.4,5 References: 1. Galderma. [Relfydess] Summary of Product Characteristics. January 2026. 2. Sundberg ÅL, Ståhl U. Poster presented at: TOXINS 2021Virtual Conference; January 16–17, 2021. 3. Do M, et al. Poster presented at: TOXINS 2022 Conference; New Orleans, US; July 27–30, 2022. 4. Gerber PA, et al. Poster presented at: International Master Course on Aging Science World Congress; Paris, France; January 26–28, 2023.5. Galderma Laboratories. MA-59692. Clinical Study Report for Protocol 43QM2106: RELAX. Fort Worth, TX: 2023. 6. Schlessinger J, et al. Presentation at: AAD; Orlando, FL; March 7 -11, 2025. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.


99% Please scan the QR code to access PI & AE reporting

of injectors agreed RelfydessTM reduced preparation time and hassle compared to standard powder neuromodulators requiring reconstitution*5,6

Galderma portfolio available at our distribution partners

medfx

© 2026 Galderma S.A. All rights reserved. UKI-REL-2600067 DOP October 2026


Acne Scarring Polynucleotides

@aestheticsjournaluk

Considering Polynucleotides for Atrophic Acne Scarring Independent nurse prescriber Bernadette Tobin examines the role of polynucleotides for acne scarring treatment As interest in polynucleotides (PNs) continues to grow, the clinically useful question is not simply whether they can ‘treat acne scars’, but which component of the scar they can realistically change. A tethered rolling scar, a sharply defined ice-pick scar and diffuse shallow atrophy are structurally different problems. That distinction should determine whether PNs are used alone, as an adjunct or not at all.1-3 Acne scarring results from altered wound healing following inflammation, with loss or excess of collagen producing atrophic, hypertrophic or keloid scars. Atrophic scars are the most common facial presentation and are generally classified as rolling, boxcar or ice-pick scars. Each has different structural characteristics, meaning a treatment that improves overall dermal quality may still be insufficient for a deeply tethered or sharply defined scar.1-3 Current evidence suggests that PNs may improve aspects of atrophic scarring and surrounding skin quality, but their most credible role is as a regenerative option within a wider morphology-led pathway, rather than as a universal scar treatment.4

Understanding the scar before selecting the treatment Assessment should begin with control of active acne. Clinically, active disease is identified by inflammatory lesions such as papules, pustules or nodules, whereas scarring represents the residual textural or structural change after inflammation. National Institute for Health and Care Excellence (NICE) guidance emphasises treating ongoing disease to reduce the risk of further scarring and recommends considering specialist referral where acne is severe, treatment-resistant, causing persistent pigmentary change, producing scarring or contributing to psychological distress.5 Where acne-related scarring is severe and persists one year after the acne has cleared, NICE recommends referral to a consultant dermatologist-led team. This is particularly relevant where specialist scar procedures are required or the presentation falls beyond the practitioner’s competence or scope.5 Once inflammatory disease is stable, assessment should consider scar morphology, depth, distribution and tethering, alongside skin type, risk of post-inflammatory hyperpigmentation, previous isotretinoin or procedural treatment, healing history and any tendency towards hypertrophic or keloid scarring. For consistency, baseline photography and a recognised scar-grading system, such as the Goodman and Baron qualitative or quantitative systems, can help document severity and change over time.6 Rolling scars are often broad and undulating, with fibrous attachments tethering the dermis to deeper tissue. Boxcar scars have more defined edges and may be shallow or deep, while ice-pick scars are narrow at the surface and extend more 48

Aesthetics

Aesthetics

aestheticsjournal.com

deeply into the dermis.1-3 This classification immediately shapes realistic expectations. Diffuse shallow atrophy and textural irregularity may respond to treatments that stimulate controlled dermal remodelling. Deep ice-pick scars commonly require focal techniques such as chemical reconstruction of skin scars (CROSS) or punch procedures, while tethered rolling scars frequently require mechanical release with subcision.1-3 It’s worth noting that subcision is as an advanced technique and practitioners should only work within the scope of their competence.1-3 It is also important to acknowledge where the evidence ends. Available PN studies have not reported outcomes separately for rolling, boxcar and ice-pick scars. Recommendations based on morphology therefore represent reasoned clinical extrapolation from established scar-management principles, rather than proven differential efficacy of PN between individual scar subtypes.1-4 Although testosterone and other androgens contribute to skin physiology, their direct influence on hydration, dermal thickness and firmness should be interpreted cautiously. Skin ageing is a multifactorial process involving intrinsic biological ageing, collagen degradation, ultraviolet exposure, environmental influences and lifestyle factors. Consequently, changes in skin quality cannot be attributed solely to declining testosterone concentrations.6

The three-question PN scar check1-5 1. Is the active acne controlled and the skin clinically suitable for treatment? 2. Is the dominant concern structural tethering, focal depth or diffuse textural change? 3. Is PN being selected as a product-appropriate and evidence-supported objective? If these questions cannot be answered clearly, the treatment plan should be reconsidered.

Exploring the regenerative rationale PNs are biopolymers composed of nucleotide chains. Nucleotides are the building blocks of nucleic acids, including DNA and RNA. In medical aesthetics, PNs are predominantly DNA-derived polymers and are commonly obtained from highly purified salmonid material, including salmon and trout. Their proposed biological effects include supporting fibroblast activity, extracellular matrix (ECM) remodelling, hydration and tissue repair.7,8 Some of the biological rationale is drawn from wider PN and polydeoxyribonucleotide (PDRN) literature. However, PN and PDRN are related DNA-derived materials, but the terminology has been used inconsistently within scientific literature. Differences in molecular weight, chain length, formulation and physicochemical properties mean that findings involving one material should not automatically be extrapolated to every product containing the other.8 The rationale is relevant to atrophic acne scarring because the condition involves collagen loss, altered ECM remodelling and changes in dermal architecture following inflammation. Biological plausibility, however, is not the same as proven clinical effectiveness.1,7 A 2025 systematic review of PNs in medical aesthetics identified nine studies involving 219 PN-treated patients. Only one of the nine studies specifically evaluated atrophic acne scarring (Araco and Araco), while the remaining studies examined other aesthetic indications, including crow’s feet, female pattern hair loss,

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

post-inflammatory facial hyperpigmentation, cheek skin quality and nasolabial folds. They included studies varied in population, formulation, injection technique, treatment interval and outcome measure; formulations included PN and PDRN, and protocols ranged from weekly to four-weekly treatment intervals. Outcomes included measures of wrinkles, skin elasticity, pigmentation, skin texture and acne-scar appearance. The review rated the available evidence as low or moderate quality and found substantial heterogeneity between studies.4

Selecting patients for PN treatment PN treatment is most defensible when the objective is to improve diffuse atrophic texture, dermal quality and the appearance of shallow scars, particularly where the patient understands that improvement is likely to be progressive, variable and incomplete.4 It may also be considered where the surrounding skin appears thin, dehydrated or uneven following previous acne, provided active inflammation has resolved and the selected product is suitable for the intended area and purpose. Patients with mixed scar patterns may still benefit, but the treatment plan must identify what PN can and cannot address. A patient with rolling scars and clear tethering may require subcision before regenerative injectable treatment. Deep ice-pick scars may require focal scar-directed treatment, while widespread shallow boxcar scars may be more suited to a controlled remodelling procedure such as microneedling, fractional radiofrequency (RF) or fractional laser, with PN considered as an adjunct rather than the sole intervention.1-3 Treatment should not proceed with overactive inflammatory acne, local infection, active dermatitis or unresolved barrier disruption. Medical history, medications, bleeding risk, allergies, previous procedures, abnormal scarring and expectations should be assessed carefully. Contraindications and precautions must be determined by the relevant product instructions for use and the practitioner’s clinical governance framework.

Matching treatment to scar morphology A morphology-led plan avoids the common mistake of applying one treatment evenly across every scar. For tethered rolling scars, subcision targets the fibrous attachments pulling the skin surface down. Once bruising and acute inflammation have resolved, PN may be considered to support the quality of the treated dermis. However, controlled evidence for a specific subcision-plus-PN sequence is not currently available.3,4 For shallow boxcar scars and broader textural change, microneedling, fractional RF or fractional laser may be selected according to scar depth, skin type, pigmentation risk, downtime tolerance and practitioner competence. PN can be staged alongside these approaches but should be considered an adjunct rather than a replacement where a procedure is required to address the underlying scar structure.2,3 PN can be staged within this pathway, but a combination should not be described as evidence-based solely because the proposed mechanisms appear complementary. Timing should follow the relevant device and product instructions, and injectable treatment should be deferred until the skin has re-epithelialised and acute inflammation has settled. Deep boxcar and ice-pick scars may require focal CROSS, punch elevation or excision.1-3 In these patients, PN may improve the surrounding field of skin but is unlikely to provide adequate correction of the deepest scars in isolation. The reason is structural; PN may support tissue quality, but it does not release fibrous tethering or physically elevating or excising a deep scar.1-4

Acne Scarring Polynucleotides

This distinction should be made clear during consultation: an improvement in overall texture is different from the removal of an individual scar. An in-focus study of PN-HPT for atrophic acne scars PN-HPT refers to PN high-purification technology. Araco and Araco conducted a prospective, randomised, double-blind, placebo-controlled study involving 20 non-smoking women aged 30-50 with Goodman grade 3-4 atrophic acne scars and no active acne during the preceding five years. Ten participants received PN-HPT and ten received saline placebo.9 In the Araco study, this was the specific PN formulation/technology evaluated, so the findings should not be treated as evidence for every PN product.9 The published protocol used an average total volume of 4ml, delivered subdermally as approximately 30 microdroplets of 0.1-0.2ml using a 30G, 13mm needle. Two sessions were performed three weeks apart.9 The PN-HPT group showed statistically significant improvement from baseline at one and three months, whereas the saline group did not. No minor or major adverse effects were reported.9 As a clinical interpretation, this provides useful, controlled evidence, but it remains a preliminary study involving only ten treated patients from a highly selected, all-female population. Follow-up was short, outcomes were not stratified by scar subtype, and the findings relate to one formulation and protocol. The study therefore supports cautious use; it does not establish a universal dose, prove superiority to established scar procedures or confirm long-term durability. Reviewing the newer acne-scar evidence A prospective, multicentre, real-world study evaluated a combined formulation containing PN-HPT 10 mg/ml and hyaluronic acid (HA) 10 mg/ml in 62 adults aged 20-60 with moderate-to-severe atrophic facial acne scars.10 The cohort included 32 White and 30 Asian participants, comprising 19 men and 43 women. Participants received four intradermal treatment sessions at two-week intervals and were followed for six months.10 In the prospective multicentre study reported in reference 10, at three and six months, 46.8% achieved at least a one-grade reduction on the Acne Scar Assessment Scale, while 54.8% reported an improvement in scar appearance. One mild, transient episode of wheal formation was reported and resolved without intervention.10 The larger and more diverse cohort is encouraging, but fewer than half of participants achieved the predefined one-grade improvement. The study was uncontrolled and assessed a combined PN-and-HA formulation, meaning it cannot isolate PN’s contribution or establish superiority to existing interventions.10 The authors reported that Mastelli S.r.l. provided unconditional support limited to the article-processing charge. This should be considered transparently alongside the design and other limitations when appraising the findings.10 The results therefore represent a signal of potential benefit rather than proof of comparative effectiveness. Additional acne-scar evidence has since emerged. A 2026 randomised comparative study of 100 participants compared fractional CO2 laser alone with fractional CO2 laser combined with topical polynucleotide and exosome-mimetic nanovesicles. After three treatment sessions, the combination group had a greater reported reduction in ECCA score than laser alone (47.3% vs 35.9%; p<0.001), with improvements reported across ice-pick, boxcar and rolling scar subtypes. However, because PN was used as part of a combination treatment, the study cannot isolate the contribution of PN itself.11

Aesthetics | November 2026

49


AESTHETIC EDUCATION. EVOLVED. Don’t just learn what to do. Learn why.

� Assessment � Treatment Planning

ASSESS

See before you treat

� Skin Quality

DECIDE

Choose the right treatment

ADAPT

� Volume Restoration � Wrinkle Relaxation

No two patients are the same

UNDERSTAND

Anatomy. Ageing. Pathology

TREAT

See techniques demonstrated

EVOLVE

Never stop learning

Aesthetic medicine doesn’t stand still. Techniques change, Innovation advances, Evidence expands. So should the way we practice.

WATCH ANYWHERE Desktop | Tablet | Mobile

LEARN IN MINUTES

Focused bite-sized education

KEEP EVOLVING

A growing library rather than a static course

aevo.co SEE HOW AEVO CAN CHANGE THE WAY YOU PRACTICE

500+ clinical videos Continuously evolving platform


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Acne scarring treatment for a male patient The below illustrates a case study for a male acne-scarring case study. Patient details and history A 38-year-old male patient presented with facial acne scarring, present for approximately eight years. He had no significant medical history, was not taking prescribed or over-the-counter medication and reported no allergies. There was no active acne at assessment; his last outbreak had been approximately three years previously. He had been assessed by a dermatologist approximately two years earlier. A further specialist referral was discussed, but he was not keen to pursue re-referral; this was documented as part of shared decision-making. Clinical observation and assessment Assessment identified significant and widespread rolling atrophic scarring across the mid-face and cheek regions, with some hyperpigmentation to the chin. The objective was to improve dermal quality, skin texture and rolling-scar appearance rather than achieve complete resolution. Treatment protocol The patient underwent three PN treatment sessions at four-week intervals. Each session consisted of 40mg of PNs in 2ml, administered using a 30G, 13mm needle with a microdroplet technique, giving a total of 120mg across the three sessions. This was the protocol used in this individual case and should not be interpreted as a published standard dose or universally recommended protocol for acne scarring. Clinical outcome A clinically observed improvement in overall skin quality and dermal appearance was noted. The most notable improvement was in the rolling acne scarring, with an apparent reduction in scar depth and visibility and a smoother overall skin surface. The scarring did not fully resolve, but an apparent improvement in dermal quality, including skin texture and hydration, was observed. Improvement was gradual and became more apparent following the third session. Interpretation No validated acne-scar score or objective imaging measurement was recorded. The findings should be understood as a clinical observation rather than quantitative evidence of treatment efficacy. The case does not establish efficacy or demonstrate that rolling scars respond better to PN than other scar types.

Planning treatment, safety and aftercare Treatment planning must remain product specific. PN formulations differ in composition, concentration, rheological properties, intended treatment depth, applicable UK regulatory requirements and recommended treatment course. In the UK, practitioners should confirm the regulatory status and intended use of the specific product being used rather than assuming that all products described as PNs have the same regulatory classification. The Medicines and Healthcare products Regulatory Agency notes that a product’s intended purpose is determined by the manufacturer’s stated intended use, including information supplied in labelling and instructions for use.12 Practitioners should follow the manufacturer’s instructions for use rather than transferring a published protocol from one formulation to

Acne Scarring Polynucleotides

another. Product selection should be based on its intended purpose, supporting evidence, patient factors and the practitioner’s training, rather than brand familiarity or popularity.12 Baseline photography should be standardised and scar severity recorded consistently. Review should allow sufficient time for progressive dermal change rather than judging the result immediately after treatment. Where PN is combined with subcision, needling or resurfacing, the rationale, sequence and recovery interval should be documented. There is currently no robust evidence supporting one universal combination protocol. The published PN-HPT monotherapy study used two sessions three weeks apart, while the 2025/2026 real-world PN-HPT/ HA study used four sessions two weeks apart; these intervals should not be transferred automatically to other products or combination procedures.9,10 Reported short-term effects include papules, erythema, swelling, tenderness and bruising.4,7 However, the available studies are too small to establish the frequency of rare complications.4,7 Treatment should therefore be undertaken with appropriate aseptic technique, anatomical knowledge, emergency procedures and a clear pathway for managing infection, hypersensitivity, persistent nodules or an unexpected inflammatory response. Consensus guidance for injectable aesthetic practice recommends appropriate aseptic technique and attention to patient selection, infection control and post-treatment care.13 Escalating pain, spreading erythema, marked swelling or other symptoms outside the expected recovery pattern require prompt clinical assessment.13 Aftercare should follow the selected product guidance and any additional procedure performed. A gentle cleanser, bland barrier-supportive moisturiser and broad-spectrum SPF 50 provide sensible foundations while the skin settles. Makeup, vigorous exercise, heat exposure and potentially irritating active skincare may need to be paused during the immediate recovery period. Specific restrictions should follow the selected product guidance and any additional procedure performed, rather than being treated as a universal 24-48-hour rule. Maintenance should not be promised at a fixed interval. Some patients may be reviewed after an initial course; others may gain more from a scar-specific procedure than from repeated PN treatment. Standardised photography, scar grading and patient-reported outcomes should guide whether further treatment is clinically justified.

Positioning PNs honestly in acne-scar practice PNs offer a credible regenerative option for selected patients with atrophic acne scarring, particularly where the objective is to improve dermal quality, shallow scar appearance and overall texture.4,9,10 The controlled evidence remains small, while newer real-world findings are promising but do not establish comparative effectiveness or an optimal protocol.4,9,10 Their value is therefore not in replacing morphology-led scar treatment, but in adding another option to a carefully sequenced plan. Bernadette Tobin is an independent nurse prescriber, with more than 20 years’ clinical experience, including 12 years in medical aesthetics. Tobin is a former senior university lecturer at Anglia Ruskin University, and founder of Visage Aesthetics and Aesthetics Unlocked, providing evidence-led clinical education and practical support for aesthetic practitioners across the UK. Qual: MSc, ANP, RN

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026

51


Advertorial Teoxane

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Redensity 1 combines non-crosslinked hyaluronic acid with 10mg/g Concentrated Dermo Restructuring Complex, containing zinc, copper, antioxidants and amino acids complex.* Clinical evaluation has shown measurable changes after just nine days,3 including: +1,400% glycosaminoglycans (GAGs) +98% collagen type IV +28% elasticity improvement These findings help demonstrate why Redensity 1 sits at the centre of the Teoxane babyGLOW™ concept. The formulation is not simply being used as a delivery vehicle for hydration; the clinical evaluation provides evidence of measurable changes associated with the skin environment following treatment.³ For practitioners, this gives the treatment conversation a clear scientific foundation and supports a skin-quality proposition that can be discussed beyond an immediate cosmetic effect. It allows Teoxane babyGLOW™ to bring together a recognisable patient-facing concept with the established formulation and evidence base of Redensity 1.

Skin Quality, Redefined Meet babyGLOW™ by Teoxane A precise, easy-to-adopt treatment concept designed for the way patients want to look and feel today. As demand continues to shift towards fresher, more natural-looking results with minimal disruption, skin quality has become an increasingly important part of the aesthetic conversation. babyGLOW™ by Teoxane is an adapted injection protocol using Teosyal Redensity 1 (3ml), creating a treatment experience designed around precision, comfort and visible skin revitalisation.1 At the heart of the protocol are eight validated injection points on each side of the face, identified using four anatomical landmark lines.2 The result is a clear, reproducible treatment framework that is simple to integrate into practice and easy to communicate to patients.

For patients, the proposition is simple: fresher, more hydrated-looking skin, minimal downtime and results designed to look natural.4 That balance is important in a category where patients may want to see a difference without feeling that their features have been altered. Patient-reported data collected on Redensity 1 and the Teoxane babyGLOW™ protocol supports the focus on a refreshed, natural-looking outcome.4 In practice, this creates a treatment story that is easy to understand: a precise protocol, a product developed for skin revitalisation and an outcome centred on looking fresher and more hydrated, while remaining recognisably yourself. *Specially designed for Teoxane and diluted to 1/100 in the manufacture of our gels.

For healthcare professionals (HCPs), that structure is central to the concept. Rather than presenting skin revitalisation as a broad or abstract treatment goal, Teoxane babyGLOW™ gives the consultation a defined framework: clear anatomical landmarks, validated treatment points and a consistent approach that can be explained from assessment through to treatment.1,2 This supports a more coherent patient journey while keeping the focus on skin quality, rather than changing facial identity. The protocol is designed to make precision feel practical, helping practitioners communicate what is being treated, why those points have been selected and what patients can realistically expect from the treatment experience.

Powered by Redensity 1

Now, Teoxane babyGLOW™ is evolving Introducing babyGLOW™ for HIM by Teoxane. Created specifically with the male patient in mind, Teoxane babyGLOW™ for HIM takes the same principles of precision, comfort and skin revitalisation and adapts the treatment points to better reflect male facial anatomy and masculine aesthetic ideals.1,4 The aim is not to noticeably change the face. It is to help male patients look fresher, more energised and well-rested, while preserving their natural appearance. For male patients, the way that proposition is communicated can 52

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

be just as important as the treatment itself. Teoxane babyGLOW™ for HIM provides practitioners with a specific entry point into the skin-quality conversation, with treatment points adapted to male facial anatomy and aesthetic ideals while retaining the core Teoxane babyGLOW™ principles.¹,⁴ The emphasis remains on subtlety: supporting a fresher, more rested appearance without creating an overtly treated look. This makes the concept particularly relevant when speaking to patients whose priority is not transformation, but an improvement in how their skin looks and how refreshed they appear. For practitioners, it creates an opportunity to open the skin quality conversation to a broader patient audience, including men who may be considering injectable treatments for the first time. The distinction also gives clinics a clearer way to tailor communication without creating two completely separate treatment philosophies. The original Teoxane babyGLOW™ and Teoxane babyGLOW™ for HIM are connected by the same Redensity 1 (3ml) foundation and the same focus on precision, comfort and natural-looking skin revitalisation.1,4 What changes is the conversation around the patient: their anatomy, their priorities and the way the treatment is positioned. For HCPs, this provides flexibility to introduce skin quality in a way that feels more relevant to the individual sitting in front of them.

One treatment concept. Two patient conversations. · Teoxane babyGLOW™: For patients looking for a fresh, hydrated

and revitalised appearance. · Teoxane babyGLOW™ for HIM: Adapted for male patients seeking subtle, natural-looking skin quality improvements. Both are powered by Redensity 1 (3ml) and supported by a structured protocol designed to bring precision and consistency into practice. Together, the two approaches broaden the role skin quality can play within an aesthetic practice. They give practitioners a defined concept for existing injectable patients while creating a straightforward conversation for those newer to treatment and looking for a subtle starting point. The clinical protocol remains structured, while patient communication can be personalised. In this way, Teoxane babyGLOW™ provides a clear framework for discussing skin revitalisation with different patient groups while maintaining consistency in product choice and treatment philosophy.

This advertorial was written and supplied by

For more information, scan the QR code to be put in contact with your local Product Specialist.

Advertorial Teoxane

Dr Pamela Benito spotlights babyGLOWTM by Teoxane 1. What makes Teoxane babyGLOWTM stand out in the market? What makes Teoxane babyGLOWTM stand out is its focus on skin quality and subtle, natural-looking results rather than changing facial features. In my practice, the aim is always to enhance what is already there, helping the skin look fresher, more hydrated and radiant while preserving the patient’s natural appearance. It is a versatile treatment that can be tailored to the individual and incorporated into a preventative or revitalising approach to aesthetics, depending on the patient’s needs. For me, the best aesthetic results are often the most subtle ones, where the skin looks healthier and more luminous, but the treatment itself is not obvious. 2. How did you implement Teoxane babyGLOW™ into your clinic? Teoxane babyGLOWTM was an easy integration into my clinic because we have been using Teoxane Redensity 1 for many years. Teoxane babyGLOWTM is a new technique that uses Redensity 1, so it builds on a product we already know and trust, while offering a specific approach to enhancing overall skin quality and radiance. It fits naturally into my treatment philosophy, which focuses on personalised, subtle results and maintaining the skin’s health and wellbeing. I find that patients are increasingly interested in improving their skin quality rather than simple addressing individual lines or wrinkles, making Teoxane babyGLOWTM a valuable addition to our bespoke treatment offering. We incorporate babyGLOWTM into bespoke treatment plans following an individual assessment, whether the goal is to maintain skin quality or address early signs of ageing. I believe that successful aesthetic medicine is about understanding what each patient needs and selecting the right treatment, rather than applying the same approach to everyone. 3. Have you seen an uptake of male patients since offering babyGLOW™ for HIM? Yes, we have definitely seen an increase in male patients enquiring about Teoxane babyGLOWTM and treatments focused on skin quality. Men are becoming more interested in aesthetic treatments that help them look refreshed and maintain a healthy appearance without changing their natural features. At our clinic, our patient demographic is now approximately 70% female and 30% male patients, reflecting the growing interest we are seeing from men in aesthetic medicine. I think treatments such as Teoxane babyGLOWTM are appealing because the emphasis is on skin quality and it involves minimal discomfort and little to no downtime, making it an attractive option for patients with busy lifestyles. Ultimately, men want the same thing as many of my female patients: to look like the best version of themselves with natural looking results and glowing skin!

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM Aesthetics | November 2026

53


Menopause Assessment

@aestheticsjournaluk

Rethinking Aesthetic Assessment in the Menopausal Patient Dr Jessica Halliley explores assessment and treatment planning in menopausal patients An increasing number of women are seeking aesthetic treatment during the peri- and post-menopausal years. For the aesthetic practitioner, this can present a different clinical challenge from conventional age-related facial ageing. Although chronological ageing remains an important contributor, declining ovarian oestrogen has additional effects on the skin and connective tissues, including reduction in collagen, dermal thickness, elasticity, hydration and wound healing.1-5 The result is that the patient may present with a relatively sudden change in her perception of her face. The patient’s skin may feel thinner or drier, fine lines may appear more prominent, facial contours may soften and previously successful treatments may no longer produce the same perceived result. This raises an important question for aesthetic practitioners; should we assess and treat the menopausal face differently? The answer is not that every menopausal patient requires a different treatment. Rather, menopause provides an important clinical context. Understanding the underlying biological changes can help practitioners distinguish between skin quality concerns, dynamic rhytides, volume loss and tissue laxity, and develop a treatment plan that addresses the patient’s anatomy rather than simply responding to the treatment the patient may initially request.

Menopause and the aesthetic presentation Oestrogen receptors are present in multiple cutaneous cell types, including keratinocytes, fibroblasts and melanocytes.² It is therefore no surprise that during menopause, declining oestrogen is associated with a reduction in collagen, dermal thickness, elasticity and skin hydration.3,4 These changes are clinically relevant to aesthetic practice. Reduced collagen and dermal thickness contribute to lines, laxity and increased fragility, while changes in hydration and barrier function causes dryness, a dull complexion and often trigger inflammatory skin conditions like rosacea and perioral dermatitis.1,3 Wound healing can also be impaired in post-menopausal skin.1,3 However, the menopausal face cannot be explained by the skin alone. Facial ageing is a three-dimensional process involving skin, subcutaneous fat, muscle, retaining structures and the underlying skeleton. Changes in facial adipose compartments contribute to alterations in volume and contour, while progressive skeletal remodelling also contributes to changes in facial architecture.6,7 This distinction certainly matters clinically. A patient describing “sagging” may have a combination of dermal thinning, descent of fat pads, volume redistribution, ligamentous change and skeletal degradation. Treating only the skin may therefore produce an incomplete result, so we must create a holistic treatment plan to gain optimum results.7 54

Aesthetics

Aesthetics

aestheticsjournal.com

Consultation A detailed consultation becomes particularly important when a patient presents during the menopausal transition. Practitioners should begin by establishing what has changed and when. Questions such as, “What are you noticing today, that you didn’t notice two or three years ago?” can be more informative than simply asking what their concerns are, as patients can often become hyper-focused on individual issues rather than stepping back and seeing their face as a whole. The patient’s menopause history should form part of the broader medical history. This should include the patient’s age, menstrual status, what stage in their menopause journey they are at, determining if they are on hormonal-related therapy (HRT) or any other systemic medication for symptom control and any previous gynaecological malignancies. It is also important to know their individual symptom burden. The purpose is not to diagnose or manage menopause within an aesthetic consultation, but to understand the clinical context and identify when another healthcare professional should be involved, and refer onwards if so.

Assessment The facial assessment should then be systematic. Practitioners should consider all factors that can be affected during menopause, including:6

· Skin quality, hydration, texture and discolouration (both pigment and redness/facial vessels)

· Static and dynamic lines, as well as their relationship to

muscle activity Facial proportions and asymmetry Facial fat compartments and volume loss Tissue laxity Balance and proportion Previous aesthetic treatments and their cumulative effect An equally important component is understanding the patient’s expectations. Any sign of unrealistic expectations can quickly be diffused during the consultation itself, through honesty and education. A female patient who says, “I suddenly look tired” may not be asking for wrinkle reduction even if that’s what she has decided to book. She may be describing a combination of periorbital volume change, skin-quality deterioration, facial deflation and altered facial proportions.6 The consultation therefore needs to focus on biological and anatomical changes that may be contributing to the patient’s concern.

· · · · ·

Treatment planning Management should be individualised according to the patient’s anatomy, skin type, concerns, previous treatment and expectations. Whether or not they decide to have HRT can also affect their end result. A systematic review and meta-analysis published in 2024 found that systemic hormone therapy was associated with improvements in skin elasticity, thickness and collagen content as the oestrogen was re-introduced.5 For patients whose predominant concern is skin quality, energy-based devices can be useful. Microneedling on a regular basis may be a suitable treatment for menopausal patients who are not initially ready to consider injectables. The collagen decline during menopause is rapidly accelerated compared with the rest of a woman’s life, and microneedling is well studied as a treatment that stimulates collagen production.⁸ A 2025 systematic review of microneedling for facial rejuvenation demonstrated improvements in multiple outcomes, including wrinkling and skin texture.⁸ It is increasingly popular in this age group due to its cumulative collagen induction, natural healing process, low downtime and relatively low cost for patients compared with ultrasound and radiofrequency (RF)

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

microneedling. All treatments come with their own potential risks. For microneedling, these include post-inflammatory hyperpigmentation (PIH), infection, contact dermatitis, persistent erythema, scarring and granulomatous reactions.9 RF microneedling may be considered where additional dermal remodelling is required, including for concerns around skin laxity and texture, but has the added potential risks of nerve injury and unwanted fat loss.10 Laser can be used where more substantial resurfacing is appropriate, and is particularly useful in the treatment of redness, facial vessels and pigmentation. The risk of burns and pigmentation has to also be considered.11 The decline in oestrogen associated with menopause accelerates changes in the skin and underlying facial tissues, including loss of collagen and dermal thickness, reduced elasticity and progressive changes in facial volume.12 Treatment should therefore be individualised according to the predominant features identified on assessment rather than menopause itself. Botulinum toxin is primarily useful for dynamic rhytides caused by muscular activity, as well as lifting the depressors of the lower face.13 HA dermal fillers should be considered when structural volume loss is contributing to the patient’s concern. The majority of patients need a degree of temple, mid-face and chin filler. Collagen-stimulating treatments may also have a role in selected patients. A recent systemic study shows improvements in skin quality, thickness and facial appearance with poly-L-lactic acid, for example.14 Before

After

Menopause Assessment

shadow. Moderate nasolabial folds, marionette lines and jowling were also noted. Following a comprehensive consultation, medical-grade skincare was recommended. Treatment initially focused on restoring facial volume and improving overall facial proportions using HA dermal filler, with the aim of achieving an immediate yet natural-looking outcome. A longer-term plan to address skin quality was deferred until after the wedding. In the temporal region, 0.5ml of Restylane Volyme was injected supraperiosteally to provide support to the lateral brow. The mid-face was treated with 1.2ml of Restylane Lyft to restore projection and structural support. A further 0.2ml of Restylane Lyft was placed supraperiosteally within the piriform fossa using a needle. To soften the nasolabial folds, 0.5ml of Restylane Volyme was placed using a 25G, 38mm cannula. The lips were treated with 0.7ml of Restylane Refyne using a needle. A combination of linear threading, curved threading and tenting techniques was used to improve vermilion definition and hydration. For chin projection and lower-face lengthening, 1ml of Restylane Lyft was administered as three supraperiosteal boluses. A further 1.7ml of Restylane Defyne was placed using a cannula to blend the chin shadow and marionette lines, creating a smoother transition between the lower-face subunits. Capillary refill was monitored throughout the procedure, and aspiration was performed before all bolus injections. The patient looked significantly more refreshed in the photos taken immediately after treatment, the jowls are disguised and she looks happier. Maintenance is typically required approximately one year post treatment. The patient was advised to avoid applying cosmetics, strenuous exercise, heat exposure and alcohol for a minimum of 24 hours. She was also counselled on the signs and symptoms of vascular occlusion and the need for urgent review should these occur.

Menopause and facial ageing Menopause does not create an entirely new type of facial ageing, but it can accelerate and alter several of the biological processes that contribute to the ageing face. For aesthetic practitioners, the key change should therefore be in assessment rather than simply treatment choice. A menopausal patient presenting with wrinkles, laxity or volume loss should be assessed holistically, considering skin quality, soft tissue, muscle and skeletal anatomy alongside the patient’s wider medical context and expectations. Treatment should then be selected according to the underlying problem, with realistic discussion of evidence, limitations and risk. Figure 1: 54-year-old female patient receiving HRT, before and immediately after treatment of Restylane dermal filler across the temples, mid-face, piriform fossa, nasolabial folds, lips, chin and marionette lines.

Case study A 54-year-old menopausal female patient receiving HRT presented with concerns regarding facial descent, fatigue and an increasingly downturned facial appearance. She sought a treatment plan capable of delivering a visible, proportionate improvement ahead of her daughter’s wedding, scheduled several weeks later. Clinical assessment identified moderate facial tissue laxity, reduced skin radiance, a lateral nasal deformity secondary to a previous road traffic accident and multiple corrective procedures, and relative shortening of the lower facial third. Volume depletion was present in the temporal region, mid-face, piriform fossa and pre-jowl/chin

Most importantly, medical aesthetics should sit alongside, rather than replace, appropriate menopause care. A well-conducted aesthetic consultation can provide an opportunity to recognise the complex biological changes occurring during this stage of life and to develop a treatment plan that restores proportion and skin quality, without attempting to erase normal ageing. Dr Jessica Halliley is a general practitioner, aesthetic practitioner and founder of Your Beauty Doctor in Nottingham. She graduated from the University of Sheffield with Honours. With postgraduate qualifications in Women’s Health and Medical Aesthetics, she has a particular interest in menopause and holistic patient care. Dr Halliley is a key opinion leader for Alastin, Ameela, Galderma, SkinPen and SuneKOS. Qual: MBcHB(Hons) MRCGP DRCOG PGDIPAES

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026

55


Advertorial Nouveau Visage

@aestheticsjournaluk

One Complex, Five Solutions

Aesthetics

Aesthetics

aestheticsjournal.com

· NEWDERM Bright – pigmentation. Tranexamic acid,

The formulation science behind Nouveau Visage’s regenerative microneedling system Regenerative aesthetics keeps moving further from replacement and closer to repair, and practitioners are increasingly weighing up formulations on how well they stimulate the skin’s own regenerative pathways, not on a single headline ingredient. Nouveau Visage, the French biomedical aesthetics brand launched in the UK by Fox Pharma in partnership with MedFx, combines a core regenerative technology with tailored active ingredients across five targeted formulations, allowing practitioners to address a specific indication within each protocol.1

arbutin and glutathione work alongside the core complex to target melanogenesis and unify tone. Paired serum: Le Serum NewSkin. · NEWDERM Eye – periorbital concerns. Ascorbyl glucoside, arbutin and azelaic acid are formulated for the finer skin of the eye contour, addressing dark circles and fine lines. Paired serum: Le Serum NewEye. · NEWDERM Hair – hair loss. B vitamins, ginseng and PDRN act on follicular stimulation and scalp microcirculation to support density and hair health. Paired serum: Le Serum NewHair. · NEWDERM Lift – firmness. DMAE and silanetriol combine with the core complex to support collagen architecture and cutaneous firmness. Paired serum: Le Serum NewLift. Each protocol runs as a course of four sessions (six for Hair) at 15-day intervals, repeated at four months or as clinically indicated, delivered via microneedling.

An early clinical view Regen³ Complex: one core technology, five formulations At the centre of the range sits Regen³ Complex, Nouveau Visage’s signature technology bringing plant-derived exosomes, polydeoxyribonucleotide (PDRN) and biomimetic peptides together within a single formulation.1 The three components are selected for complementary roles in fibroblast stimulation, cellular communication and extracellular matrix renewal.2-4 Each component plays a distinct role. Plant-derived exosomes act as signalling vesicles, carrying proteins, lipids and nucleic acids between cells to support intercellular communication.2 PDRN has been shown to enhance the proliferation of human skin fibroblasts through A2 purinergic receptors,3 and has been associated with improved skin elasticity.5 Biomimetic peptides mimic the skin’s natural signalling pathways to encourage collagen and elastin production.4 Delivered via microneedling, the three are intended to work through complementary pathways to support tissue repair and extracellular matrix renewal across the treatment course. Rather than applying one blend across every concern, the NEWDERM™ range reweights the actives around Regen³ Complex to match five specific presentations, each with its own paired at-home serum:

· NEWDERM Age Control – antiageing. Dimethylaminoethanol

(DMAE), HA and the biomimetic peptides Acetyl Hexapeptide-1 and Palmitoyl Tetrapeptide-72 Amide support dermal density, hydration and elasticity. Paired serum: Le Serum NewAge.

56

“Regenerative aesthetics is increasingly focused on how we stimulate the skin’s own repair mechanisms, rather than simply replacing volume or masking signs of ageing. What makes Nouveau Visage particularly interesting from a clinical perspective is the way the Regen³ Complex combines three complementary regenerative technologies within one formulation. In practice, this allows practitioners to achieve improvements in skin texture, elasticity and radiance through a structured treatment course that is both clinically grounded and easy to incorporate into existing microneedling protocols,” says Dr Apostolos Vlachogiorgos, plastic surgeon and early UK adopter.

This advertorial was written and supplied by

Nouveau Visage has launched across more than twenty international markets and is manufactured to International Organization for Standardization (ISO) standards. Fox Pharma is the exclusive UK launch partner and distributor. For further information on the Nouveau Visage system, contact nv@foxpharma.co.uk

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Clinical Papers Abstracts

A Summary of the Latest Clinical Studies The latest research highlights from Professor Sebastian Cotofana

· The male facial soft tissues contain more retinacula cutis per

· The request for male aesthetic procedures is increasing · Males have different aesthetic needs and require a different

A male facial shape and outline is square with a smaller facial angle compared to an oval or heart-shaped female facial outline, which requires an aesthetic practitioner to not slim the lower face but instead to increase the lateral projection of the angle of the mandible and of the lower face; the zygomatic region, however, should never be increased in males compared to females. The width of the chin in males should be adjusted to the width of the mouth (= distance between both oral commissures), whereas the width of a female chin should be adjusted to the intercanthal distance or to the width of the nose. This would require wider chin implants in males and two soft tissue filler injection points compared to one single midline injection point in females.

Key Takeaways

treatment approach · There are substantial differences in male vs. female facial anatomy which result in different facial features

Title: Minimally Invasive Aesthetic Treatments in Men: A Systematic Review and Meta-Analysis. Authors: Aina García Dinnbier, et al. Published: Dermatoloogic Surgery, October 2026 Keywords: Sex dimorphism, Soft tissue differences, Subcutaneous architecture The worldwide number of cosmetic surgical and non-surgical procedures performed in men increased in 2025 by 14.4% and 15.2% compared in previous years, according to the annual statistics of The International Society of Aesthetic Plastic Surgery (ISAPS). This trend is not surprising in today’s society as both women and men are seeking aesthetic treatments to address their aesthetic needs and to comply with increased peer pressure to look young and healthy and to overcome ageing. Whereas the products and the procedures are identical, the surgical and the non-surgical approaches are fundamentally different due to the underlying anatomic differences. Both the facial hard and soft tissues display sex dimorphism which is imprinted in the genetic code of both sexes:

· The male facial skeleton is generally larger, has a flatter

forehead angle, has a wider bi-gonial distance, has a wider chin, and displays a more prominent frontal bossing compared to a female skull

area, have a greater dermal thickness, have thicker facial muscles, and have an overall more robust superficial fascial system compared to females These major differences result in the apparent visual differences between a male and a female face, and these differences need to be understood and respected when conducting facial aesthetic procedures.

When it comes to soft tissue filler product choices, it needs to be understood that due to the increased subdermal stability of the superficial fascial system in males, a more robust product needs to be selected and more material might be required to achieve a similar skin surface projection when compared to females. Understanding the sex dimorphism between male and female faces enables any aesthetic practitioner to drive their aesthetic outcomes toward the desired appearance. Depending on whether a more masculine or if a more feminine facial appearance is desired, the respective facial features need to be enhanced or hidden. Especially in today’s gender fluid society, this anatomic knowledge is essential for successful practice. This abstract was supplied in partnership with Cotofana Academy.

Aesthetics top picks · Title: Hyaluronic acid-based skin booster with glutathione combined with 1064-nm Nd:YAG laser and oral tranexamic acid for melasma: A prospective comparative study. Authors: Jie Ling Bai, et al. Published: Medicine, October 2026. · Title: Redefining the Facial Artery Safe Zone: A Dynamic, Segment-Based Vascular Risk Analysis. Authors: Emre Kaygin, et al. Published: Aesthetic Plastic Surgery, October 2026.

Find out more

Aesthetics | November 2026

57


Panel Discussion CCR 2026

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Exploring What it Takes to be a Key Opinion Leader Company representatives offered a behind-the-scenes perspective on their search for a KOL at CCR 2026 At the Clinical Cosmetic Regenerative Congress (CCR) 2026, the In Practice theatre hosted ‘Behind the Selection: How Companies Choose KOLs,’ a panel discussion exploring how companies select key opinion leaders (KOLs) and the challenges that can arise during the process. This year at CCR, we set out to change the narrative by shifting the focus away from KOLs themselves and towards the professionals working behind the scenes. This fresh perspective gave attendees genuine, practical insights, dispelled common myths surrounding the role and equipped them with the knowledge to stand out in an increasingly saturated market. Chaired by journalist and The Tweakments Guide founder Alice Hart-Davis, the discussion brought together representatives from pharmaceutical companies Galderma and IBSA Derma, aesthetic manufacturer Teoxane and device company BTL Aesthetics. The panel featured Wojciech Konczalik, head of training and medical education UK&I at Galderma; Anita Sandhu, medical science liaison at IBSA Derma; Rifat Khan, medical science liaison UK&I at Teoxane; and Lauren Clements, head of marketing at BTL Aesthetics.

Considering the traits of a suitable candidate Konczalik described identifying potential KOL leaders in medical aesthetics as a “multifaceted process” rather than a straightforward yes-or-no assessment. He shared, “We consider both a clinician’s current capabilities and their future potential. This includes clinical excellence, educational ability, curiosity and a willingness to challenge.” For Konczalik, a successful KOL is motivated to create positive change not only for themselves, their business and their patients, but also for the wider medical-aesthetics community. He notes this contribution may range from hosting patient education events to advancing research, regulation and professional standards through established institutions and 58

peer-reviewed work. He emphasised that passion encapsulates these qualities, adding, “When that passion is evident, our team is willing to invest in the individual and support their development through collaboration and shared growth.” Hart-Davis asked Konczalik whether companies look for someone with a strong personality alongside their medical expertise. He replied, “Aesthetics brings a lot of vibrant people to this specialty, and I wouldn’t say that a little eccentricity or a more personalised touch would preclude anybody from developing here, provided they have strong qualities elsewhere.” Following on, Hart-Davis asked Sandhu what the qualities of a KOL are beyond clinical proficiency. Sandhu highlighted the importance of finding practitioners who combine clinical knowledge with credibility and a readiness to be transparent. For her, that means choosing KOLs who are prepared to share not only their successes, but what went wrong and what they learned from it. “We want someone whose peers want to listen to and to learn from,” shared Sandhu. Sandhu said IBSA Derma is particularly interested in clinicians who can openly discuss when a treatment or approach hasn’t delivered the intended result, how they adapted their strategy and what ultimately produced a better outcome for the patient, clinic or team. She stated, “Authenticity is key, practitioners don’t need to present themselves as perfect, but they should demonstrate curiosity and a willingness to keep learning.” Sandhu concluded, “We are really focusing on prioritising the medical aspect of medical aesthetics,” adding that the practitioners who share this mindset and want to help move the specialty forward are the ones the company is looking to support. Analysing the process after identification Turning to the overall process, Hart-Davis asked how companies proceed once a practitioner has been identified as a potential KOL. Clements explained that recognising a promising individual is only the first step; the next is to establish whether there is genuine alignment between the practitioner, the technology and the brand. She explained this involves input from multiple teams, from

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

Panel Discussion CCR 2026

aestheticsjournal.com

marketing and sales to the wider business and, in some cases, the build team, to gain a fuller understanding of the practitioner’s interests, experience and areas of expertise. “We need to make sure that it’s not just the social presence. We look at what they’re doing and whether that aligns with what we’re looking for educationally,” she added, saying that ultimately, the aim is to ensure that the practitioner is the right fit for the brand.

Discussing the importance of company engagement Hart-Davis proposed a question to Khan, asking how practitioners can proactively engage with companies and put themselves on the companies radar. Khan emphasised that becoming a KOL is a long-term journey that requires initiative and authentic relationship-building. She encouraged practitioners to proactively approach companies and sales representatives associated with products they already use and have experience with, advising, “Bring your true authentic self to these conversations.” She explained that building such relationships forms part of a broader process of professional development, adding, “It’s all about your pathway and your journey.” She likened identifying the right KOL partnership to a Venn diagram, in which a practitioner’s own passions and interests overlap with the company’s priorities. “That little thing in the middle, that’s your sweet spot,” she said. Ultimately, Khan encouraged practitioners to focus on building their credentials over time, from developing strong case studies and conducting research, to having meaningful conversations with specialty contacts. “There is a whole journey, and I think that’s what people have to understand,” she said.

Addressing common misconceptions The panel also addressed the perceived importance of social media in becoming a KOL. Sandhu acknowledged that building an effective social-media presence can be challenging but stressed that it is not necessarily an accurate reflection of a practitioner’s capabilities. “Social media is hard; if you manage to achieve it, congratulations, because it is a difficult beast to try and perfect. However, I do not believe it is necessarily reflective of you as a practitioner,” noted Sandhu. Clements echoed this, adding, “I see a lot of individuals who are discouraged from putting themselves forward because they think they need a significant following, but that’s not actually what brands are looking at.” She confirmed credibility and communication within the field goes much further. Khan shared this view, arguing that the strongest candidates are not necessarily the most visible on social media. “The best KOLs probably hardly have time to post on social media. They’re in the background doing the work, seeing their patients and getting the results,” she said. Khan observed that some practitioners may be surprised when companies approach them, prompting them to question whether they should increase their social media activity or expand their online following. Konczalik agreed that misconceptions persist, particularly the assumption that simply approaching a company is enough. Instead, he highlighted the importance of genuine product advocacy, particularly for product-specific KOL roles. Konczalik shared, “I cannot list the number of times where practitioners approach me for specific training on a product and have never used it themselves. Of course, we can teach somebody how to inject a product, but the true value for a company in an educational scenario is those clinical insights that are generated only through prolonged and extensive use.”

The four panellists share their checklist advice Anita Sandhu: “Communication skills are a really big factor. That doesn’t mean you have to speak at conferences; It’s about communicating what you’ve learnt, whether through smaller groups, training or teaching. Developing a way of communicating your authentic self is important, so people know they’re hearing the real you.” Wojciech Konczalik: “Define your niche, develop and pursue it, and make sure it aligns with your passion or professional interests. Companies look for a variety of people – researchers, social media contributors, advisors and speakers. There are many pathways you can develop, but you need to clearly communicate your direction to companies; they won’t be able to guess it.” Rifat Khan: “With some KOLs, you see their authentic self when discussing clinical research case studies – that’s what they bring to the table. Everyone has a business persona, but one-to-one conversations reveal their true drivers, passions and what they bring. That’s when their authentic self really comes alive.” Lauren Clements: “Find your niche but also engage with the brand. Find one that aligns with what you’re already doing. Attend webinars, speak to companies and build those relationships. Then let it grow into becoming a player.” However, he noted that established product experience is not essential for every clinician-company collaboration. Practitioners with specialist expertise, such as anatomy or facial feminisation and masculinisation, can bring value without an established product background. What matters most, he stressed, is authenticity. “We don’t want to fake advocacy. It needs to be organic, and real,” he said, adding that this authenticity ultimately shines through in how KOLs engage with and educate other clinicians.

Start the conversation The panel concluded by encouraging clinicians and researchers not to be intimidated by specialty companies. All panellists aligned that building these relationships does not have to be daunting; often, it starts with simply having the confidence to approach someone and start a conversation.

Aesthetics Business Show

at ACE 12 & 13 March 2027

At Aesthetics, we believe business-focused guidance is just as important as clinical expertise. Whether you enjoyed the In Practice content at CCR, regularly read our monthly business features, or simply want to learn how to transform your clinic into a high performing business, make sure to register your interest in the Aesthetics Business Show (ABS). The new event will be launching at the Aesthetics Conference & Exhibition on March 12-13, 2027, scan the QR code to register your interest today.

Aesthetics | November 2026

59


Clinic Performance Patient Retention

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

There is no single retention target that suits every clinic; appropriate return intervals differ by treatment, patient goals and clinical judgement. Clinicians should establish a baseline over the first 30 days, then set realistic improvement goals for the next quarter. For example, if 40% of eligible patients currently book an appropriate follow-up before leaving, a clinic might aim to increase that to 45% over the next three months. Review the numbers monthly and ask what changed before attributing an improvement to a particular tactic.

Evaluating Retention as the Growth Strategy in Aesthetics Founder of a growth consultancy firm Amy Kapolnek shares a practical guide to measuring patient retention, improving the patient journey and building sustainable clinic growth Clinics often track enquiries, new bookings and advertising spend. A less consistently monitored metric is what happens after a patient’s first appointment, specifically whether they receive appropriate follow-up and attend subsequent visits when clinically appropriate. Acquisition matters, but sustainable growth also depends on retention because clinics that maintain appropriate relationships with existing patients are less reliant on continually replacing them with new ones. Acquiring a new patient can cost five times more than retaining an existing one, whether that be through the advertising involved, sales and marketing on top of developing their trust.1 In a five-year study of a resident-run clinic providing nonsurgical facial aesthetic treatments, 247 of 380 patients (65%) returned for at least one additional visit after their initial appointment.2 Thus underlying the value in existing patient relationships. This article explores how clinics can turn retention into a measurable, patient-centred part of their growth strategy.

Defining and implementing retention When approached strategically, retention can help clinics understand whether they are meeting patient needs, maintaining trust and delivering an experience that encourages patients to return when it is appropriate to do so. Retention can take several forms; a patient returning for a clinically appropriate review or maintenance appointment; continuing with a suitable treatment plan; remaining active over a defined period; or choosing the practice again when a new need arises. These behaviours will look different depending on the clinic’s treatment mix, patient population and care pathways, so there is no single definition that works for every practice. Clinics should establish what retention means in their context by choosing a defined period (such as six or 12 months) identifying which types of return visits count and excluding patients for whom further treatment is not clinically indicated. They can then build it into everyday processes, from follow-up and appointment planning to reviewing patient feedback and identifying gaps in the patient journey. 60

A simple illustration shows why the measure matters. If a clinic has 1,000 active patients spending an average of £600 per year, that represents £600,000 in annual revenue. A hypothetical 10% increase in average annual spend would add £60,000 before accounting for treatment costs, margins, capacity or any additional staffing. This is an illustration, not a forecast; clinics should model their own figures and should never recommend unnecessary treatment to reach a revenue target.

Practical ways to enhance retention Retention is shaped by the whole experience, not a single reminder message. Organising actions around the patient lifecycle gives teams clear responsibilities and helps ensure that follow-up is relevant, timely and clinically appropriate. Design the patient journey Clear expectations can reduce confusion, thoughtful aftercare can reinforce trust and continuity, and an agreed next step makes it easier for patients to continue appropriate care without feeling pressured.

· Before the first appointment: Retention starts with trust. Set · · · ·

·

clear expectations on fees, consultation outcomes and consent so patients feel informed and confident choosing the practice. During the consultation: Patients return when they feel heard, not sold to. Base recommendations on their goals, clinical need and informed choice – not sales targets. At checkout: Turn a single visit into ongoing care by agreeing an appropriate next step, timing and support route. Make follow-up easy, without pressure to book. After treatment: Timely check-ins and clear recovery guidance show patients that care continues after treatment. This reassurance builds trust, especially when concerns arise. Between visits: Stay relevant through permission-based, personalised communication and clinically appropriate reminders. Useful contact keeps the practice top of mind without being intrusive. At review points: Reassess outcomes and whether further care is genuinely needed. Honest advice – even when no treatment is required – builds credibility, loyalty and future return visits.

Use technology to support better review conversations Patients are more likely to stay engaged with a clinic when communication gives them a clear reason to do so, understanding what was discussed, what progress may reasonably look like and when a review is clinically appropriate. Review conversations also give patients an opportunity to ask questions, revisit their goals and feel that their care is being followed over time. Digital skin-analysis tools can support retention when they make those review conversations clearer and more useful, rather than simply adding technology to the consultation. Standardised images or measurements can help clinicians document visible skin concerns and compare changes over time. At consultation and review points, this can give patients a more consistent way to revisit their original goals and decide, with the clinician, whether a treatment plan remains suitable.

Aesthetics | November 2026


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

Make follow-up useful Personalised follow-up should reflect the service provided, the patient’s consent and the clinical protocols. A post-treatment check-in may focus on expected recovery and when to contact the clinic, while a maintenance message may remind an eligible patient when a review could be appropriate. There is no universally correct message length or cadence. Agree the timing with the clinical team, test whether messages are helpful and monitor opt-outs, replies, rebooking and complaints as well as bookings. Useful, relevant communication helps maintain continuity between appointments and reinforces that the relationship extends beyond the transaction itself – helping patients feel supported, remembered and more confident returning when care is appropriate. Automation can support consistency, but a named team member must own the process. Clinics should define who monitors responses, what counts as a clinical concern and how quickly those concerns are escalated.

Retention scorecard: what to track and how to calculate it Metric

Simple calculation

What it helps you understand

Repeat-visit rate

Patients with two+ visits in the period ÷ patients seen in the period × 100

Whether patients are returning; define the period and patient cohort consistently

Rebooking rate

Eligible patients who book their next appointment before leaving ÷ eligible patients seen × 100

Whether the next step is clear and convenient. Exclude patients for whom follow-up is not clinically indicated

Average time between visits

Total days between consecutive visits ÷ number of visit intervals

Whether appointment timing broadly matches the care plan and service mix

Revenue per active patient

Revenue in the period ÷ unique active patients in that period

How much revenue is associated with the active patient base; review alongside costs and treatment mix

Membership retention

Members still active at period end ÷ members active at period start × 100

Whether a membership continues to deliver value and meet patient needs

Patient lifetime value (LTV)

A clinic-defined estimate of revenue or gross profit per patient over the relationship

Longer-term value. State the time window and whether the figure is revenue or profit

Memberships Memberships can make planned maintenance more convenient and give clinics a more predictable revenue stream, but they are not automatically the right model for every patient or practice. A membership should solve a real problem for the patient, such as spreading the cost of eligible services over several months, simplifying regular skincare replenishment or making appropriate maintenance appointments easier to plan.

Clinic Performance Patient Retention

Potential structures include monthly facial plans, skincare replenishment programmes, treatment credits or priority booking. Before launching one, model the cost of delivering the benefits, provider capacity, unused credits, cancellation terms and the effect on appointment availability. Explain exactly what is included, what costs extra and whether credits expire or roll over. Lead with tangible value and realistic expectations rather than urgency or discounts. Where images are used to explain outcomes, make sure they are genuine, properly consented and not presented as a guarantee.

A practical plan To turn retention measurement into meaningful action, clinics can follow a simple 90-day plan to establish benchmarks, test targeted improvements and refine their approach based on outcomes. Days 1-30: establish the baseline; choose three to five metrics, define each calculation and identify the data source. Map the patient journey and note where patients commonly drop out. Assign an owner for follow-up and confirm consent, privacy and clinical escalation procedures. Days 31-60: test one or two changes. Pilot a small number of improvements, such as checkout rebooking for appropriate follow-up, a tailored post-treatment check-in or a clearer written treatment roadmap. Train the team and document the process. Avoid changing several things at once if you want to understand what is working. Days 61-90: review and refine. Compare results with the baseline, including patient feedback, opt-outs and complaints. Ask the clinical team whether the workflow supports safe, appropriate care. Keep the changes that help patients and the practice; revise or stop those that do not. How to see if the plan is working New-patient bookings and monthly revenue do not show whether patients are returning. Track a small, consistent retention scorecard – such as repeat-visit rate, rebooking rate, time between visits, revenue per active patient and membership retention – to identify where patients disengage and where service needs attention. The clinic director or practice manager should own the scorecard, supported by accurate booking and follow-up data from front-of-house teams. Review results monthly, segment where useful, and consider patient feedback and clinical suitability alongside commercial measures.

The takeaway Retention is not about persuading every patient to spend more. It is about making appropriate care understandable, consistent and easy to navigate, while giving the clinic a clearer view of its long-term performance. A focused scorecard, thoughtful follow-up and regular review can help practices identify where relationships are working and where the patient experience needs attention. Amy Kapolnek is the founder of the fwrd group, a growth consultancy for emerging and independent beauty and wellness consumer goods, medical aesthetic spas, and private medical practices. Her portfolio includes Gucci Beauty, Burberry Fragrance, Olay, Pantene, Braun, AIREM Medical Aesthetic Spa and Dr. Sue Decotiis. Kapolnek holds a Bachelor of Science in Psychology, with a minor in Business, from the University of Iowa’s College of Liberal Arts and Sciences, and an Executive MBA from New York University’s Stern School of Business. She is also a speaker and contributing expert.

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026

61


CCR Roundtable Insights

@aestheticsjournaluk

Aesthetics

Highlighting the Voices from the Roundtables at CCR 2026 CCR roundtables expose the biggest debates, challenges and takeaways shaping aesthetic practice Sustainability, key opinion leaders (KOLs), medical longevity clinics, complication management and the role of dermatology within aesthetics were the focus of five roundtables held at the Clinical Cosmetic Regenerative Congress (CCR) on October 1-2. Bringing together practitioners and specialty leaders, this article highlights the key discussions that were explored.

Sustainability roundtable Environmental action can be both an ethical responsibility and a commercial opportunity, according to the invited participants on the sustainability roundtable. As one participant phrased it, “Sustainability is now less of a value staple, and more like an operational and procurement requirement.” Featured in this discussion was consultant plastic surgeon Mr Adrian Richards, director of consultancy company Ashley McKenna, chief executive officer of clinical management company Corrinne Sawers and hospital director Greg Thorpe. The contribution of smaller clinics The table highlighted the role of small clinics, as according to the group, despite their size, they can have an impact on the wider sustainability goals of the specialty. The discussion centred on making sustainability practical and commercially relevant, especially within these small clinic settings. Rather than undertaking a full emissions report, the group recommended that clinics focus on simple, measurable actions that support both environmental goals and the bottom line. “I would start by looking at three things. Who is your energy provider, and how much of their energy is green? If you are in a clinic setting, estimate your waste and identify any obvious areas where you can cut back. Finally, do not leave devices switched on or on standby,” one participant noted. The group also highlighted opportunities to reduce clinical-waste costs through more efficient supply chains and by identifying avoidable waste. This could include expired or excess stock, which can oftentimes be the result of stock piling as products such as dermal fillers go out of date. 62

Utilising purchasing power While smaller clinics may have limited control of the overall emissions produced by larger corporations, the group felt they still have agency through their purchasing decisions. Asking suppliers about carbon footprints, packaging and labour conditions can encourage larger companies to improve transparency and adopt more sustainable practices. One participant added, “Once companies realise that clinics care and want to know, they’ll start doing their own work. They have much more resources and capacity than the clinics.” The discussion also acknowledged that, although Gen Z patients are increasingly interested in eco-conscious practices, convenience remains central to their decision-making. For sustainability to influence patient choice, the group agreed it must be embedded within a seamless, high-quality patient experience – not positioned as an added compromise.

KOL roundtable The group explored what truly defines a KOL, from their responsibilities and ethical standards, to what differentiates this role from a commercial influencer. Led by nurse prescriber Julie Scott, the table featured insights from Dr Kam Lally, Dr Yousrah Ahmed and Dr Lee Walker. Defining leadership The consensus from the group was that genuine influence should be grounded in clinical experience, evidence-based science and the ability to contribute meaningfully to the profession – not simply in social media reach. While online platforms can offer visibility, the group agreed they do not automatically translate into clinical credibility or effective teaching. “If you’ve got 200,000 followers on Instagram, that should not make you a KOL; that doesn’t necessarily mean that what you’re saying is either correct or evidence-based,” one participant noted. The table argued that passion and an ethical backbone are essential to influence the next generation securely. “People are often thrown into an arena where they’re expected to teach because they’re very good injectors. That doesn’t necessarily mean that they can get across the concepts that are required for the audience to understand how to become better,” explained another participant. Aesthetics | November 2026

Aesthetics

aestheticsjournal.com

Professional standards Maintaining independence as a KOL can be challenging, particularly when working closely with commercial partners. The round table emphasised that KOL activity should be recognised as a professional consultancy service, with clear boundaries to protect impartiality. “The work we do is basically a consultancy, we are offering our services to these companies, and therefore we shouldn’t be biased towards one company or another,” said a participant. In tandem, another participant noted the ethical positioning of a KOL, adding, “There’s an element of ethics that needs to be at the forefront, and declarations of conflicts of interest. If you are being paid to say or spread a certain message, I think that should be overt, so that people can then make their own judgment.” This segment of the discussion concluded on the sobering thought of how some practitioners within the specialty may be attracted to the “vanity” of KOL positions, where they seek titles for glamour or income without possessing the underlying skill set. The discussion suggested that genuine KOLs are distinguished not by title or visibility, but by credible expertise, ethical independence and meaningful contributions to their field. A useful test they raise is whether someone would remain relevant even without commercial support. The discussion suggested that genuine KOLs are distinguished by credible expertise, ethical independence, and meaningful contributions. A useful test they raise is whether someone would remain relevant even without commercial support.

Longevity clinics roundtable Medical aesthetics is increasingly intersecting with prevention, functional and lifestyle medicine as well as longevity care. However, the roundtable discussion highlighted the importance of clinics defining clearly what longevity means within their own practice, rather than being led solely by patient demand or commercial opportunity. Dr Mayoni Goonerante, founder of the UK Society of Medical Longevity, chaired this discussion, and was joined by fellow practitioners Dr Cemal Kavasogullari, nurse practitioner Tracey Denninson, Dr Paulina Charlesworth, Dr Souphi Samizadeh, entrepologist and naturopathic doctor, Megan Walker and Dr Gina Schoeman. Taking a holistic approach to care The group explored how aesthetics can form part of a holistic approach to care. A dermatologist shared how visible skin concerns can sometimes reflect wider issues related to metabolism or hormonal health. In these cases, a curious, history-led


@aestheticsjournaluk

Aesthetics

approach can be valuable. For example, considering whether acne or excess hair growth could be associated with an underlying condition such as polycystic ovary syndrome, rather than focusing only on a surface-level treatment. According to the group, this approach positions aesthetic care as a possible starting point for a wider health conversation, rather than a substitute for appropriate diagnosis, investigation or referral. While this can add value to aesthetic practice, the group was clear that professional boundaries must be maintained. Practitioners need to recognise when a patient requires further assessment, collaborate with other healthcare professionals where appropriate, and refer into conventional care when necessary. Working with informed patients A strong theme throughout the discussion was that longevity should not be reduced to the latest intervention. “There’s a real strain and tension between how we deploy this in a manner where we are mindful of standards and regulations, and how do we satisfy the immediate needs that patients have coming through the door,” a participant noted. Lifestyle, education and patient involvement in their own health decisions were seen as equally important. As one attendee explained, “We are not doing things to patients. We are working with them, and they’re educated, informed and responsible.” For aesthetic practitioners, the key message was that longevity should not be framed solely around procedures, products or biomarkers. A patient’s goals, habits, understanding and ability to sustain meaningful change are all part of the picture.

Complications roundtable A central theme of the complication’s roundtable was practitioner confidence when responding to medical emergencies. The session included experts within the field of complications and was chaired by consultant ophthalmologist and oculoplastic surgeon Ms Elizabeth Hawkes. The remaining group consisted of Dr Alison Coleville, nurse prescriber Sharon King, Dr Martin King, Dr Ashi Baig, Dr Carol Mastropierro, Dr Asad Naqvi, Dr Rebecca Norman and Dr Laila Hassan. Online support and clinical preparedness Although serious complications are uncommon, the group questioned whether their rarity could leave practitioners with too little hands-on experience to recognise and manage them confidently when they arise. In some cases, this can lead to complacency; in others, it can cause panic when a practitioner is faced with an unfamiliar situation. One participant elaborated, “I think we’re getting better at talking about

Aesthetics

aestheticsjournal.com

complications, and we’re all aware of it. But I think in practice would practitioners feel genuinely comfortable managing it because it is a stressful scenario.” Online complication groups, WhatsApp networks, photographs and videos have made it easier to share cases, seek advice and access management guidance. However, the discussion also raised an important question; when practitioners regularly turn to these groups for help, does this reflect healthy clinical caution, or a gap in training and preparedness? The value of a second opinion The group agreed that seeking a second opinion should not be viewed as a weakness. In an often-isolated area of practice, many aesthetic practitioners no longer work within the collaborative clinical environments they may have experienced earlier in their careers. “I think it’s a healthy practice that people reach out to other people and say, ‘I think this. Do you agree with me,” one noted. Access to colleagues can provide reassurance, help counter the emotional pressure of managing a distressed patient and ensure that the chosen approach reflects current guidance rather than outdated protocols. As one attendee explained, “It’s that second opinion and level of support, just to make sure I’m not missing anything.” Experience beyond textbook presentations The group challenged the assumption that teaching or writing about complications automatically makes someone an expert. One participant noted that vascular occlusions may not always involve pain or immediate symptoms, and signs can overlap with other conditions. This can make assessment more difficult and cause practitioners to question their judgement. As one participant noted, “Even with everything I learned, I can’t say that the presentation of the occlusions that I had were textbook occlusions.” The group also called for more regular, practical training. Rare events can be difficult to manage from memory, particularly when practitioners have never encountered them directly. Periodic refresher courses and simulated emergency drills could help teams respond more calmly and effectively. “It should be either part of the appraisal, or it should be a mandatory course where every four years you have a refresher,” a participant concluded.

Dermatology roundtable The final panel discussed how dermatology and medical aesthetics overlap, what each can learn from the other and how to make Aesthetics | November 2026

CCR Roundtable Insights aesthetic care safer. General practitioner with an extended role in dermatology Dr Kat Bennett guided the discission which featured opinions from fellow dermatologists Dr Clare Kiely, Dr Emma Wedgeworth and Dr Alexis Granite. Where dermatology and aesthetics meet Their central message was that aesthetic treatments can offer real benefits, but they should be grounded in sound diagnosis, appropriate training, good evidence and continuity of care. According to the dermatologists present, the boundary between dermatology and aesthetics is often less clear than it may appear. Dermatologists routinely treat concerns such as acne scarring, pigmentation, benign lesions and photoageing – areas that may also be addressed within aesthetic practice. “Aesthetic care can be a continuation of medical care, a patient may first seek help for acne, then ask about residual redness or scarring or later raise concerns about wrinkles,” said one participant. Rather than distancing themselves from this growing area, one participant noted, “Historically, dermatology has been slow to interact with this growing demand but we have an important role to play in raising standards in a field patient are already actively seeking out.” Putting patient safety before treatment One of the strongest messages from the discussion was the importance of not treating a lesion before fully understanding what it is. This is particularly relevant before using ablative or otherwise aggressive treatments. “Pigmented lesions can be difficult to assess, and conditions such as lentigo maligna or subtle basal cell carcinomas may be missed,” one participant noted. Where there is uncertainty, the group agreed that the patient should be referred for specialist assessment rather than the area being treated empirically. Fragmented care was identified as a key challenge, with patients often moving between dermatologists and aesthetic practitioners without a clear record of previous diagnoses or treatments. The group called for stronger referral links, virtual specialist advice and a patient-held treatment passport to help ensure continuity of care.

Bringing the discussions into focus The CCR roundtables’ offered a snippet into how medical aesthetics is evolving, what change is needed and how the field can support progress across these five core themes. 63


Subscribe now COMBINATION TREATMENTS March 2026 | VOLUME 14 - ISSUE 4

The Resource for Medical Aesthetics Professionals

UNLOCK THE REGENERATIVE POWER OF THE SKIN

THE FIRST AND ONLY PROVEN REGENERATIVE BIOSTIMULATOR THAT INCREASES COLLAGEN, ELASTIN AND SKIN THICKNESS1-5

Available at our distribution partners

For information on reporting adverse events, scan the QR code.

medfx

References: 1. Sculptra. IFU. 2. Widgerow A, et al. Poster presented at IMCAS World Congress. 01-03 February 2024. Paris, France. 3. Huth S, et al. J Drugs Dermatol. 2024 Apr 1;23(4):285-288. 4. Galderma. Date on File (MA-60875). 5. Zhang Y, et al. Regen Biomater 2021;8(5):rbab042.

UKI-SCU-2600016 DOP February 2026

GALDAERAMA_FRONT_PAGE_ADVERT.indd 1

CPD: Treating Muscle Loss with Devices Dr Nestor and Amanda Demosthenous explore the effect of GLP-1s on muscle composition

The UK’s top aesthetics platform for CPD-approved content, expert opinions and updates on the latest trends and techniques. aestheticsjournal.com @aestheticsjournaluk

Aesthetics

Aesthetics

Special Feature: Layering Injectables for Profile Balancing Considering the Suture Lift for Definition and Contour

ALSO IN THIS ISSUE

13/02/2026 10:37

Dr Nina Bal discusses combining chemical peels and LED Joëlle Rotsaert explores genderaffirming care in aesthetic practice

Join Our Community


@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

“There should always be good self-reflection. That is where real growth happens” Dr Zunaid Alli shares how establishing yourself in aesthetics requires adaptability, continued learning and professional purpose Dr Zunaid Alli has built a multifaceted career in medical aesthetics, spanning clinical practice, education, training and research. Based at his clinic, Edition Clinic in London, he balances treating patients with mentoring roles as well as contributing to the evolving evidence base within the specialty. His path into aesthetics began far from the clinic he runs today. Growing up in Johannesburg, South Africa, Dr Alli initially saw his future in psychology and psychiatry, driven by his fascination with both the art and science of the specialty. He enrolled on a Bachelor of Medical Sciences course at the University of the Witwatersrand in Johannesburg, majoring in psychology, and later graduated in 2000. “As my education within medical specialties grew, naturally I developed new passions, picturing myself in a number of different roles. As a result the dream of psychiatry drifted slowly away,” he recalls. Alongside his medical training, Dr Alli completed a Master of Business Administration at Milpark Business School, graduating in 2007. He then returned to the University of the Witwatersrand to complete a Bachelor of Medicine and Bachelor of Surgery, qualifying in 2009. After practicing in South Africa for several years, Dr Alli moved to the UK in 2014 and gained experience across a range of hospital-based roles in London, including accident and emergency, trauma medicine and general medicine. He also worked as a general practitioner (GP) locum until 2020 before completing a fellowship in medical oncology at The London Clinic in association with Guys and Thomas’ Hospital. It was during his GP locum work that Dr Alli’s interest in medical aesthetics began to develop. “While performing minor surgical procedures, I was exposed to botulinum toxin (BoNT) and dermal filler treatments during lump removals, ultrasound and within joint injections, sparking a passion that would ultimately shape the next stage of my career,” he explains. In 2014, what began as out-of-hours work within several of his colleagues’ clinics, his work within aesthetics soon developed. “Once I completed my oncology fellowship, medical aesthetics became my full-time career; this period was a real catalyst moment for the life I lead today,” he says. Between 2021 and 2023, he completed a Master of Surgery in Minimally Invasive Aesthetics at University College London, a dermatology diploma through the Royal College of Physicians

In Profile Dr Zunaid Alli

of Ireland, as well as a Diploma in Aesthetic and Regenerative Medicine at Université Paris-Est Créteil. “These courses provided the opportunity to combine the three pillars that matter most to me, clinical practice, clinical research, teaching and training and mentoring,” he notes. In 2023, Dr Alli opened the doors to his clinic. Explaining the reasoning behind this next step, he says, “I wanted to bring everything under one roof. A space where I could treat patients; offer a broad range of energy-based devices (EBDs); laser and light therapies; and teach, train and mentor others.” In the early days of his practice, Dr Alli focused on core treatments such as BoNT and dermal fillers, before gradually incorporating skincare, chemical peels and microneedling. “At the time, these were the main modalities available to us. Interestingly, despite the alleged recent decline in filler use, I still perform a significant amount of filler work today. BoNT treatments, particularly the three upper-face areas, remain among the most popular treatments I provide,” he says. Dr Alli notes treatment planning is becoming more dynamic, with biostimulators and EBDs enabling personalised plans across the year. He believes combination treatments are the future of medical aesthetics. Dr Alli has a longstanding passion for education and research – one that has naturally led to him becoming an international key opinion leader (KOL) for aesthetic manufacturer VIVACY in addition to holding a KOL position for aesthetic manufacturer WiQo. “I am also head of faculty for VIVACY UK, overseeing faculty activity and educational content across their portfolio including Stylage, Rejuran and Novuma. I also speak internationally for VIVACY and provide clinical support to practitioners across the country when treatment-related questions or issues arise,” he explains. Working with WiQo, he has supported the international launch of new product formulations in Australia, the Philippines, South Africa, Saudi Arabia and the US. “I will not represent a brand unless I understand how its products are made, trust its manufacturing standards and feel confident in its clinical and scientific evidence base,” he emphasises. Dr Alli adds, “I also believe it is essential to use the products I represent in clinic every day.” Looking ahead, Dr Alli is particularly excited by the development of biostimulators and their increasingly innovative applications. However, he urges caution, “This remains a massively untapped field, and, in many ways, we are venturing into the unknown. We must balance innovation with appropriate patient care, avoiding the overhyping or overmarketing of treatments.” For the next generation of practitioners, Dr Alli’s advice is to take a deep breath, begin with the basics and progress slowly. “Build your skills and training gradually and steadily. As you begin to think more independently and scientifically as a clinician, there should always be good clinical reflection and self-reflection. That is where real growth within the specialty happens,” he concludes. What are the biggest lessons learnt through mistakes made? Don’t do too many courses concurrently. What is the most recent treatment you added to clinic and why? Dual combination therapy of high-intensity ultrasound and radiofrequency microneedling. Where is your favourite holiday destination? Koh Phangan in Thailand.

Aesthetics | November 2026

65


The Last Word Subscriptions

@aestheticsjournaluk

Aesthetics

Aesthetics

aestheticsjournal.com

surgeries they regret as they attempt to pursue cosmetic surgeries to remedy their perceived flaws.4 As these procedures are prepaid, with cancellation fees and rollover credits, it can create a psychological and financial burden that makes patients feel unable to back out of their procedures, regardless of whether they have had a change of mind. For this reason, I believe it is important that subscription models are designed with the flexibility to allow patients to pause or cancel treatments without being financially penalised.

When subscription models can support patient autonomy

Are Subscription Models Dismantling Informed Consent? Cosmetic surgery solicitor Michael Saul argues how clinic subscriptions affect patient consent The UK medical aesthetics field has experienced astronomical value growth in previous years, with an annual increase of 8-9%.1 The rise of aesthetics subscription models has contributed to this swift expansion.2 Aesthetic subscriptions are recurring monthly memberships for in-clinic cosmetic treatments. The monthly payment allows individuals to spread out the cost of their treatments, instead of paying a large lump sum for each procedure. But even as aesthetics subscriptions become mainstream, there remains no settled view on whether they’re compatible with consent law and clinical safeguarding. The pre-scheduled and prepaid nature of these treatment structures raises questions about whether meaningful, ongoing informed consent can be maintained throughout the treatment journey, leaving practitioners with the responsibility to close that gap themselves.

When subscriptions put informed consent at risk Although aesthetics subscriptions themselves don’t violate consent, treating these subscriptions as a pre-agreed administrative transaction with pre-signed forms violates UK clinical and legal standards. Under Montgomery v Lanarkshire (2015), consent is a process tied to the patient’s circumstances at the time of each treatment, rather than a one-off formality established at the initial consultation.3 This may have implications for practitioners, as operating under a subscription model could lead them to overlook the need to obtain consent before each treatment. Effective informed consent requires a continuous conversation with fresh clinical assessment of a patient’s medical history and current health prior to a procedure. This involves checking whether a patient’s health, medication, expectations, understanding of risks and wishes to proceed with the procedure has changed. At this stage, the practitioner should clarify that the individual has understood all aspects of the treatment, including risks and alternatives. Failure to gain this consent creates the potential for missed signs of psychological matters, as there is no built-in checkpoint to reassess patient motivations. With no measures to assess a patients’ motivations, expectations or suitability individuals with conditions such as Body Dysmorphic Disorder (BDD) may be at increased risk of 66

The ethical risk in aesthetic subscriptions lies not in the model itself, but in how consent is handled. When consent is built into the structure and subscriptions are managed responsibly, I believe they can support patient autonomy. Subscriptions may be more cost-effective than regular procedures and, for patients on a budget, can provide access to regular skin or maintenance treatments without being exploitative. Regular treatment at the same clinic can also improve patient wellbeing, enabling clinicians to understand evolving needs and provide more consistent advice and care, reducing the likelihood of complications or unwanted results. In many cases, the issue is not the subscription model, but poor implementation of consent processes. Some clinics build in reassessment checkpoints, including a consultation before each procedure and flexible opt-out options without cancellation fees. Comparable payment-plan structures already exist in other areas of healthcare and aesthetics without automatically breaching consent standards. Clinics can respect autonomy by allowing capable patients to commit to a payment plan or membership in advance, digitally or in person. However, this must never be treated as consent to a specific procedure; each treatment requires fresh, point-of-treatment consent. This supports self-management while maintaining clinical safety and ethical oversight.

Protecting consent as the market expands A subscription should pay for access to care, not commit a patient to treatment. To reduce legal risk and improve patient protection, aesthetic subscriptions require clearer regulation. This should include mandatory, documented point-of-treatment consent for every procedure, alongside routine BDD and psychological screening throughout the subscription period rather than solely at sign-up. Financial structures must not trap patients into unwanted treatment. Cooling-off and opt-out rights should be proportionate to the value of any pre-payment; larger financial commitments should carry longer cancellation periods and clear refund provisions, protecting a patient’s ability to decline. Clinics should also face clearer rules on marketing and advertising. Discounts and promotional offers can place pressure on patients to undergo unnecessary procedures and must be presented responsibly. These safeguards would protect informed consent while allowing subscriptions to remain a responsible and accessible care model. Michael Saul is a partner and heads Cosmetic Surgery Solicitors, TJL Solicitors’ specialist cosmetic surgery negligence department. He has extensive experience handling claims involving cosmetic procedures and treatments, including landmark litigation. As a recognised specialty spokesperson, Saul regularly contributes to national media and has worked in the law field for more than 30 years.

VIEW THE REFERENCES AT AESTHETICSJOURNAL.COM

Aesthetics | November 2026


Brand Directory Your guide to the unmissable companies at the Aesthetics Conference & Exhibition (ACE) and the Aesthetics Business Show (ABS)

Explore the Brands at ACE / ABS 2027:

Key Key Sponsors Aesthetics Business Show (ABS)

#

A

B

C

D

E

F G H

3D Aesthetics 4T Medical Acclaro Corporation ACRE Aerolase Aesthetic Medical Partnership Ltd Aesthetic Source Aesthetic Web Aesthipharma Allergan Aesthetics ALLSKIN | MED Alma Amory London Ltd Aquaceuticals® Arthrex Ltd Beautyform Medical BTL Aesthetics CACI International Candela (U.K.) Ltd Cellap Laboratory UK Church Pharmacy Cosmetic Courses Croma Pharma UK Cutera Daesung Medi CO.,LTD Dermafocus Ltd Dermapenworld DermasupplyUK Elenzia Limited EMA Aesthetics Ltd Energist Ltd Evolus Fotona UK Galderma (UK) Ltd Halo IV Harley Academy

Shire Leasing PLC

Healthxchange Hexagon Aura Reality Hydrafacial HYPO21 I

IBSA UK iiaa InMode

T

Inspire to Outstand Interface Aesthetics IVANMED J

John Bannon Pharmacy

K

K-Laser UK

L

Laboratoires Fillmed LPG Clinics Wholesale LPG Systems UK Lumenis Lynton Lasers Ltd

M

Med-Fx UK Merz Aesthetics

N

W

Z

skinade SkinCeuticals Smart Group Sofwave Medical UK Limited SOOVIA CARE LTD Teleta The Glow Group Totally Derma TSK Laboratory UK WeRX Health Wigmore Medical Limited Zemits UK Ltd Zenoti Zero Gravity Skin ZO Skin Health

NEW at ACE 2027

Neauvia Neunova Biotech Novus Medical UK

O

Opatra

P

Pabau Phorest Professional Derma SA PRP PURE LTD

Sponsored by

Pure Tone Aesthetics Q

Quad Aesthetics Quirky Frog

R

REGEN LAB SA Revance Revolve Medicare

S

Sciton UK Sculpt Pro Aesthetics

Directory is correct as of time of print. Updates may be made before the event.

A dedicated space for professionals focused on building, scaling and future-proofing successful clinics. Practical, results-driven strategies for the business of aesthetics.


Targets Deep-Set Wrinkles and Pores Minimise Pore Appearance from One Week*

Aesthetic Skincare Brand

Recommended by UKI Dermatologists in Private Practice*** *Average results, clinical study 77 subjects, visual grading. **If you are considering an aesthetic treatment, always consult a Medical Professional. P-Tiox Cream is a cosmetic skincare product for topical use. Do not inject. Only apply on healed skin. ***Based on a survey with 162 private dermatologists from the UKI, using a pre-defined list of aesthetic skincare brands.


Turn static files into dynamic content formats.

Create a flipbook
November 2026: Male Aesthetics by Aesthetics & CCR - Issuu